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Hypothalamic gonadotropin-releasing hormone (GnRH) (GnRH I) is the central 
regulator of the mammalian reproductive system.  Most vertebrates studied also 
possess a second form of GnRH, GnRH II.  GnRH I acts on its cognate G protein-
coupled receptor (GPCR) on pituitary gonadotropes and activates Gq/11-mediated 
signalling pathways to stimulate the biosynthesis and the release of luteinising 
hormone (LH) and follicle-stimulating hormone (FSH).  Both GnRHs have also been 
suggested to inhibit cellular proliferation, an action which has largely been proposed 
to be mediated by the coupling of the receptor to Gi/o.  However, the range of G 
proteins activated by the GnRH receptor and the signalling cascades involved in 
inducing antiproliferation remain controversial. 
 
To delineate the G protein coupling selectivity of the mammalian GnRH receptor and 
to identify the signalling pathways involved in GnRH I-mediated cell growth 
inhibition, I examined the ability of the receptor to interact with Gq/11, Gi/o and Gs in 
Gαq/11 knockout MEF cells.  My results indicate that the receptor is unable to interact 
with Gi/o but can signal through Gq/11.  Additionally, my data do not support the 
suggestion of GnRH receptor-Gs interaction.  Furthermore, I show that the GnRH I-
induced inhibition of cell growth is dependent on Gq/11, src and extracellular signal 
regulated kinase (ERK) but is independent of the activity of protein kinase C (PKC), 
Ca2+, jun-N-terminal kinase (JNK) or P38.  Based on these findings and previous 
research within our group, I propose a mechanism whereby GnRH I may induce 
antiproliferation. 
 
Previous studies from our laboratory suggest that the GnRH receptor can adopt 
distinct active conformations in response to the binding of GnRH I and GnRH II.  
These data thus account for our hypothesis of ligand-induced selective signalling 
(LiSS).  Given my previous results, I examined the ability of the GnRH receptor to 
couple to G12/13.  My work indicates that the receptor can directly activate G12/13 and 
the downstream signalling cascades associated with this G protein family.  Indeed, I 
provide evidence, in several cellular backgrounds, to suggest that GnRH receptor-
G12/13-mediated signalling is involved in the regulation of GnRH-induced MAPK 
                                                                                                                               Abstract 
 21
activity, SRE-driven gene transcription and cytoskeletal reorganisation.  
Furthermore, I propose a role for these G proteins in the transcriptional regulation of 
LHβ and FSHβ.  Finally, I confirm previous results from our laboratory indicating 
that the GnRH receptor may interact with src Tyr kinase and show that GnRH I but 
not GnRH II may, independently of Gq/11, stimulate the Tyr phosphorylation and thus 
the activation of this protein.  I propose that this differential signalling accounts for 
the distinct effects of GnRH I and GnRH II on cellular morphology and SRE-
promoted transcriptional activity. 
 
The research presented within this thesis provides evidence to refute published 
conclusions based on largely circumstantial experimental data, describes novel 
GnRH receptor signalling pathways and offers support for the concept of LiSS.  It 
may assist in the development of new therapeutic compounds which selectively 
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1.0  Introduction 
This literature review is divided into three parts.  In the first, guanosine-5-
triphosphate (GTP) binding (G) protein-coupled receptors (GPCRs) will be 
introduced and a summary of both G protein-dependent and -independent signalling 
by GPCRs given.  Subsequently, the concept of ligand-induced receptor activation 
and signalling will be reviewed and, finally, gonadotropin-releasing hormone 
(GnRH) and the signalling associated with the activation of the GnRH receptor 
examined. 
 
1.1  GPCRs and G Protein-Dependent and -Independent Signalling 
With more than 800 members, the G protein-coupled receptor family represents the 
largest group of cell surface molecules involved in eukaryotic signal transduction and 
accounts for approximately 2% of the total genes encoded by the human genome 
(Fredriksson et al., 2003).  Their dysfunction contributes to some of the most 
prevalent diseases affecting man as represented by the fact that they are targeted by 
approximately 50% of all therapeutic agents currently in clinical use (Dorsam and 
Gutkind, 2007, Fredholm et al., 2007).  In the following sections, an overview of 
GPCR structure and classification, synthesis and trafficking, activation and both G 
protein-dependent and -independent signalling is provided. 
 
1.1.1  GPCR Structure and Classification 
In 1986, the cloning of the gene and complimentary DNA (cDNA) for the 
mammalian β2-adrenergic receptor, and the realisation that it shares a high degree of 
sequence homology and a predicted seven-transmembrane (7-TM) structure with 
bovine rhodopsin, led to the idea that a large family of receptors existed (Dixon et 
al., 1986).  This hypothesis was rapidly confirmed by the successful cloning of the 
muscarinic acetylcholine receptor (Kubo et al., 1986), the α2-adrenergic receptor 
(Kobilka et al., 1987) and the serotonin 5-HT1A receptor (Fargin et al., 1988).  
GPCRs are therefore known to share a common structural architecture (figure 1.1).  
They are composed of a single polypeptide with 7-TM α helices connected by 
alternating hydrophilic intracellular and extracellular loops (ICLs and ECLs 
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respectively).  The amino-terminus is located on the extracellular side of the 




TM1 TM2 TM3 TM4 TM5 TM6 TM7
carboxy-terminus
ICL1              ICL2               ICL3
ECL1            ECL2             ECL3
 
 
Figure 1.1 Overall topology of the GPCR family.  Members of the GPCR 
family possess a conserved structure consisting of 7-TM α helices (7-TM domain) 
connected by alternating hydrophilic ICLs and ECLs, an amino-terminus on the 
extracellular side of the membrane and a carboxy-terminus on the intracellular side. 
 
High resolution structural information is essential for understanding the molecular 
mechanisms of protein function (Kobilka and Schertler, 2008, Wess et al., 2008).  
Structural analysis of GPCRs has, however, been somewhat hindered by the inherent 
difficulties associated with producing and purifying sufficient amounts of 
recombinant protein (Kobilka, 1995).  In 2000, Palczewski and colleagues described 
the three dimensional crystal structure of bovine rhodopsin at a resolution of 2.8 Å 
(Palczewski et al., 2000) and thus confirmed the arrangement of the 7-TM domain 
(Meng and Bourne, 2001, Lu et al., 2002).  More recently, crystal structures have 
been determined for the human β2-adrenergic receptor (Cherezov et al., 2007, 
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Rasmussen et al., 2007, Rosenbaum et al., 2007), the turkey β1-adrenergic receptor 
(Warne et al., 2008) and the human A2A adenosine receptor (Jaakola et al., 2008).  
These structures highlight the similarities and the differences between different 
GPCRs and provide improved templates for homology modelling of other receptors.  
However, crystal structures of GPCRs bound to different ligands and/or in complex 
with G proteins or other signalling partners are still largely undefined (Scheerer and 
colleagues very recently published the first crystal structure of opsin in its G protein 
interacting conformation (Scheerer et al., 2008)).  Interestingly, Park and colleagues 
described the crystal structure of ligand free opsin at 2.9 Å (Park et al., 2008).  This 
represents the first successful crystallisation of the opsin apoprotein in the empty 
state.  The authors postulate that it may provide insight into the retinal uptake and 
release mechanism as well as ligand binding to, and the activation of, GPCRs in 
general. 
 
Several classification systems have been adopted to further divide the GPCR family.  
Attwood and Findlay made the first attempt in 1993 when they devised a system 
based on the sequence homology of the 7-TM domains (Attwood and Findlay, 1993).  
Later, in 1994, they extended their dataset from 240 to 393 and noted that 61 
sequences made imperfect matches suggesting that motifs within the transmembrane 
regions are not conserved between GPCR subfamilies (Attwood and Findlay, 1994).  
In the same year, Kolakowski presented the well known A, B, C, D, E, F and O 
classification system which was designed to be representative of all GPCRs 
(Kolakowski, 1994).  The usefulness of this system is, however, debated given that 
some subfamilies do not exist in humans.  Fungal pheromone receptors and 3,5-
cyclic adenosine-5-monophosphate (cAMP) receptors are represented by subfamilies 
D and E respectively and subfamily F contains archaebacterial opsins.  Following 
publication of the first draft of the human genome in 2001 (Lander et al., 2001, 
Venter et al., 2001), Fredriksson and colleagues divided 802 known and predicted 
human GPCRs into subfamilies based on phylogenetic criteria (Fredriksson et al., 
2003).  The authors noted that there exist five subfamilies of GPCRs in humans 
termed rhodopsin, glutamate, secretin, adhesion and frizzled/taste2.   
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1.1.2  GPCR Synthesis and Trafficking 
As with all nascent integral membrane proteins, the life of GPCRs begins in the 
endoplasmic reticulum (ER) where they are synthesised and folded (Drake et al., 
2006, Gurevich and Gurevich, 2008).  Correctly folded receptors are packaged into 
ER derived COP2 coated vesicles (Barlowe et al., 1994) which traverse from the ER 
to the ER-Golgi intermediate complex (ERGIC), the Golgi apparatus and the trans-
Golgi network (TGN) (Duvernay et al., 2005).  It is during this migratory step that 
they may undergo post-translational modification (such as glycosylation) before final 
targeting to the plasma membrane (figure 1.2).  Evidence suggests that GPCR export 
trafficking is a highly regulated process (Dong et al., 2007).  Interaction with ER 
chaperones promotes the proper folding of the immature receptor and stabilises this 
conformation thereby promoting the delivery to the plasma membrane.  Additionally, 
homo- and hetero-dimerisation of GPCRs may play an important role.  Indeed, some 
studies have indicated that it is a requirement for the successful delivery of certain 
receptors (such as the α1B-, the α1D- (hetero-dimerisation) and the β2-adrenergic 
(homo-dimerisation) receptors) from the ER to the cell surface (Hague et al., 2004, 
Salahpour et al., 2004). 
 
Numerous quality control mechanisms ensure that, in most cases, improperly or 
incompletely folded proteins are targeted for degradation (Bernier et al., 2004).  As 
such, mutations which result in the misfolding and the subsequent misrouting of a 
GPCR are known to be the cause of a number of human pathologies (Tan et al., 
2004, Conn et al., 2007).  Examples of such ailments include retinitis pigmentosa 
(rhodopsin) and hypogonadotropic hypogonadism (HH) (the GnRH receptor).  
Interestingly, it has been suggested that membrane permeant small molecule GPCR 
antagonists (which act as pharmacological chaperones) can correct mutant GPCR 
misfolding and thus facilitate the proper trafficking of the receptor to the plasma 
membrane (Milligan et al., 2002, Bernier et al., 2004, Conn et al., 2007).  At the cell 
surface, certain mutants (such as E90K with reference to the GnRH receptor) have 
been shown to be functional at levels comparable with wild-type GPCRs (Morello et 
al., 2000, Janovick et al., 2002).  This pharmacological chaperone action of GPCR 
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Figure 1.2 GPCR synthesis and export.  GPCRs are synthesised and folded in 
the ER.  They migrate from the ER through the Golgi and are finally delivered to the 
plasma membrane.  Misfolded receptors are usually targeted for degradation however 
membrane permeant GPCR antagonists may be able to rescue receptor surface 
expression.  Figure adapted from Conn et al., 2007.  G protein-coupled receptor 
trafficking in health and disease:  lessons learned to prepare for therapeutic mutant 
rescue in vivo.  Pharmacol Rev, 59, 225-250. 
 
After the successful delivery to the plasma membrane, binding of an agonist causes 
the receptor to change conformation leading to the recruitment and the activation of 
intracellular effectors.  Thereafter, receptor desensitisation (figure 1.3) and 
internalisation may sequentially take place.  Initially, GPCR kinases (GRKs) 
recognise activated GPCRs and become themselves catalytically activated (Premont 
and Gainetdinov, 2007).  This results in the phosphorylation of the receptor at both 
Ser and Thr residues localised within either ICL3 or the carboxy-terminal tail 
(Ferguson, 2001).  Subsequently, high affinity arrestin binding to the phosphorylated 
receptor takes place, sterically hindering receptor-G protein interaction (Moore et al., 
2007).  Additionally, the arrestins serve as adapter molecules linking GPCRs to the 
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endocytic machinery of the cell (Marchese et al., 2003, Reiter and Lefkowitz, 2006).  
Interestingly, as well as facilitating receptor internalisation, evidence suggests that 
the arrestins are able to act as signal transducers in their own right by recruiting a 
broad spectrum of signalling molecules to GPCRs in a strictly activation-dependent 
fashion (Lefkowitz and Shenoy, 2005, Lefkowitz, 2007).  Following internalisation, 
GPCRs are subject to one of two sorting fates in the early endosome - recycling or 
degradation.  The recycling pathway facilitates the return of the internalised 
receptors to the cell surface resulting in functional resensitisation and the degradative 
pathway results in their transport to lysosomes prior to proteolysis (Hanyaloglu and 




Figure 1.3 GPCR desensitisation.  Agonist-induced receptor activation 
facilitates G protein activation and signalling (Active).  The GPCR may then be 
phosphorylated by GRKs (GRK phosphorylated) prior to arrestin binding (Arrestin-
bound).  Arrestin binding sterically hinders receptor-G protein interaction, facilitates 
GPCR internalisation and may initiate a second wave of signalling.  Internalised 
GPCRs are sorted for recycling or degradation.  Figure taken from Premont and 
Gainetdinov, 2007.  Physiological roles of G protein-coupled receptor kinases and 
arrestins.  Annu Rev Physiol, 69, 511-534. 
 
1.1.3  GPCR Activation 
Various theoretical models that explain and predict receptor behaviour have been 
proposed.  In 1980, DeLean and colleagues put forward the ternary complex model 
(TCM) (DeLean et al., 1980).  In this study, experiments on the frog and the turkey 
erythrocyte β-adrenergic receptor provided a general model for the activation, by 
agonists, of GPCR systems.  The model states that the activation of a GPCR requires 
the agonist-promoted formation of an active ternary complex (HRX) consisting of 
agonist (H), receptor (R) and G protein (X).  In contrast, the inactive state of a GPCR 
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is characterised by the absence of the G proteins in the system.  This theory is 
supported by the earlier observation that an agonist-receptor complex 
([3H]hydroxybenzyl-isoproterenol-β2-adrenergic receptor) had an apparent larger 
molecular size than an antagonist-receptor complex ([3H]dihydroalprenolol-β2-
adrenergic receptor) (Limbird and Lefkowitz, 1978).   
 
In 1993, a study by Samama and colleagues extended the TCM to include the 
capability of receptors to, in the absence of an agonist, adopt an active conformation 
and couple to a G protein (Samama et al., 1993).  Mutation of Leu266, Lys267, His269 
and Leu272 of the β2-adrenergic receptor to the corresponding residues from the 
hamster α1B-adrenergic receptor (Ser
266, Arg267, Lys269 and Ala272) was sufficient to 
cause the agonist-independent activation of adenylyl cyclase.  The extended TCM 
(ETCM) accommodates both the observation of the ligand-independent receptor-
mediated activation of the G proteins and the behaviour of the various classes of 
ligand.  According to the model, GPCRs exist in equilibrium between an inactive 
state (R) and an active state (R*).  They must undergo transition from R into R* in 
order to bind to and activate the G proteins.  In the absence of agonist, the 
equilibrium is shifted towards the R state.  Nevertheless, a proportion of the receptors 
may spontaneously move into the R* state as the energy barrier between R and R* is 
sufficiently low.  Mutations which result in constitutively active GPCRs alter the 
equilibrium between R and R* and shift a higher proportion of the receptor 
molecules into R*.  Traditional agonists bind with the highest affinity to the 
receptors in the R* state, shift the equilibrium towards R* and elicit a functional 
response.  Neutral antagonists bind with the same affinity to the receptors in both the 
R and the R* states and thus cause no change in the equilibrium between the two.  
They do, however, prevent the binding of an agonist and therefore avert any cellular 
response.  Inverse agonists stabilise the inactive R state shifting the equilibrium away 
from R*.  Basal receptor activity is inhibited and basal receptor signalling is 
decreased.  The ETCM has been instrumental in shaping our view of the receptor 
activation process.  Specifically, it highlights that agonist-induced receptor-mediated 
signalling requires the transition of the receptor from an inactive to an active 
conformation. 
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Mutational approaches have shed light on the process of GPCR activation by agonist 
ligands (figure 1.4).  For receptors of the rhodopsin subfamily, these studies suggest 
that small ligands are able to enter deep within the central crevice of the receptor 
while larger peptide ligands mainly interact with the ECLs and the exofaces of the 
transmembrane regions (TMs) (Gether, 2000, Lu et al., 2002).  Additionally, they 
infer that, upon agonist binding, TM3 and TM6 play a critical role in the transition of 
GPCRs to their fully activated conformation.  Specifically, an anticlockwise rotation 
of TM6 (when viewed from the extracellular side), relative to TM3, accompanied by 
an outward movement of both intracellular ends is thought to be involved in the 
activation process.  Agonist-induced changes in receptor conformation with 
reference to TM3 and TM6 are supported by a number of elegant studies.  Farrens 
and colleagues utilised Cys spin labelling and disulphide cross linking to demonstrate 
the involvement of these TMs in rhodopsin activation (Farrens et al., 1996).  
Magnetic dipolar interactions between the spin labels in TM3 and TM6 revealed 
their proximity.  Furthermore, changes in these interactions upon receptor activation 
suggested the occurrence of a rigid body movement of these α helices.  Indeed, TM3-
TM6 disulphide cross linking prevents the rhodopsin-mediated activation of Gt, data 
which demonstrate the importance of such a movement.  Additionally, Sheikh and 
colleagues engineered Zn2+ binding sites between the intracellular surfaces of the 
transmembrane helices of rhodopsin with the aim of restraining specific activation-
induced conformational changes (Sheikh et al., 1996).  Mutation of residues in TM3 
(V138H) and TM6 (T251H) blocked rhodopsin activation in the presence of Zn2+.  
Later, the authors reported similar findings at the β2-adrenergic receptor and the 
parathyroid hormone receptor (Sheikh et al., 1999).  These data indicate a direct 
reliance of receptor activation on a change in the spatial arrangement of TM3 and 
TM6. 
 
In 1999, Elling and colleagues, based on presumed agonist interaction sites on the 
exofacial regions of TM3 and TM7 of the β2-adrenergic receptor, constructed
 a Zn2+ 
binding site between residues in these TMs (D113H and N312C respectively) (Elling 
et al., 1999).  Signal transduction in the mutant receptor was not activated by β2-
adrenergic receptor agonists (such as pindolol) but increases in cAMP accumulation 
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were apparent after the addition of Zn2+.  These findings were later replicated with 
the neurokinin NK1 receptor (Holst et al., 2000).  In this study, the authors concluded 
that the observed partial agonism in response to Zn2+ was due to the lack of critical 
interactions with residues in TM6.  Similarly, Lu and colleagues showed that His 
substitution of residues in TM3 (L116H), TM6 (F374H) and TM7 (N414H) creates 
high affinity Zn2+ binding sites in the M1-muscarinic receptor and thus demonstrated 
their close proximity in the inactive state (Lu and Hulme, 2000).  Ala substitution 
(L116A), however, had previously been shown to increase the acetylcholine binding 
affinity and the basal receptor activity implying a shift of the receptor into the active 
conformation (Lu and Hulme, 1999).  Taken together, these studies demonstrate that 




Figure 1.4 Conformational changes during GPCR activation.  Upon binding 
of agonist ligands, rotation of TM6 (VI) (thin arrow), relative to TM3 (III), 
accompanied by an outward movement of the intracellular ends of TM3, TM6 and 
TM7 (VII) (thick arrows) occurs.  The α helices and the ICLs of rhodopsin are shown 
as seen from the intracellular side.  Figure adapted from Meng and Bourne, 2001.  
Rhodopsin activation: what does the rhodopsin structure tell us?  Trends Pharmacol 
Sci, 22, 587-593. 
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1.1.4  GPCR-Mediated G Protein-Dependent Signalling 
Despite some structural diversity between the GPCR subfamilies, the G protein 
round of signalling initiated by these receptors is remarkably uniform (Gurevich and 
Gurevich, 2008) (figure 1.5).  As discussed earlier, when an agonist interacts with a 
GPCR on the surface of a cell it induces a conformational change of the receptor that 
activates the heterotrimeric G proteins (composed of Gα, Gβ and Gγ subunits) on the 
intracellular side of the membrane (Cabrera-Vera et al., 2003).  Both the Gα and the 
Gγ subunits are thought to have lipid modifications that serve as hydrophobic 
membrane anchors (Wedegaertner et al., 1995).  In the basal state, the guanosine-5-
diphosphate- (GDP) bound Gα subunit and the Gβγ complex are associated.  Upon 
interaction of the activated receptor with the heterotrimeric complex, a series of 
conformational changes are propagated through the Gα subunit to the GDP binding 
site and GDP is exchanged for GTP (McCudden et al., 2005).  Subsequently, 
according to the traditional G protein activation model, the GTP-bound Gα subunit 
dissociates from the Gβγ complex.  Both the Gα-GTP subunit and the Gβγ complex 
are now free to modulate the activity of a variety of intracellular effectors.  The 
duration of this modulation is determined by the intrinsic GTPase activity of the Gα 
subunit (although there exist mechanisms that accelerate signal termination).  The 
activation cycle is completed by the hydrolysis of GTP to GDP and the subsequent 
reassociation of the Gα-GDP subunit with the Gβγ complex. 
 
More recent models concerned with G protein activation have suggested that the 
dissociation of the subunits that make up the heterotrimeric complex may not be 
absolutely required for downstream signalling (Robishaw and Berlot, 2004).  This 
theory, termed the clamshell model of G protein activation, is supported by 
fluorescence resonance energy transfer (FRET) studies of fluorescently tagged G 
protein subunits.  Bunemann and colleagues showed that, although a conformational 
change takes place upon G protein activation, dissociation of the Gα subunit (Gαi1) 
and the Gβγ complex does not necessarily occur (Bunemann et al., 2003).  According 
to the model, GPCR activation-induced changes in G protein conformation expose 
previously inaccessible domains on the Gα subunit and the Gβγ complex.  This 
conformational change is necessary for the activation of intracellular effectors and 
Chapter One                                                                                               Literature Review                        
 33
suggests that G proteins may act more as scaffolds for the recruitment of other 
signalling molecules.  Signal termination occurs, not by the reassociation of the 
heterotrimeric complex, but by another set of conformational changes that obscure 
the effector interaction sites on the Gα subunit and the Gβγ complex.   
 
Although the intrinsic GTPase activity of the Gα subunit dictates the duration of G 
protein-mediated effector modulation, and effector-mediated negative feedback can 
regulate this activity, this regulation is not exclusive.  Instead, it can be augmented 
by a number of factors.  For example, some of the Gα subunits (such as Gαz and 
Gα12) and a Gγ subunit (Gγ12) may be modified by phosphorylation and this 
modification also appears to play a role in the regulation of signalling duration (Chen 
and Manning, 2001).  Indeed, protein kinase C- (PKC) induced phosphorylation of 
Gαz has been shown to inhibit the interaction of this Gα subunit with the regulator of 
G protein signalling (RGS) proteins (RGSZ1) (Wang et al., 1998).  Inhibition of this 
interaction may therefore prolong the activation of Gαz-mediated signalling.  RGS 
proteins are a large family of signalling proteins which share a conserved signature 
catalytic domain (RGS domain) (Hollinger and Hepler, 2002).  However, many are 
multifunctional in that they possess two or more domains which can mediate protein-
protein interactions (Birnbaumer, 2007).  Initially, they were considered to act 
simply as GTPase activating proteins (GAPs) that bind directly to activated Gα 
subunits (Watson et al., 1996).  More recently, however, evidence suggests that more 
complex RGS proteins (those which possess many domains) may act as integrators 
rather than negative regulators of G protein signalling.  One key example comes 
from the observation that RGS proteins (specifically, in this case, p115 RhoGEF) can 
directly link the Gα13 subunits to the activation of the Rho monomeric G proteins.  
p115 RhoGEF consists of a RGS domain, a Dbl homology (DH) domain and a 
pleckstrin homology (PH) domain (figure 1.6).  The RGS domain acts as a GAP for 
Gα12 and Gα13 (Kozasa et al., 1998) while the DH domain is required for Rho 
guanine nucleotide exchange activity (Hart et al., 1998).  It is thought that the PH 
domain is necessary for plasma membrane localisation of the protein (Bhattacharyya 
and Wedegaertner, 2003).   
 




Figure 1.5 GPCR-mediated G protein-dependent signalling.  In the inactive 
state, the GDP-bound Gα subunit is associated with the Gβγ complex.  GPCR 
activation induces a conformational change in the Gα subunit which results in the 
exchange of GDP for GTP.  This facilitates the dissociation of the GTP-bound Gα 
subunit from the Gβγ complex.  Both the GTP-bound Gα subunit and the Gβγ 
complex may go on to modulate the activity of various intracellular effectors.  The 
duration of the cycle is determined by the intrinsic GTPase activity of the Gα 
subunit.  The hydrolysis of GTP to GDP and the subsequent reassociation of the 
heterotrimeric complex completes the cycle.  Figure adapted from Milligan and 





Figure 1.6 Structure of p115 RhoGEF.  p115 RhoGEF consists of a RGS 
domain, a DH domain and a PH domain.  The RGS domain acts as a GAP for Gα12 
and Gα13 while the DH domain is required for Gα13-mediated Rho guanine 
nucleotide exchange activity.  The PH domain is thought to be necessary for plasma 
membrane localisation.  The protein is orientated such that the amino-terminus is 
shown on the left and the carboxy-terminus on the right.  Figure adapted from 
Hollinger and Hepler, 2002.  Cellular regulation of RGS proteins: modulators and 
integrators of G protein signalling.  Pharmacol Rev, 54, 527-559. 
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According to current knowledge, sixteen genes encode the Gα subunits, five encode 
the Gβ subunits and twelve encode the Gγ subunits in man (Cabrera-Vera et al., 
2003).  Classically, on the basis of the sequence homology of the Gα subunit, the 
heterotrimeric G proteins are divided into four families (Gs, Gi/o, Gq/11 and G12/13) 
which define, to a large extent, effector specificity (Neves et al., 2002).  The 
exception appears to arise when a signal is promulgated by the Gβγ complex.   
 
Conversion of a G protein heterotrimeric complex from the inactive to the active 
state is promoted by an interaction with GPCRs.  However, another class of 
signalling proteins, termed the receptor-independent activators of G protein 
signalling (AGS), has also been identified.  As their name suggests, the AGS proteins 
activate heterotrimeric G protein complexes independently of receptor activation.  
The Gα subunits which they positively regulate, however, appear to differ between 
members of the protein family.  Indeed, Takesono and colleagues demonstrated that, 
in yeast strains selectively expressing different Gα subunits, AGS3 is only efficient 
in promoting the activation of Gαi2 and Gαi3 whereas AGS2 activates Gαs, Gαi2, Gαi3 
and Gα16 (Takesono et al., 1999).  Additionally, recent evidence suggests that the G 
protein subunits may be activated by other families of receptors.  Shan and 
colleagues showed that Gα13 is essential for the receptor Tyr kinase- (RTK) induced 
migration of mouse embryonic fibroblast (MEF) cells to occur (Shan et al., 2006).  
Furthermore, Gα13 involvement in cell migration is retained in a carboxy-terminus 
Gα13 mutant (which is defective in GPCR coupling) suggesting that the platelet 
derived growth factor- (PDGF) induced migration is independent of GPCR 
signalling.  Conversely, GPCRs do not exclusively activate the heterotrimeric G 
proteins.  Several lines of evidence indicate that they may also regulate the activity of 
the monomeric G proteins (Bhattacharya et al., 2004) as well as the non-G protein 
effectors such as the arrestins (Lefkowitz and Shenoy, 2005) and the src family Tyr 
kinases (Sun et al., 2007b).  These observations add to the already extensive 
signalling repertoire initiated by GPCRs making them truly one of the most 
interesting families of signalling proteins currently under investigation.  Each of the 
Gα subunits and the Gβγ complex will be discussed in more detail in the following 
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sections.  Additionally, the monomeric G proteins and GPCR-mediated G protein-
independent signalling will be reviewed. 
 
1.1.4.1  Gα 
Gα subunits contain two distinct domains joined by two linker regions (linker 1 and 
linker 2) (Lambright et al., 1994).  The GTPase domain is conserved throughout the 
G protein family and the α helical domain is unique to the Gα subunits.  Between 
these domains lies a deep cleft within which the guanine nucleotide is tightly bound.  
Evidence suggests that the α helical domain is divergent between G protein families.  
As such, this domain has been proposed to represent the Gα effector binding site 
(Masters et al., 1986, Coleman et al., 1994).  Additionally, it has been suggested that 
this region is involved in the interaction of the Gα subunits with the RGS proteins 
(Skiba et al., 1999, Kreutz et al., 2007).   
 
1.1.4.1.1 Gαs 
The initial demonstration by Sutherland and colleagues (which revealed that cAMP 
accumulation is stimulated by both glucagon and epinephrine) was the first in a 
series of milestones that would eventually lead to the successful purification of the 
Gαs G protein α subunits (Berthet et al., 1957, Rall and Sutherland, 1958, Sutherland 
and Rall, 1958).  It was later realised that there is a GTP-dependent step in the 
hormonal regulation of cAMP (the ATP used as a previous substrate was 
contaminated with sufficient GTP to disguise this requirement), data which at the 
time implied that there existed a stimulatory regulatory component (Rodbell et al., 
1971).  This was confirmed in a series of landmark papers (Ross and Gilman, 1977, 
Ross et al., 1978, Northup et al., 1980, Northup et al., 1983) and culminated in 
Alfred Gilman and Martin Rodbell being awarded the 1994 Nobel Prize for 
Physiology or Medicine.  We now know that it is the ubiquitously expressed Gαs G 
protein α subunits that mediate GPCR-dependent adenylyl cyclase activation.  Gαs 
can be activated by a number of well characterised GPCRs such as the β2-adrenergic 
receptor, the D1 dopamine receptor and the H2 histamine receptor.  In turn, 
membrane-bound adenylyl cyclase isoforms catalyse the conversion of adenosine-5-
triphosphate (ATP) to cAMP.  In 1968, Walsh and colleagues purified a cAMP-
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dependent protein kinase from rabbit skeletal muscle and, in doing so, identified 
what is now commonly known as protein kinase A (PKA) (Walsh et al., 1968).  PKA 
is a major effector of cAMP signalling and catalyses the phosphorylation of target 
proteins, such as src Tyr kinase (Schmitt and Stork, 2002), on Ser and Thr residues.  
In addition, evidence suggests that cAMP may exert PKA-independent effects.  
DeRooij and colleagues characterised Epac (exchange protein activated directly by 
cAMP) as a PKA-independent Rap1GEF (DeRooij et al., 1998). 
 
As well as mediating the activity of the adenylyl cyclase isoforms, Gαs is thought to 
be involved in the direct regulation of other effectors (table 1.1).  Ma and colleagues 
demonstrated that Gαs stimulates the Tyr kinase activity of src and hck by directly 
binding to their SH1 domains (Ma et al., 2000).  The Gα subunit was shown to alter 
their protein conformations facilitating an increase in substrate accessibility to their 
active sites.  Additionally, Roychowdhury and colleagues demonstrated that this Gα 
subunit upregulates the GTPase activity of tubulin and, in doing so, inhibits 
microtubule assembly (Roychowdhury et al., 1999).  This variety of effector 
regulation, however, is apparently not shared by Gαolf, another member of the Gs G 
protein family.  Gαolf was originally characterised in 1989 as a G protein α subunit 
specific for olfactory tissue (Jones and Reed, 1989).  It was shown to activate 
adenylyl cyclase isoforms and thus mediate increases in intracellular cAMP.  In 
addition, it was found to be highly homologous (88%) to Gαs.  Interestingly, Gαolf 
appears to be more widely expressed than first thought and has been detected in 
human digestive and urogenital epithelial cells (Regnauld et al., 2002) and rat 
placenta (Itakura et al., 2006).  Thus, this Gα subunit may be involved in the 
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Family Subunit Effector Reference 
Gαs Gαs
* Adenylyl cyclases ↑ (Northup et al., 1983) 
  Src Tyr kinases ↑ (Ma et al., 2000) 
  GTPase of tubulin ↑ (Roychowdhury et al., 1999) 
 Gαolf Adenylyl cyclases ↑ (Jones and Reed, 1989) 
 
Table 1.1 Primary effectors of Gαs subunits.  Table compiled from Neves et 
al., 2002.  G protein pathways.  Science, 296, 1636-1639; Cabrera-Vera et al., 2003.  
Insights into G protein structure, function and regulation.  Endocr Rev, 24, 765-781; 
Wettschureck and Offermanns, 2005.  Mammalian G proteins and their cell type 
specific functions.  Physiol Rev, 85, 1159-1204; Milligan and Kostenis, 2006.  
Heterotrimeric G proteins: a short history.  Br J Pharmacol, 147, s46-s55 and 




In the early studies, it was recognised that certain hormones (such as dopamine) 
could inhibit adenylyl cyclase and thus cause a resultant decrease in cAMP levels 
(DeCamilli et al., 1979).  However, the exact mechanism by which the inhibition of 
this enzyme came about was not fully understood.  Work by Katada and colleagues 
demonstrated that islet activating protein (IAP) (now commonly known as pertussis 
toxin (PTX)) dramatically decreases the α2-adrenergic receptor-mediated inhibition 
of glucose-induced insulin release (Katada and Ui, 1981).  Furthermore, the same 
group later showed that IAP is able to ADP ribosylate a 41 kDa membrane protein 
(Katada and Ui, 1982).  Purification of the IAP substrate from the rabbit liver by 
Bokoch and colleagues identified it as the Gαi subunit (Bokoch et al., 1984).  
Additionally, electrophoretic separation revealed that a 35 kDa protein and a 10 kDa 
protein were also present in both the Gi and the Gs preparations used by the authors, 
at the time suggesting that these G proteins were highly similar to Gt. 
 
The Gαi1-i3 subunits of the Gi/o family are widely and highly expressed.  Due to their 
high expression levels, GPCR-dependent activation of these Gα subunits has been 
postulated to be the major facilitator of Gβγ complex-mediated signalling.  
Functionally, they are frequently studied using PTX in second messenger 
experiments.  Indeed, PTX may ADP ribosylate most Gαi/o subunits, with the 
exception of Gαz, on a Cys residue close to their carboxy-terminus (Locht and 
Antoine, 1995).  This ribosylation results in the uncoupling of the G protein α 
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subunit from the GPCR.  It was this sensitivity to PTX that resulted in the naming of 
Gαo/other.  Huff and colleagues purified two proteins, each of approximately 40 kDa, 
from the bovine cerebral cortex which were substrates for ADP ribosylation by PTX 
(Huff et al., 1985).  Moreover, Pines and colleagues demonstrated the differential 
reactivity of antisera raised against Gαt1 to them (Pines et al., 1985).  These data then 
suggested that, as PTX was able to ADP ribosylate both proteins but that they were 
immunologically different, they were distinct yet related Gα subunits.  Gαo/other was 
so named as its function was then unclear. 
 
Several GPCRs such as the M2-muscarinic receptor, the D2 dopamine receptor and 
the prostaglandin EP3 receptor are known to directly interact with the Gαi/o subunits.  
Additionally, these Gα subunits mediate the activity of a wide variety of intracellular 
effectors (table 1.2).  Most are well established as inhibitors of the activity of 
adenylyl cyclase and thus cause a reduction in intracellular cAMP (Taussig et al., 
1994, Kozasa and Gilman, 1995).  Interestingly, the Gαo/other, the Gαt, the Gαz and the 
Gαg/gust Gα subunits possess a more restricted expression pattern than Gαi1-i3 
suggesting that they may have highly specialised functions within their respective 
tissues.  Indeed, Gαt is highly expressed in the retina and has been shown to potently 
activate phosphodiesterase enzymes resulting in the closure of Na+ channels (Fung et 
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Family Subunit Effector Reference 
Gαi/o Gαi1-i3 Adenylyl cyclases ↓ 
Src Tyr kinases ↑ 
Rap1GAP isoform 2 
recruitment ↑ 
Binds GRIN 
PI3 kinase isoform γ ↑ 
(Taussig et al., 1994) 
(Ma et al., 2000) 
(Mochizuki et al., 1999) 
 
(Chen et al., 1999) 
(Takeda et al., 1999) 
 Gαo/other
* Adenylyl cyclases ↓ 
Rap1GAP isoform 1 
sequestration ↓ 
Binds GRIN 
(Taussig et al., 1994) 
(Jordan et al., 1999) 
 
(Chen et al., 1999) 
 Gαt1-t2 cGMP PDE ↑ (Fung et al., 1981) 
 Gαz Adenylyl cyclases ↓ 
Binds GRIN 
(Kozasa and Gilman, 1995) 
(Chen et al., 1999) 
 Gαg/gust Unknown  
 
Table 1.2 Primary effectors of Gαi/o subunits.  Table compiled from Neves et 
al., 2002.  G protein pathways.  Science, 296, 1636-1639; Cabrera-Vera et al., 2003.  
Insights into G protein structure, function and regulation.  Endocr Rev, 24, 765-781; 
Wettschureck and Offermanns, 2005.  Mammalian G proteins and their cell type 
specific functions.  Physiol Rev, 85, 1159-1204; Milligan and Kostenis, 2006.  
Heterotrimeric G proteins: a short history.  Br J Pharmacol, 147, s46-s55 and 
references shown above.  * Gαo has two splice variants (Gαo1/A and Gαo2/B).  GRIN, G 
protein regulated inducer of neurite outgrowth; cGMP PDE, cyclic guanosine 
monophosphate phosphodiesterase.  ↑, enhances function; ↓, reduces function. 
 
1.1.4.1.3 Gαq/11 
The Gαq/11 pathway is the classical signalling pathway that stimulates the activity of 
phospholipase Cβ (PLCβ) to produce the intracellular messengers inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG).  IP3 triggers Ca
2+ release from 
intracellular stores and DAG recruits PKC to the membrane and activates it.  Gαq 
was purified by Taylor and colleagues and successfully characterised as a PTX 
insensitive 42 kDa PLCβ activator (Taylor et al., 1990).  Evidence suggests that the 
Gαq/11 subunits share a differential ability to activate each of the PLCβ isoforms.  
Indeed, the rank order of potency of such activation has been shown to be PLCβ1 ≥ 
PLCβ3 > PLCβ2 (Smrcka and Sternweis, 1993).  PLCβ4 is also activated by Gαq/11 
but the basal activity of this enzyme is significantly decreased by ribonucleotides 
thus making the determination of the extent of the activation difficult (Lee et al., 
1994).  In addition to the modulation of the activity of PLCβ, Gαq/11 may also 
directly affect the activity of other intracellular effectors (table 1.3).  Recently, Lutz 
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and colleagues identified p63 RhoGEF as a novel direct downstream effector of these 
Gα subunits (Lutz et al., 2005).  The authors demonstrated that the effect of this 
protein on Rho-induced transcriptional activity is mediated by protein-protein 
interactions between Gαq/11 and the p63 RhoGEF PH domain.  This study therefore 
provided a direct link between the Gq/11-coupled GPCRs and the regulation of the 
activity of the Rho monomeric G proteins.   
 
Family Subunit Effector Reference 
Gαq/11 Gαq PLCβs ↑ 
BTK ↑ 
p63 RhoGEF ↑ 
(Lee et al., 1992a) 
(Ma and Huang, 1998) 
(Lutz et al., 2005) 
 Gα11 PLCβs ↑ 
p63 RhoGEF ↑ 
(Lee et al., 1992a) 
(Lutz et al., 2005) 
 Gα14 PLCβs ↑ (Lee et al., 1992a) 
 Gα15/16
* PLCβs ↑ (Lee et al., 1992a) 
 
Table 1.3 Primary effectors of Gαq/11 subunits.  Table compiled from Neves et 
al., 2002.  G protein pathways.  Science, 296, 1636-1639; Cabrera-Vera et al., 2003.  
Insights into G protein structure, function and regulation.  Endocr Rev, 24, 765-781; 
Wettschureck and Offermanns, 2005.  Mammalian G proteins and their cell type 
specific functions.  Physiol Rev, 85, 1159-1204; Milligan and Kostenis, 2006.  
Heterotrimeric G proteins: a short history.  Br J Pharmacol, 147, s46-s55 and 
references shown above.  * Gα15 and Gα16 are mouse and human orthologues 
respectively (Wilkie et al., 1991).  BTK, Brutons Tyr kinase.  ↑, enhances function. 
 
Both the Gαq and the Gα11 subunits are almost ubiquitously expressed while the other 
Gα subunits of this family show a more restricted expression pattern.  Their 
biological importance is well established as evidenced by the fact that the deletion of 
both the Gαq and the Gα11 genes results in mouse embryonic lethality (embryonic 
day 10.5) arising from a defect in cardiomyocyte proliferation (Offermanns et al., 
1998).  Interestingly, given that Gα15 is primarily expressed in haematopoietic cells, 
Gα15 knockout mice show normal haematopoietic and inflammatory responses 
(Davignon et al., 2000).  Thus, the physiological significance of these Gα subunits is 
not currently clear.  Gα14 is primarily expressed in the kidney, the lung and the 
spleen.  As with Gα15/16, the physiological relevance of this Gα subunit is currently 
undefined.  A recent study demonstrated that Gα14 activation can lead to the 
activation of signal transducer and activator of transcription 3 (STAT3) (Lo and 
Wong, 2004).  Furthermore, STAT3 has been characterised as a potent oncogenic 
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molecule that plays a role in the formation of lung adenocarcinomas (Qu et al., 
2009).  These data, when viewed collectively, may suggest a role for Gα14 in the 
pathological context. 
 
Direct pharmacological inhibition of the Gαq/11 G protein subunits has only recently 
become possible.  Takasaki and colleagues developed YM-254890, a specific Gαq/11 
inhibitor (Takasaki et al., 2004).  The authors showed that this compound potently 
and completely inhibits Gαq/11-induced gene transcription.  Furthermore, the 
mechanism by which this inhibition comes about was characterised and shown to 
involve blockade of GDP/GTP exchange.  GDP exchange for GTP is, as reviewed, 
essential for Gα subunit activation and consequent downstream signalling.  This 
inhibitor therefore represents a powerful tool for the study of Gαq/11-mediated 
signalling and, as such, has been used in several of the studies detailed within this 
thesis.   
 
1.1.4.1.4 Gα12/13 
Of the four G protein families, the G12/13 family is now perhaps the most intensively 
studied.  The two members, G12 and G13, were discovered through sequence 
homology (< 45%) with known Gα subunits and are expressed ubiquitously 
(Strathmann and Simon, 1991, Milligan et al., 1992).  They have received 
considerable attention as regulators of both cellular morphology and gene 
transcription.  Indeed, constitutively active forms of both α subunits stimulate actin 
stress fibre formation and focal adhesion assembly in quiescent Swiss 3T3 cells 
(Buhl et al., 1995).  Similarly, in Gαq/11 knockout MEF cells, agonist stimulation of 
the serotonin 5-HT2C receptor leads to the rapid formation of stress fibres in a Rho-
dependent manner (Gohla et al., 1999).  In Gα13 knockout MEF cells, stimulation of 
the same receptor has no cytoskeletal effect.  At the level of gene transcription, Mao 
and colleagues demonstrated that constitutively active Gα12 (Gα12Q231L), Gα13 
(Gα13Q226L), Rho (RhoG14V) and cdc42 (cdc42G12V) induce serum response 
element- (SRE) promoted luciferase activity (Mao et al., 1998a).  Furthermore, 
specific inhibition of Rho with C. botulinum C3 transferase (C3) completely inhibits 
the luciferase signal induced by the Gα12, the Gα13 and the Rho mutants.  More 
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recently, Orth and colleagues showed that P. multocida toxin (PMT) induces SRE-
driven transcription in HEK293 cells (Orth et al., 2005).  Inhibition with either 
dominant negative Gα13 (Gα13G225A) or YM-254890 significantly reduces the 
PMT-mediated luciferase signal.  The authors went on to show that PMT stimulates 
Rho activation in a Gαq/11 knockout MEF cell line and that this activation is not 
inhibited by YM-254890.   
 
The early studies described previously implied that a link existed between Gα12/13 
and Rho.  Subsequently this was confirmed and the activation of Rho was shown to 
involve the interaction of Gα12 and Gα13 with RhoGEFs.  Hart and colleagues 
demonstrated that Gα13 and, to a lesser extent, Gα12 bind to p115 RhoGEF (Hart et 
al., 1998).  Furthermore, Gα13, but not Gα12, stimulates its capacity to catalyse 
guanine nucleotide exchange on and thus activation of Rho.  Similarly, Fukuhara and 
colleagues showed that the Lsc homology domain of PDZ RhoGEF forms stable 
complexes with Gα12 and Gα13 and suggested that this RhoGEF mediates the 
activation of Rho by these G protein α subunits (Fukuhara et al., 1999).  More 
recently, Suzuki and colleagues characterised the interaction of leukaemia-associated 
RhoGEF (LARG) with Gα12 and Gα13 (Suzuki et al., 2003).  Analogous to earlier 
results obtained with p115 RhoGEF (Kozasa et al., 1998), the RGS domain of LARG 
was shown to possess GAP activity for both Gα12 and Gα13.  Furthermore, LARG 
activity was demonstrated to be stimulated by constitutively active Gα13 
(Gα13Q226L) and, when LARG is Tyr phosphorylated by Tec kinase, constitutively 
active Gα12 (Gα12Q229L).  These data therefore provide strong evidence to indicate 
that the G12/13 G proteins positively regulate Rho.  It is important to note, however, 
that such regulation by GPCRs is not limited to G12/13-coupled receptors.  Vogt and 
colleagues showed that Gαq/11 also activates Rho in PTX treated Gα12/13 knockout 
cells (Vogt et al., 2003).  Given that the potency of this activation is approximately 
twenty-fold lower than that observed in PTX treated Gαq/11 knockout cells, the 
authors hypothesised that RhoGEF proteins are less sensitive to regulation by the 
Gαq/11 subunits than by the Gα12/13 subunits.  The Gα12/13 subunits along with their 
primary effectors are summarised in table 1.4. 
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Family Subunit Effector Reference 
Gα12/13 Gα12 PDZ RhoGEF ↑ 
LARG* ↑ 
RasGAP isoform 1 ↑ 
BTK ↑ 
(Fukuhara et al., 1999) 
(Suzuki et al., 2003) 
(Jiang et al., 1998) 
(Jiang et al., 1998) 
 Gα13 PDZ RhoGEF ↑ 
LARG ↑ 
Radixin ↑ 
p115 RhoGEF ↑ 
(Fukuhara et al., 1999) 
(Suzuki et al., 2003) 
(Vaiskunaite et al., 2000) 
(Hart et al., 1998) 
 
Table 1.4 Primary effectors of Gα12/13 subunits.  Table compiled from Neves 
et al., 2002.  G protein pathways.  Science, 296, 1636-1639; Cabrera-Vera et al., 
2003.  Insights into G protein structure, function and regulation.  Endocr Rev, 24, 
765-781; Wettschureck and Offermanns, 2005.  Mammalian G proteins and their cell 
type specific functions.  Physiol Rev, 85, 1159-1204; Milligan and Kostenis, 2006.  
Heterotrimeric G proteins: a short history.  Br J Pharmacol, 147, s46-s55 and 
references shown above.  * Gα12 only stimulates the RhoGEF activity of LARG when 
LARG is Tyr phosphorylated by Tec kinase.  BTK, Brutons Tyr kinase.  ↑, enhances 
function. 
 
Interestingly, there is an extremely strong trend for coincident coupling of a GPCR to 
members of the G12/13 and the Gq/11 G protein families.  Additionally, synchronised 
signalling by both Gq/11 and G12/13 has previously received attention at the level of 
gene transcription, cellular transformation and the activation of the mitogen activated 
protein kinase (MAPK) cascades (Fukuhara et al., 2000, Gratacap et al., 2001, 
Marinissen et al., 2003, Orth et al., 2005).  Such a strong trend in GPCR coupling 
specificity has been proposed to suggest that certain GPCR structural elements that 
underpin G protein activation may be conserved between Gq/11- and G12/13-coupled 
GPCRs (Riobo and Manning, 2005).  This hypothesis, however, is difficult to 
reconcile with the fact that not all Gq/11-coupled receptors interact with G12/13 and, 
reciprocally, not all G12/13-coupled receptors interact with Gq/11. 
 
The Gα12/13 subunits have frequently been studied in relation to cellular proliferation, 
migration and transformation (Kelly et al., 2007).  It is unsurprising then that, 
pathologically, they have implied roles in tumour cell invasion and metastasis.  Kelly 
and colleagues demonstrated that Gα12 is more highly expressed in invasive prostate 
adenocarcinomas than in benign prostate tissue and that expression of constitutively 
active Gα12/13 mutants (Gα12Q231L and Gα13Q226L respectively) in prostate cancer 
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cell lines increases cell invasion in a Rho-dependent manner (Kelly et al., 2006b).  
Additionally, the authors documented similar findings with regards to breast cancers 
(Kelly et al., 2006a).  Constitutively active Gα12/13 (Gα12Q231L and Gα13Q226L 
respectively) increases breast cancer invasion in vitro, inhibition of Gα12/13 reduces 
metastatic dissemination of breast cancer cells in vivo and Gα12 is more highly 
expressed in invasive adenocarcinomas of the breast.  These proposed pathological 
roles in what are, generally, migratory cellular responses are reflected well in work 
by Stefan Offermanns (Offermanns et al., 1997).  Disruption of GNA13, the gene 
encoding Gα13, was shown to result in mouse germ line embryonic lethality as a 
result of a failure to develop a functional vascular system due to impaired 
angiogenesis.  Significantly, in vitro these data were shown to correlate with the 
complete abrogation of thrombin-induced cell migration in Gα13 knockout cells 
suggesting that Gα13 is an absolute requirement for angiogenesis to occur. 
 
1.1.4.2  Gβγ 
The Gβ subunit possesses an amino-terminal α helix followed by a β propeller 
structure composed of seven β sheets (Lambright et al., 1996, Dupre et al., 2008).  
Each β sheet is made up of four antiparallel β strands and the structure is linked by 
WD repeats.  The Gγ subunit is made up of two α helices.  The amino-terminal α 
helix forms a coiled-coil with the amino-terminal α helix of the Gβ subunit and the 
carboxy-terminal α helix interacts with the β propeller region.  The interaction 
between the Gα subunit and the Gβγ complex involves the interaction of residues 
within the switch regions of the Gα subunit (which are flexible in the Gα-GDP 
inactive conformation) with residues at the top of the β propeller domain.  
Additionally, residues in the amino-terminal α helix of the Gα subunit interact with 
residues on the side of the β propeller. 
 
Historically, the Gβγ complex was regarded as little more than a passive membrane 
anchor of the Gα subunit.  Consistent with this role, isoprenylation of the Gγ subunit 
at a Cys residue in the carboxy-terminal tail is thought to be essential for membrane 
localisation (Clapham and Neer, 1997).  However, evidence now suggests that the 
Gβγ complex, when freed from the Gα-GTP subunit, can regulate the activity of 
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various intracellular effectors (table 1.5).  The first experimental verification of this 
came to light when Logothetis and colleagues demonstrated that the Gβγ complex 
activates a K+ channel in cardiac atrial cells (Logothetis et al., 1987).  Since then, a 
plethora of different effectors regulated by the Gβγ complex has been uncovered.  
Upon GPCR activation, conformational changes in the switch regions of the Gα 
subunits reduce their affinity for the Gβ subunits and promote the dissociation of Gα-
GTP and the Gβγ complex (Lambright et al., 1994, Lambright et al., 1996).   
 
Family Effector Reference 




isoforms 1, 5, 6 and 8 ↓ 
 
Adenylyl cyclase 
isoforms 2, 4 and 7 ↑ 
 
K+ channels ↑ 
Ca2+ channels ↓ 
PI3 kinases ↑ 
 
Protein kinase D ↑ 
Ca2+-calmodulin-
mediated activation of 
calmodulin kinase 
isoform 2 ↓ 
Tsk kinase ↑ 
 
GTPase of dynamin 1 ↑ 
Src Tyr kinases ↑ 
(Camps et al., 1992) 
(Langhans-Rajasekaran et al., 
1995) 
(Tang and Gilman, 1991) 
(Bayewitch et al., 1998) 
(Steiner et al., 2006) 
(Tang and Gilman, 1991) 
(Gao and Gilman, 1991) 
(Yoshimura et al., 1996) 
(Logothetis et al., 1987) 
(Ikeda, 1996) 
(Stephens et al., 1994) 
(Tang and Downes, 1997) 
(Jamora et al., 1999) 




(Langhans-Rajasekaran et al., 
1995) 
(Lin and Gilman, 1996) 
(Shajahan et al., 2004) 
(Gentili et al., 2006) 
 
Table 1.5 Primary effectors of the Gβγ complex.  Table compiled from 
Cabrera-Vera et al., 2003.  Insights into G protein structure, function and regulation.  
Endocr Rev, 24, 765-781; Wettschureck and Offermanns, 2005.  Mammalian G 
proteins and their cell type specific functions.  Physiol Rev, 85, 1159-1204; Milligan 
and Kostenis, 2006.  Heterotrimeric G proteins: a short history.  Br J Pharmacol, 
147, s46-s55 and references shown above.  BTK, Brutons Tyr kinase.  ↑, enhances 
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1.1.4.3  Monomeric G Proteins 
The monomeric G protein family may be subdivided, on the basis of structural 
similarity, into five subfamilies (Ras, Rho, Rab, ARF and Ran) (Matozaki et al., 
2000, Bhattacharya et al., 2004, Bos et al., 2007).  In general, the Ras subfamily 
regulates cell signalling events that culminate in gene transcriptional responses, the 
Rho subfamily function as actin cytoskeleton regulators and can also mediate gene 
transcription, the Rab and the ARF subfamilies control vesicular trafficking between 
different cellular compartments and the Ran subfamily regulates nucleocytoplasmic 
transport.  As with their heterotrimeric counterparts, the monomeric G proteins exist 
in a GDP-bound inactive state which is converted into an active GTP-bound state by 
the association of a guanine nucleotide exchange factor (GEF) (the activity of which 
is regulated by an upstream signal) (Takai et al., 2001).  GTP binding induces a 
conformational change in the effector binding domain of the protein and the 
interaction with target molecules ensues.  Switching off of the system is mediated by 
the intrinsic GTPase activity of the monomeric G protein and the subsequent 
hydrolysis of GTP to GDP.  Interaction with a GAP accelerates this process. 
 
The major effectors of the Ras subfamily are Raf kinases, phosphatidylinositol-3-
kinase (PI3 kinase) isoforms and RalGEFs (Shields et al., 2000, Eisenberg and 
Henis, 2008).  In regulating these and other signalling molecules, Ras monomeric G 
proteins control processes involved in cell growth, proliferation, differentiation and, 
enigmatically, apoptosis (Cox and Der, 2003).  Thus, Ras regulation of cell cycle 
progression is complex and is thought to involve the interplay of multiple signalling 
cascades.  Indeed, constitutively active Ras induces a proliferative phenotype in 
human thyroid epithelial cells in vitro (Gire et al., 2000).  Conversely, Ras has been 
demonstrated to effectively promote apoptosis through the Raf pathway (Kauffmann-
Zeh et al., 1997).  These data therefore suggest that the combined outcome of Ras-
induced signalling is likely to determine final cellular fate. 
 
Like Ras, the Ras homologue (Rho) proteins serve as key regulators of extracellular 
stimulus-mediated signalling and regulate cytoskeletal reorganisation, cell cycle 
progression and gene expression.  The best characterised members of this subfamily 
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are Rho, Rac and cdc42 (Wennerberg et al., 2005).  With reference to the regulation 
of the actin cytoskeleton, Rho mediates the formation of stress fibres and focal 
adhesions (Ridley and Hall, 1992) while Rac induces the formation of lamellipodia 
(Ridley et al., 1992).  Cdc42 regulates the formation of filopodia (Nobes and Hall, 
1995).  For some time now, it has been appreciated that Rho may be inhibited by 
Rac/cdc42 and, conversely, Rac/cdc42 may be inhibited by Rho.  The molecular 
mechanisms underlying this mutual antagonism are poorly understood.  Sander and 
colleagues demonstrated that sustained Rac/cdc42 activity results in the inhibition of 
the activity of Rho and correlates with decreased levels of Rho-GTP (Sander et al., 
1999).  The authors speculated that the increased activity of a RhoGAP or the 
decreased activity of a RhoGEF was central to their observations as the inhibition of 
Rho activity appeared to occur either upstream of or directly at the monomeric G 
protein level.  Their conclusions are supported by an earlier study by Leeuwen and 
colleagues which showed that the Rac-induced inhibition of Rho signalling is 
completely overcome by the expression of constitutively active Rho (Leeuwen et al., 
1997).  These data therefore imply that GTP loading on Rho is the target of the Rac-
/cdc42-mediated negative regulation.  More recently, and in agreement with this 
suggestion, Nimnual and colleagues provided evidence to suggest that the Rac-
induced production of reactive oxygen species inhibits the low molecular weight 
protein Tyr phosphatase and thus increases the Tyr phosphorylation of p190 
RhoGAP (Nimnual et al., 2003).  Furthermore, it has been reported that p21 activated 
kinase 1 (Pak1) binds, in a Rac-dependent manner, to p115 RhoGEF and thus 
disrupts thrombin-induced Rho activation by an as yet unknown mechanism 
(Rosenfeldt et al., 2006).  Finally, Barac and colleagues demonstrated that PAK4, a 
cdc42 effector, directly interacts with and phosphorylates PDZ RhoGEF (Barac et 
al., 2004).  Such phosphorylation results in the abolishment of the ability of this 
RhoGEF to mediate Gα12/13-induced GTP loading on Rho.   
 
As highlighted in the previous paragraph, it is now also generally accepted that 
Rac/cdc42 may be inhibited by Rho.  One of the earliest pieces of evidence to 
support this interpretation came from the work of Leeuwen and colleagues in 1997 
(Leeuwen et al., 1997).  The authors demonstrated that Rac-induced neurite 
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formation is potentiated by transfecting a dominant negative Rho mutant into an 
NIE115 neuroblastoma cell line.  S19NRho, the dominant negative the authors used, 
is thought to inhibit endogenous Rho function by forming unproductive complexes 
with RhoGEFs and thereby halting GDP/GTP exchange (Hart et al., 1998).  More 
recently, Yamaguchi and colleagues showed that transfection of constitutively active 
Gα12 or Rho (Gα12Q231L or RhoG14V respectively), or incubation with Y-27632 
(an inhibitor of Rho kinase (ROCK)), completely abolishes the Rho-induced 
inhibition of Rac in PC12 cells (Yamaguchi et al., 2001).  These results suggest that 
Rho-mediated inhibition of Rac occurs downstream of Rho but is reliant on Rho-
GTP loading.  Furthermore, they imply that ROCK may play a central role.  The 
latter part of this suggestion is in contrast to a recent paper in which ROCK was 
shown to be uninvolved in the Rho-induced Rac inhibition in vascular smooth 
muscle cells (Takashima et al., 2008).  Thus, the Rac- and the Rho-mediated 
pathways oppose each other by a mechanism which still remains to be fully 
elucidated.  It is recognised, however, that the balance between these monomeric G 
proteins plays a prominent role in the regulation of cellular morphology. 
 
Rab monomeric G proteins regulate vesicular protein transport during export 
trafficking, endocytosis, exocytosis and endosome fusion.  They constitute the largest 
group of monomeric G proteins and each member has a distinct intracellular 
localisation (Zerial and McBride, 2001).  Multiple members of this subfamily have 
been reported to regulate transport of GPCRs from the ER to the Golgi as well as 
their trafficking between early, late and recycling endosomes and lysosomes 
(Seachrist and Ferguson, 2003).  Indeed, the β2-adrenergic receptor has been shown 
to colocalise with Rab5 in early endosomes following isoproterenol stimulated 
internalisation (Moore et al., 1995).  Furthermore, expression of Rab5Q79L (a 
constitutively active Rab5 mutant) has been demonstrated to significantly increase 
the rate of dopamine-induced D2 receptor endocytosis (Iwata et al., 1999).  
Rab5S34N (a dominant negative Rab5 mutant) had the opposite effect on both the D2 
dopamine receptor (Iwata et al., 1999) and the β2-adrenergic receptor (Seachrist et 
al., 2000).  Expression of a dominant negative Rab4 mutant (Rab4N121I) prevents 
plasma membrane recycling of the β2-adrenergic receptor from endosomes (Seachrist 
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et al., 2000) and expression of a Rab7 dominant negative mutant (Rab7T22N) 
prevents the lysosomal targeting of the human CXCR2 chemokine receptor after 
prolonged agonist exposure (Fan et al., 2003).  These data thus confirm that the Rab 
family of monomeric G proteins are intricately involved in the regulation of GPCR 
trafficking. 
 
The ARF subfamily of monomeric G proteins may associate with rhodopsin 
subfamily GPCRs which possess the NPxxY motif at the intracellular end of TM7 
(Mitchell et al., 1998).  They are thought to play an essential role in regulating 
membrane trafficking events involved in endocytosis.  Additionally, accumulating 
evidence indicates that the ARF proteins are important regulators of the actin 
cytoskeleton and are involved in the regulation of cell adhesion, migration and 
neurite outgrowth (Myers and Casanova, 2008).  One way in which ARFs are 
thought to influence the actin cytoskeleton is through their effects on the lipid 
microenvironment.  All ARFs are activators of phospholipase D (PLD) which 
cleaves phosphatidylcholine to generate phosphatidic acid (PA).  PA alters the 
physical properties of membrane bilayers and, as such, facilitates membrane bending 
at sites of vesicle formation.  Additionally, some studies suggest that PA may 
stimulate stress fibre formation (Ha and Exton, 1993) or play a role in membrane 
ruffling (O'Luanaigh et al., 2002).  Members of the ARF subfamily have been found 
in all eukaryotic organisms examined to date and show a high degree of sequence 
conservation (Nie et al., 2003).   
 
Ran proteins are known for their role in nucleocytoplasmic transport of both 
ribonucleic acid (RNA) and protein molecules.  Unlike other monomeric G proteins, 
their function is dependent on a spatial gradient of the active GTP-bound form 
(Weis, 2003).  There is a high concentration of Ran-GTP in the nucleus which 
facilitates the directionality of nuclear import and export by direct interaction with 
members of the importin and exportin protein family of related transport carriers 
respectively.  Additionally, Ran has been implicated in the regulation of mitotic 
spindle assembly, DNA replication and nuclear envelope assembly (Li et al., 2003). 
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1.1.5  GPCR-Mediated G Protein-Independent Signalling 
Increasing evidence indicates that GPCRs may relay signals independently of 
heterotrimeric G protein activation.  Indeed, it has been shown that they may interact 
with non-G protein effectors such as the Janus kinases (JAKs) (Ali et al., 2000) and 
the src family Tyr kinases (Cao et al., 2000).    GPCR-mediated regulation of the src 
family Tyr kinases will, in this section, be briefly discussed. 
 
Src is a non-receptor Tyr kinase involved in the regulation of many physiological 
responses including cell proliferation, survival, differentiation, adhesion and 
migration (Sun et al., 2007b).  It is a member of the src family of protein Tyr kinases 
(SFK) along with lyn, hck, lck, blk, fyn, yes and fgr.  All members of the SFK share 
a similar domain arrangement and possess an amino-terminal region followed by a 
src homology 3 (SH3) domain, a src homology 2 (SH2) domain, a kinase or src 
homology 1 (SH1) domain and a carboxy-terminal tail (Ingley, 2008).  The activity 
of src is highly regulated by intramolecular interactions involving the SH3, the SH2 
and the kinase domains.  Inactive src exists in a conformation where the SH3 and the 
SH2 domains fold back against the kinase domain making intramolecular 
interactions that lock the kinase in the inactive conformation (Boggon and Eck, 
2004).  Src activation is initiated by engagement of an activating protein with either 
the SH2 or the SH3 domain.  This results in the disruption of the intramolecular 
constraints within the molecule.  Additionally, dephosphorylation of the 
autoinhibitory Tyr residue in the carboxy-terminal tail results in kinase activation.  
These activation events enable autophosphorylation of a Tyr residue within the 
kinase domain and the consequent induction of full catalytic activity.   
 
It is widely accepted that src can be activated by many of the canonical signalling 
pathways initiated by GPCRs including those mediated by arrestins.  Indeed, the 
neurokinin NK1 receptor has been shown to, upon substance P stimulation, form a 
scaffolding complex comprising the internalised receptor, β-arrestin and src (DeFea 
et al., 2000).  Similarly, the interleukin 8 activated CXCR1 receptor stimulates the 
rapid formation of β-arrestin complexes with hck and fgr (Barlic et al., 2000).  
Formation of β-arrestin-hck complexes leads to hck activation.  These data therefore 
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provide evidence to indicate that GPCR-arrestin complexes may interact with and 
activate members of the SFK.  However, an evolving body of evidence suggests that 
src may associate with, and be activated directly by, the intracellular domains of 
certain GPCRs independently of G proteins or arrestin scaffolds.  In line with this, 
based on the observation that src activation by the β2-adrenergic receptor is possible 
in PTX treated Gαs and β-arrestin knockout cells, taken together with the finding that 
this GPCR activates src in an in vitro system in the absence of G proteins, Sun and 
colleagues proposed that the β2-adrenergic receptor-mediated activation of src is 
initiated by the formation of a direct interaction between the two signalling proteins 
(Sun et al., 2007a).  Fan and colleagues earlier suggested a similar scheme (Fan et 
al., 2001).  Moreover, the authors proposed that association of src with the β2-
adrenergic receptor involves an interaction of the GPCR with the src SH2 domain 
(the carboxy-terminal tail of this receptor possesses a Tyr residue (Y350) flanked by 
a putative SH2 binding domain).  It was suggested that, upon agonist-induced 
phosphorylation of this Tyr residue, the SH2 binding domain becomes functional and 
recruits SH2 domain containing partners.  Similarly, Yun and colleagues showed that 
that the carboxy-terminus of the serotonin 5-HT6 receptor interacts with fyn and that 
this interaction is mediated by the fyn SH3 domain (Yun et al., 2007).  Activation of 
this GPCR leads to the fyn-dependent activation of extracellular signal regulated 
kinase (ERK).  These studies therefore provide support for the suggestion that the 
GPCR-mediated activation of src and the consequent src-dependent signalling may 
occur independently of both G protein activation and arrestin binding. 
 
Of particular interest, in relation to the data presented within this thesis, is the 
cytoskeletal reorganising potential of this Tyr kinase.  For example, the protein 
product of the viral oncogene v-src has been shown to facilitate the rapid induction 
of membrane ruffling (Boschek et al., 1981).  More recently, a constitutively active 
src mutant, in cooperation with Tiam1, was demonstrated to markedly induce the 
formation of lamellipodia (Servitja et al., 2003).  The authors showed that Tiam1, a 
specific RacGEF, is Tyr phosphorylated by src and that this phosphorylation results 
in the pronounced elevation of Rac-GTP.  Src has additionally been shown to 
directly Tyr phosphorylate and thus activate FRG, a specific cdc42GEF, (Miyamoto 
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et al., 2003) and to, together with cdc42, Tyr phosphorylate Vav2, another RacGEF 
(Kawakatsu et al., 2005).  Thus, src is known to promote the activation of Rac.  
Indeed, laminin-induced activation of Rac has been proposed to be initiated by 
members of the SFK (Zhou et al., 2007) and, very recently, epidermal growth factor 
(EGF) has been shown to stimulate Rac activation through a src and PI3 kinase-
dependent mechanism (Dise et al., 2008).  In the latter study, Rac activation was 
associated with a doubling in the number of cells with lamellipodial extensions.   
 
Interestingly, the src-mediated regulation of Rac does not appear to be exclusive to 
the regulation of RacGEF activity.  Indeed, members of the SFK have also been 
shown to negatively regulate a RacGAP, β2-chimaerin, thereby elevating Rac-GTP 
levels (Kai et al., 2007).  Furthermore, the ability of src to regulate the activity of the 
members of the monomeric G protein family is not restricted to the modulation of 
Rac/cdc42.  Brandt and colleagues showed that PKC-induced src-dependent actin 
reorganisation correlates with a reduction in the activity of Rho (Brandt et al., 2002).  
The link between src and a reduction in Rho activity was revealed to be p190 
RhoGAP (which is Tyr phosphorylated and thus activated by src downstream of 
PKC).  It is therefore likely that the SFK enhance Rac activity and inhibit Rho 
activity through both the activation of RacGEFs and RhoGAPs and the inhibition of 
RacGAPs.  This raises the possibility that GPCRs which bind and stimulate src 
directly may also promote the activity of Rac and inhibit the activity of Rho in a G 
protein-independent manner.  In so doing, these receptors may play a role in 
processes such as gene transcription and cytoskeletal reorganisation.   
 
1.1.6  Summary 
GPCRs share a common structural architecture, are synthesised and trafficked in 
similar ways, are transited into their active state by a series of agonist-induced 
conformational changes and may signal through both G protein-dependent and -
independent pathways.  In the following section, ligand-induced receptor activation 
and signalling will be reviewed. 
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1.2  Ligand-Induced Receptor Activation and Signalling 
Early receptor theory was consistent with the notion that a single receptor existed in 
only two conformations – inactive and active.  Agonist binding was proposed to shift 
the receptor from the inactive to the active conformation.  Additionally, it was 
thought that, once activated, a given GPCR could only modulate the activity of a 
single signalling cascade.  As will be discussed, however, increasing evidence 
suggests that there exist multiple GPCR conformations which may selectively alter 
the activity of different intracellular signalling pathways.  Furthermore, different 
ligands can stabilise these different receptor conformations.  This phenomenon was 
originally termed stimulus directed trafficking (Kenakin, 1995).  In order to provide 
a comprehensive review, it is first necessary to briefly revisit how agonist binding 
initiates receptor activation. 
 
1.2.1  Agonist Binding and Receptor Activation 
As described in the preceding sections, binding of an agonist to a GPCR induces a 
conformational change of the receptor.  Current thinking proposes that this change in 
conformation involves the disruption of intramolecular interactions within the GPCR 
that constrain the receptor in the inactive state (Gether, 2000, Lu et al., 2002, Kobilka 
and Deupi, 2007).  This disruption may be facilitated by two separate mechanisms.  
Firstly, agonist binding is simply thought to disrupt the intramolecular restraint 
network.  In support of this theory, experimental evidence has shown that the 
mutation of specific residues within a GPCR may result in constitutive receptor 
activity.  For example, Lu and colleagues showed that the mutation of Leu116 
(L116A) in the M1-muscarinic receptor results in constitutive receptor activation (Lu 
and Hulme, 1999).  Furthermore, in a subsequent study, the authors suggested that 
Leu116 interacts with Phe374 and in doing so stabilises the GPCR inactive state (Lu 
and Hulme, 2000).  Thus, disruption of this interaction induces the transition of the 
receptor to an active conformation.  Secondly, agonists are thought to facilitate the 
creation of new intermolecular and intramolecular interactions.  These new 
interactions stabilise the receptor in an active conformation.  Indeed, no constitutive 
activity was observed upon the mutation of Cys279 (C279A or C279Y) or Asn315 
(N315A) in the GnRH receptor (the mutation of equivalent residues has previously 
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been shown to cause the constitutive activation of other GPCRs such as the β2-
adrenergic receptor (Shi et al., 2002) and the H1 histamine receptor (Jongejan et al., 
2005)) suggesting that disruption of these interactions is not sufficient to obtain a 
fully active receptor state (Lu et al., 2007).  Both mechanisms described above 
probably occur to some degree at a given receptor but it is thought that one may 
serve as the dominant activation facilitator.   
 
Interaction between an agonist and a receptor has been suggested to involve an initial 
interaction between the receptor and one structural group of the agonist (Kobilka, 
2004, Swaminath et al., 2004, Kobilka and Deupi, 2007).  Binding of the remaining 
structural groups is proposed to occur in a sequential manner.  Specifically, binding 
of an agonist structural group (A) to a receptor facilitates the formation of a set of 
energetically favourable interactions between the agonist and the GPCR and thus 
increases the energetic probability of an interaction between the receptor and a 
second agonist structural group (B).  This interaction in turn increases the energetic 
probability of an interaction between the GPCR and a third agonist structural group 
(C).  Importantly, each sequential interaction between the receptor and A, B and C 
results in the stabilisation of a distinct intermediate conformational state.  Indeed, 
monitoring of a fluorescently labelled β2-adrenergic receptor revealed the formation 
of distinct consecutive agonist-induced receptor active conformations over a period 
of approximately 500 seconds (Swaminath et al., 2004). 
 
GPCRs are therefore not simply constrained to two states (inactive and active) but 
may, in response to agonist binding, adopt a series of distinct receptor conformations.  
Thus, the possibility that these agonist-induced conformations have signalling 
relevance arises.  In a recent review, Brian Kobilka elegantly summarises work from 
his laboratory on the β2-adrenergic receptor which confirms this (Kobilka, 2007).  
These studies, which shall later be discussed, suggest that agonists of the same 
receptor can stabilise different receptor conformations and thus modulate different 
intracellular signalling pathways.  For the remainder of this review, I will refer to this 
concept as ligand-induced selective signalling (LiSS) (figure 1.7). 
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1.2.2  Ligand-Induced Selective Signalling 
LiSS is not a new concept and has been extensively reviewed by Terry Kenakin 
(Kenakin, 1995, Kenakin, 2001, Kenakin, 2003).  Over the years, it has variously 
been referred to as ligand directed trafficking of receptor signalling, stimulus 
directed trafficking, functional selectivity, biased agonism and agonist-induced 
signal trafficking (Kenakin, 1995, Galandrin et al., 2007).  While the former three 
terms used to describe this phenomenon are essentially accurate, biased agonism and 
agonist-induced signal trafficking may be interpreted as being unfortunate 
misnomers (Millar et al., 2004).  Indeed, these terms neglect historical 
pharmacological nomenclature given that experimental evidence suggests that both 
agonists and ligands originally classified as antagonists can signal through GPCRs 
(Yano et al., 1992, Maudsley et al., 2004).   
 
One of the early demonstrations of GPCR conformation-induced selective signalling 
states came from mutational studies of the α1B-adrenergic receptor (Perez et al., 
1996).  Mutation of Cys128 in TM3 (C128F) constitutively activated the receptor.  
Furthermore, this constitutive activation was shown to be selective in that it only 
resulted in the activation of a PLC-mediated pathway and not one mediated by 
phospholipase A2 (PLA2).  Previously, the same group had shown that the PLC- and 
the PLA2-induced pathways are activated by coupling of the receptor to different G 
proteins (Gq/11 and Gi/o respectively) (Perez et al., 1993).  Similarly, mutation of 
Cys116 in TM3 of the β2-adrenergic receptor (C116F) results in constitutive activation 
of NHE1, a Na+-H+ exchanger, without activating a Gs-mediated pathway (Zuscik et 
al., 1998).  Both studies therefore indicate that mutation-induced receptor 
conformational changes can alter the output of distinct intracellular signalling 
pathways.   
 
In 2001, Ghanouni and colleagues studied fluorescence lifetime analysis of a 
fluorophore covalently attached to Cys265 in ICL3, at the intracellular end of TM6, of 
the β2-adrenergic receptor (Ghanouni et al., 2001).  The authors demonstrated that a 
full agonist, isoproterenol, and two partial agonists, salbutamol and dobutamine, 
provoke different fluorescence lifetime distributions suggesting that they induce 
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different receptor conformational states.  In support of this conclusion, earlier 
observations by Gether and colleagues revealed that isoproterenol and propranolol 
could stimulate distinct changes in receptor conformation (Gether et al., 1995).  
Using a β2-adrenergic receptor covalently labelled with a fluorescent probe which 
was sensitive to the polarity of the surrounding environment, the authors showed that 
isoproterenol stimulation induces opposing effects on baseline fluorescence. 
 
Taken together, the studies already discussed provide some good examples of the 
ability of ligands to provoke different conformations of the same GPCR and the 
ability of mutation-induced changes in receptor conformation to propagate signals 
through selective downstream signalling pathways.  Theoretically, these results 
therefore suggest that different ligands can selectively modulate the activity of 
different intracellular signalling pathways by stimulating specific changes in the 
conformation of a given receptor.  Swaminath and colleagues provided convincing 
evidence to support this proposal (Swaminath et al., 2004).  Specifically, distinct 
agonist-induced receptor conformations were shown to correlate with the activation 
of discrete signalling cascades.  Dopamine, which lacks a hydroxyl group that is 
present in both norepinephrine and epinephrine, induced only a fast conformational 
change and stimulated Gs activation but not receptor internalisation.  In contrast, both 
norepinephrine and epinephrine induced a fast and a slow conformational change and 
stimulated Gs activation and receptor internalisation.  Furthermore, a group of 
ligands (1-2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid 
diethylamide (LSD)) with a similar ability to activate Gq/11 by binding to the 
serotonin 5-HT2C receptor display marked differences in their ability to activate Gi3 
(Cussac et al., 2002).   
 
Although GPCRs are renowned for their ability to signal through G proteins, 
evidence presented earlier in this review indicates that that they may also relay 
signals completely independently of G protein activation.  It is important to note, 
therefore, that the signalling specificity induced by different GPCR conformations is 
not thought to be confined to the alteration of the activity of the G protein-mediated 
pathways.  Indeed, experimental evidence has shown that while ICI 11851 (an 
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inverse agonist at the β2-adrenergic receptor) decreases both basal cAMP 
accumulation and cAMP response element- (CRE) mediated gene transcription, 
stimulation with propranolol (also an inverse agonist) reduces basal cAMP 
accumulation but stimulates CRE-mediated transcriptional activity (Baker et al., 
2003).  This observation could not be explained by the conventional Gs-mediated 
pathway and was found to be insensitive to PTX.  Similarly, inhibitors of the Gq/11- 
(Gö6976 or Gö6986) and the G12/13- (Y-27632) mediated signalling pathways were 
without effect.  The authors suggested that propranolol could simultaneously act as 
an inverse agonist through a Gs-coupled signalling pathway while acting as an 
agonist through a G protein-independent mechanism.  In contrast, ICI 11851 was 
thought to act as an inverse agonist at both signalling cascades.  This study therefore 
supports the proposal that LiSS is not restricted to the modulation of only the activity 















Figure 1.7 The concept of LiSS.  Early receptor theory suggested that a single 
receptor existed in only two states – inactive and active (left panel).  Structurally 
diverse ligands (L1, L2, L3 and L4) bind to the same receptor protein (RP) and 
modulate the activity of a single downstream signalling pathway (S1).  Increasing 
evidence, however, suggests that different receptor conformations can selectively 
alter the output of different intracellular signalling pathways (S1, S2 and S3) (right 
panel).  Furthermore, structurally diverse ligands can induce distinct changes in 
receptor conformation.  Thus, ligand structure dictates the activity of discrete 
signalling cascades.  Figure adapted from Kenakin, 2003.  Ligand selective receptor 
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The work discussed previously highlights an important limitation of the classical 
pharmacological classification of ligands.  In the study by Baker and colleagues, 
propranolol was observed to simultaneously act as an inverse agonist through a Gs-
coupled signalling pathway while acting as an agonist of the ERK cascade through a 
G protein-independent mechanism (Baker et al., 2003).  Thus, classifying ligands on 
the basis of their ability to modulate a single effector does not provide a complete 
and accurate description of their signalling potential.  Historically, one measure used 
to characterise ligands was efficacy.  Stephenson first used the term efficacy to 
denote the property of a ligand that caused it to activate a receptor and produce a 
pharmacological response (Stephenson, 1956).  It is considered to be a 
proportionality factor designed to quantify the power of agonists (Kenakin, 2002).  
However, the observation that GPCRs can exhibit various behaviours, including the 
ability to differentially alter the activity of multiple G proteins and non-G protein 
effectors, dictates that different ligands may possess dual, no or opposite efficacy at 
different signalling pathways (figure 1.8).  In the example mentioned previously, 
propranolol has negative efficacy at the β2-adrenergic receptor-Gs-mediated 
signalling pathway as it decreases basal cAMP accumulation.  In contrast, it has a 
positive measure of efficacy at the β2-adrenergic receptor-Gs-independent pathway as 
it stimulates a CRE-mediated transcriptional output.  Obviously, in practice, the large 
number of signalling outputs makes it difficult to represent the efficacy of a 
compound according to the ensemble of potential signalling pathways it modulates.  
Thus, most ligand descriptions may be partially inaccurate.   
 




Figure 1.8 Ligands may possess dual, no or opposite efficacy at different 
signalling pathways.  Each axis (x, y and z) represents a specific signalling 
pathway, the activity of which may be modulated by a GPCR.  The compound 
illustrated possesses a positive efficacy for x and thus activates this pathway.  It also 
possesses a positive efficacy for y and consequently stimulates the relevant 
downstream effectors.  Finally, it has a negative efficacy for z and therefore 
decreases basal activation of this signalling cascade.  Figure adapted from Galandrin 
et al., 2007.  The evasive nature of drug efficacy: implications for drug discovery.  
Trends Pharmacol Sci, 28, 423-430. 
 
The underlying basis of LiSS is the ability of ligands to promote ligand selective 
GPCR conformations which have distinct abilities to engage different downstream 
signalling pathways.  However, the specific molecular processes involved still 
remain elusive.  Yao and colleagues postulated that, upon ligand binding, 
combinations of receptor molecular switches are turned on (Yao et al., 2006).  
Furthermore, structurally diverse ligands may activate different combinations of 
these switches and each switch has the ability to alter the conformation of a specific 
receptor domain.  Such switch activation, therefore, results in the ligand specific 
rearrangement of the conformation of the GPCR.  Thus, the resulting receptor 
conformation differentially modulates distinct downstream signalling pathways.  
Future research should address precisely which switches are activated in response to 
different ligands and how this correlates with ligand structure.  Additionally, it is 
essential that the relationship between the activation of specific groups of switches 
and the modulation of specific downstream signalling pathways is established.  
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While neither of these goals will be straightforward to achieve, particularly as there 
will undoubtedly be some variation between individual receptors, the possible 
pharmacological and therapeutic gains are unquestionably worth the effort. 
 
1.2.3  Summary 
LiSS raises the possibility that novel therapeutic agents that modify only portions of 
the behaviour of a given GPCR may be designed (Kenakin, 2003).  Such agents 
could reduce the spectrum of undesirable pathological effects caused by the 
activation of a specific receptor while concomitantly potentiating a desirable 
physiological output.  To attain such signalling specificity, LiSS still requires 
thorough investigation as detailed in the previous section.  Additionally, it is 
necessary that the data gleaned from in vitro systems is rigorously assessed in terms 
of the physiological and the therapeutic relevance and that this assessment takes 
place in the context of the tissue or organ that is to be pharmacologically targeted. 
 
1.3  GnRH and GnRH Receptor-Mediated Signalling 
GnRH is the central initiator of the reproductive hormonal cascade (Millar, 2005) 
(figure 1.9).  It belongs to a group of peptides originally discovered and successfully 
isolated as factors of hypothalamic origin which control secretions of the anterior 
pituitary gland (Schneider et al., 2006).  It is processed in the hypothalamus by 
proteolytic cleavage of a precursor polypeptide and packaged into storage granules 
which are transported down axons to the external zone of the median eminence 
(Millar et al., 2004).  Here, release into the hypophyseal portal circulation occurs in a 
synchronised pulsatile manner.  Such release results in the stimulation of the 
biosynthesis and the secretion of luteinising hormone (LH) and follicle-stimulating 
hormone (FSH) (Sisk and Foster, 2004).  LH and FSH, in turn, regulate gonadal 
steroidogenesis and gametogenesis in both sexes. 
 
Most vertebrates studied possess at least two forms of GnRH (Morgan and Millar, 
2004, Pawson and McNeilly, 2005).  The hypothalamic form, GnRH I, is a 
decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) and differs from 
GnRH II by three residues in positions five, seven and eight (Lu et al., 2005, Lu et 
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al., 2007, Coetsee et al., 2008).  GnRH II (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-
Gly-NH2) was originally identified in chicken hypothalami (Miyamoto et al., 1984) 
and is conserved from teleost fish to humans suggesting that it has critical and 
specific functions.  Interestingly, one of the established biological roles of GnRH II 
is the inhibition of the M current (a K+ current found in many neuronal cell types) in 
bullfrog sympathetic neurons (Jones, 1987).  Historically, the presence of GnRH II in 
most vertebrates suggested the probable existence of cognate type II GnRH 
receptors.  However, although characterised in some non-human primates such as the 
marmoset (Millar et al., 2001) and the rhesus monkey (Neill et al., 2001), the human 
type II GnRH receptor gene is disrupted by a frame shift and premature stop codon 
(Morgan et al., 2003).  Nevertheless, both GnRH I and GnRH II can bind to the 
human type I GnRH receptor with high affinity and thus this receptor can mediate 




Figure 1.9 The hypothalamic-pituitary-gonadal axis.  GnRH is processed in 
the hypothalamus and packaged into storage granules which are transported down 
axons to the external zone of the median eminence.  Here, release into the 
hypophyseal portal circulation occurs.  This release results in the stimulation of the 
biosynthesis and the secretion of LH and FSH.  These hormones, in turn, regulate 
gonadal steroidogenesis and gametogenesis.  Figure adapted from Sisk and Foster, 
2004.  The neural basis of puberty and adolescence.  Nat Neurosci, 7, 1040-1047. 
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1.3.1  Physiological and Therapeutic Roles of GnRH 
GnRH I functions as a physiological regulator of the gonadotropins while GnRH II 
may be involved in neuromodulation (Millar, 2005).  Akin to this function, it has 
been suggested that GnRH II plays a role in the regulation of sexual behaviour 
(Millar, 2003).  Additionally, both peptides have been implicated in the modulation 
of a wide variety of other functions in extrapituitary tissues (table 1.6).  Clinically, 
synthetic GnRH analogues are used to influence ovulation in assisted reproduction.  
Furthermore, chronic stimulation with high doses of GnRH agonists is extensively 
used in the treatment of hormone-dependent diseases such as endometriosis, uterine 
fibroids, precocious puberty and sex steroid-dependent cancers.  Such stimulation 
desensitises the gonadotrope causing a resultant decrease in LH and FSH and a 
decline in ovarian and testicular function.  GnRH antagonists also inhibit the 
reproductive system but the doses required are higher than those for GnRH agonists 
(Millar et al., 2000).  Thus, these compounds present challenges for clinical 
administration.  They do, however, overcome the undesirable agonist-mediated 
initial stimulation of the reproductive system which lasts several weeks before the 
onset of desensitisation. 
 
Of interest, in the pathological context, is the frequently reiterated paradigm of the 
ability of GnRH analogues to directly inhibit the proliferation of reproductive cancer 
cells.  These effects appear to be dependent on the degree of GnRH receptor 
expression and the intracellular signalling protein milieu (Morgan et al., 2008, White 
et al., 2008b).  Quantification of functional receptor protein has, surprisingly, been 
determined in relatively few cell types and several groups have demonstrated only 
receptor expression at the messenger RNA (mRNA) level (Kottler et al., 1997, Bahk 
et al., 1998, Yin et al., 1998).  Although these studies therefore serve to highlight the 
therapeutic promise of GnRH, it is essential that more research is performed in order 
to determine the extent to which these data are translatable into the treatment of 
human malignancies.   
 
 






















Gastric parietal cell 
Modulation of hCG release 
Proliferation ↑ 
Laminin receptor expression ↑ 
Adhesion, chemotaxis and 
homing ↑ 
Progesterone secretion ↓ 
uPA expression ↑ 
PAI isoform 1 expression ↓ 
MMP isoforms 2 and 9 
expression ↑ 
TIMP isoform 1 expression ↓ 
uPA expression ↑ 
PAI isoform 1 expression ↑ 
PAI isoform 1 expression ↓ 
MMP isoforms 2 and 9 
expression ↑ 
Axon growth, cytoskeletal 
remodelling and migration ↑ 
Zona pellucida binding ↑ 
Proliferation, invasion and 
chemotaxis ↓ 
Gastric acid secretion ↓ 
GnRH I/GnRH II 
GnRH I analogue deslorelin 
GnRH I/GnRH II 
GnRH I/GnRH II 
 
GnRH I analogue alarelin 
GnRH I/GnRH II 
GnRH I/GnRH II 
GnRH I/GnRH II 
 
GnRH I/GnRH II 





GnRH I/GnRH I analogue buserelin 
 
GnRH I 
GnRH I analogue zoladex 
 
GnRH I analogue alarelin 
(Islami et al., 2001) 
(Azad et al., 1997) 
(Chen et al., 2002) 
(Chen et al., 2002) 
 
(Kang et al., 2000) 
(Chou et al., 2002) 
(Chou et al., 2002) 
(Chou et al., 2003c) 
 
(Chou et al., 2003c) 
(Chou et al., 2003a) 
(Chou et al., 2003a) 
(Chou et al., 2003a) 
(Chou et al., 2003b) 
 
(Romanelli et al., 2004) 
 
(Morales, 1998) 
(Moretti et al., 2002) 
 
(Chen et al., 2005) 
 
Table 1.6 Primary putative extrapituitary actions of GnRH I and GnRH II in humans.  Table compiled from Cheng and Leung, 
2005.  Molecular biology of gonadotropin-releasing hormone (GnRH) I, GnRH II, and their receptors in humans.  Endocr Rev, 26, 283-306 
and references shown above.  hCG, human chorionic gonadotropin; uPA, urokinase type plasminogen activator; PAI, plasminogen 
activator inhibitor; MMP, Matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.  ↑, enhances function; ↓, reduces function. 
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1.3.2  GnRH Receptor 
The GnRH receptor is a member of the rhodopsin subfamily of GPCRs (Tsutsumi et 
al., 1992, Stojilkovic et al., 1994) (figure 1.10).  In general, the ECLs and the 
superficial regions of the TMs are involved in the binding of GnRH while the TMs 
are involved in conformational changes associated with receptor activation and 
signal propagation.  The ICLs are thought to be involved in the interaction of the 
receptor with intracellular effectors.  Although the mammalian type I receptor shares 
the common structural architecture of GPCRs within the rhodopsin subfamily, it is 
unique in that the carboxy-terminal tail is completely absent.  In all other GPCRs, 
and both the non-mammalian GnRH receptors and the mammalian type II GnRH 
receptors, a carboxy-terminal tail is present and is a Ser/Thr phosphorylation target 
during receptor desensitisation.  Willars and colleagues suggested that the lack of a 
carboxy-terminal tail in the rat receptor results in the inability of the receptor to 
undergo agonist-dependent phosphorylation and that this correlates directly with a 
resistance of the receptor to rapid desensitisation (Willars et al., 1999).  Other studies 
have also demonstrated that the absence of a carboxy-terminal tail alters receptor 
trafficking dynamics.  Indeed, a recent paper demonstrated that the catfish GnRH 
receptor, which possesses a carboxy-terminal tail, displays robust agonist-dependent 
internalisation (Pawson et al., 2008).  In contrast, agonist stimulation of the human 
and the rat GnRH receptors does not significantly enhance internalisation above the 
observed constitutive level. 
 
Despite the lack of a carboxy-terminal tail highlighted above, it may be possible that 
the YxxL (YFSL) motif at the intracellular end of TM7 in the mammalian type I 
GnRH receptor plays a role in GnRH-mediated signalling.  The YFSL sequence has 
been suggested to be involved in the binding of PDZ domain containing scaffold 
proteins (Pawson and McNeilly, 2005).  Similarly, studies indicate that the pYxxL 
motif forms part of the consensus sequence thought to be involved in the binding of 
SH2 domain containing Tyr phosphatases (SHPs) to immunoreceptors (Unkeless and 
Jin, 1997).  Interestingly, however, there is only very limited evidence to suggest that 





Figure 1.10 Two dimensional representation of the human GnRH receptor.  The ECLs and the superficial regions of the TMs are 
involved in GnRH binding while the TMs (boxed) are involved in conformational changes associated with receptor activation and signal 
propagation.  The ICLs are involved in interaction with both G proteins and non-G protein effectors.  The receptor shares the common 
structural architecture of GPCRs within the rhodopsin subfamily.  However, the carboxy-terminal tail is completely absent and there exists 
a reciprocal exchange of the conserved Asp87-Asn319 pair.  Putative ligand binding sites and residues thought to be important in receptor 
structure or binding pocket formation are shown in red or green respectively.  Residues thought to be involved in receptor activation are 
shown in blue.  Residues in squares are highly conserved throughout rhodopsin subfamily GPCRs (see above).  Residues thought to be 
involved in G protein coupling are shown in orange.  Figure adapted from Millar et al., 2004.  Gonadotropin-releasing hormone receptors.  
Endocr Rev, 25, 235-275. 
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GnRH receptor expression has been reported both normally and pathologically in the 
pituitary, ovary (Oikawa et al., 1990, Kakar et al., 1994, Irmer et al., 1995, Fraser et 
al., 1996), uterus (Borri et al., 1998), prostate (Limonta et al., 1999), breast 
(Baumann et al., 1993, Kakar et al., 1994, Palmon et al., 1994, Mangia et al., 2002) 
and other non-reproductive tissues.  Additionally, activation of the receptor has been 
suggested to regulate a plethora of biological effects (table 1.6 and (White et al., 
2008b)).  Given that both GnRH I and GnRH II can bind to the mammalian type I 
GnRH receptor with high affinity, taken together with the fact that the mammalian 
type II GnRH receptor is non-functional in man, it is frequently proposed that the 
pharmacological and signalling profiles of the human receptor differ, when compared 
to the gonadotrope, in extrapituitary tissues (Maudsley et al., 2004, Millar et al., 
2004, Cheng and Leung, 2005, Lopez de Maturana et al., 2008, Millar et al., 2008).  
In the following sections, I will review both defined and contentious signalling 
pathways, the stimulation of which may be mediated by receptor activation. 
 
1.3.3  GnRH Receptor-Mediated Signalling 
Binding of GnRH to the GnRH receptor induces receptor activation and signal 
propagation.  This results from the GnRH-mediated formation of new intermolecular 
and intramolecular interactions and a subsequent conformational change (Lu et al., 
2007).  Such a change is thought to uncover previously masked residues involved in 
effector coupling.  Normal and pathological GnRH receptor signalling has been 
extensively reviewed (Stojilkovic et al., 1994, Kaiser et al., 1997, Kraus et al., 2001, 
Grundker et al., 2002, Grundker and Emons, 2003, Enomoto and Park, 2004, 
Harrison et al., 2004, Cheng and Leung, 2005, Dobkin-Bekman et al., 2006, Millar et 
al., 2008, White et al., 2008b) and, in order to retain focus, only the downstream 
regulation of the MAPK cascades and the gonadotropins will be discussed here.  In 
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1.3.3.1  MAPK 
The intracellular transmission of extracellular signals is often mediated by several 
sets of MAPK cascades (Naor et al., 2000, Cuevas et al., 2007).  They consist of tiers 
of protein kinases which sequentially activate each other by phosphorylation and 
regulate critical signalling pathways involved in the mediation of cellular 
proliferation, differentiation and apoptosis (Dobkin-Bekman et al., 2006, Goldsmith 
and Dhanasekaran, 2007).  Upon activation, MAPKs translocate from the cytoplasm 
to the nucleus where they control the activity of various transcription factors by 
phosphorylation.     
 
Much of the work presented within this thesis has involved studying the activation 
profiles and downstream effects of ERK, jun-N-terminal kinase (JNK) and P38 
MAPK, three prominent members of the MAPK family.  ERK activation by GnRH 
has been examined extensively.  I and others have shown that ERK1/2 is markedly 
activated upon GnRH stimulation of GnRH receptor expressing cell lines (Sim et al., 
1993, Sim et al., 1995, Reiss et al., 1997, Haisenleder et al., 1998, Morgan et al., 
2008, White et al., 2008a).  Inhibition of this pathway with PD98059 has been 
reported to significantly inhibit α glycoprotein subunit (αGSU) and FSHβ gene 
transcription in rat gonadotrope cells (Haisenleder et al., 1998).  Additionally, ERK 
activation has been studied with reference to the antiproliferative effects of GnRH 
and GnRH analogues.  In this case, inhibition of the ERK cascade has been shown to 
be sufficient to inhibit such a GnRH analogue- (leuprolide) mediated effect (Kimura 
et al., 1999).  Indeed, PD98059, a MEK1/2 inhibitor, was demonstrated to inhibit the 
leuprolide-induced dephosphorylation of the retinoblastoma protein, the 
hyperphosphorylation of which is a hallmark of G1-S transition in the cell cycle.   
 
In 2004, Davidson and colleagues described GnRH receptor-mediated signalling to 
ERK in HEK293 cells (Davidson et al., 2004).  The activation of ERK was proposed 
to be independent of the activation of either PLCβ or PKC.  Instead, it was suggested 
to be dependent on protein-protein complex interactions between ERK, focal 
adhesion kinase (FAK) and src at focal adhesion complexes.  The induction of the 
formation of this signalling complex assembly was shown to be mediated by the 
Chapter One                                                                                               Literature Review                        
 69
GnRH receptor-induced activation of Rac.  In contrast, in DU145 cells, GnRH-
induced activation of ERK has been proposed to involve src and transactivation of 
the EGF receptor (Kraus et al., 2004) and, in αT31 cells, ERK activation by GnRH 
has been suggested to be wholly dependent on the activation of PKC (Benard et al., 
2001) or both PKC and Gi/o (Sim et al., 1995).  These data indicate that the 
mechanism by which the GnRH receptor activates ERK may depend on the cell 
context in which experiments are carried out.  Interestingly, within these different 
cellular backgrounds, the G proteins to which the GnRH receptor couples is the 
subject of much debate. 
 
As with ERK, GnRH stimulates the activity of the JNK and the P38 MAPK 
pathways and Bonfil and colleagues showed that both MAPKs are involved in the 
GnRH-mediated induction of the ovine FSHβ promoter in LβT2 gonadotrope cells 
(Bonfil et al., 2004).  Activation of JNK has been reported to be highly dependent on 
the sequential activation of PKC, src and Rac/cdc42 in αT31 cells (Levi et al., 1998).  
P38 MAPK activation has also been shown to be reliant on PKC activation in the 
same cell type (Roberson et al., 1999).  Both JNK and P38 MAPK have additionally 
been reported to be involved in promulgating the antiproliferative effects of GnRH.  
Maudsley and colleagues implicated JNK and P38 MAPK in the attenuation of cell 
growth in response to GnRH in JEG3 and BPH1 cells respectively (Maudsley et al., 
2004) and Kraus and colleagues suggested that JNK activation may play a role in the 
apoptotic effect of GnRH in DU145 and PC3 cells (Kraus et al., 2004).   
 
1.3.3.2  Gonadotropins 
LH and FSH are heterodimeric glycoprotein hormones composed of the common 
αGSU bound to a specific β subunit (LHβ and FSHβ respectively) (Cheng and 
Leung, 2005).  While both LH and FSH are released from the gonadotrope in a 
GnRH-independent constitutive manner, the pulsatile release of LH is totally 
dependent on a pulsatile GnRH input (Pawson and McNeilly, 2005).  Although there 
is no clear association between pulsatile GnRH stimulation and the release of FSH, it 
is clear that GnRH does influence the secretion of this gonadotropin.  Specific 
inhibition of GnRH has been shown to reduce the plasma FSH concentration in ewes 
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and this reduction is associated with a decrease in pituitary FSHβ mRNA levels 
(McNeilly et al., 1991).   
 
Regulated LHβ gene transcription requires combinations of regulatory elements that 
cluster in the proximal and distal regions of the promoter (Salisbury et al., 2007).  
The proximal promoter region is conserved across all mammals and contains a 
pituitary homeobox 1 (PITX1) binding element flanked by regions that bind 
steroidogenic factor 1 (SF1) and early growth response 1 (EGR1).  GnRH stimulates 
LHβ gene expression by the transcriptional regulation of EGR1.  EGR1 binds to and 
activates the LHβ promoter by acting in combination with SF1 (Duan et al., 2002).  
GnRH and activin independently and synergistically activate FSHβ transcription 
(Coss et al., 2007).  FSHβ gene expression is the limiting factor in FSH synthesis and 
this synthesis is the rate limiting step in FSH production.  The molecular mechanisms 
underlying the transcriptional activity of this gene are not thus far fully understood.  
The rodent FSHβ promoter has been shown to bind, and become activated by, SF1, 
Lim homeodomain transcription factor 3 (LHX3), nuclear factor Y (NFY), PITX1, 
PITX2, activator protein 1 (AP1) and Smad proteins (Melamed et al., 2006).  The 
role of these proteins, specifically in GnRH-mediated FSHβ transcriptional activity, 
has, however, not been well reported. 
 
1.3.4  GnRH Receptor-G Protein Interaction 
Historically, it was generally proposed that a given GPCR always interacted with a 
particular G protein or with multiple G protein subunits within one family (Hermans, 
2003).  However, for several GPCRs, it is now accepted that simultaneous functional 
coupling with G proteins of different families can be observed and that this coupling 
leads to the modulation of multiple intracellular effectors.  Moreover, different 
ligands with distinct structures can induce differing changes in receptor conformation 
and, in doing so, alter the activity of different G protein subunits.  For example, as 
reviewed in preceding sections, a group of ligands (DOI and LSD) with a similar 
ability to activate Gq/11 by binding to the serotonin 5-HT2C receptor display marked 
differences in their ability to activate Gi3 (Cussac et al., 2002).   
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In pituitary gonadotropes, GnRH stimulates the biosynthesis and the secretion of LH 
and FSH by stimulating the GnRH receptor-mediated activation of the Gq/11 G 
proteins (Millar et al., 2008).  However, the extrapituitary actions of GnRH in the 
nervous system, as well as in extraneural and neoplastic tissues, have been suggested 
to be modulated by pharmacologically dissimilar mechanisms to those regulating the 
effects in the pituitary.  Specifically, with reference to the GnRH receptor-mediated 
inhibition of cellular proliferation and the induction of proapoptotic signalling 
mechanisms in cancer cells, it has been frequently suggested that these actions are 
mediated via the GnRH receptor-induced activation of the Gi/o G proteins (Imai et al., 
1996, Imai et al., 1997, Limonta et al., 1999, Grundker et al., 2001, Maudsley et al., 
2004, Imai et al., 2006, Millar et al., 2008).  Considering the variety of cellular 
effects influenced by GnRH, it seems plausible to postulate that coupling of the 
GnRH receptor to multiple G proteins would enable the alteration of the activity of 
multiple signal transduction pathways.  However, as shall be discussed, this 
hypothesis is not uncontested (Grosse et al., 2000, White et al., 2008a). 
 
1.3.4.1 Experimental Determination of GPCR-G Protein Interaction 
Several experimental strategies have been employed to analyse the selectivity of 
GPCR-G protein interaction.  One frequently used approach is to study the change in 
a biochemical response mediated by the stimulation of a given GPCR in the absence 
or the presence of chemical inhibitors.  While these studies provide useful 
preliminary assays to evaluate the utilisation of specific G proteins by different 
GPCRs, they do not provide direct evidence of the interaction of a given GPCR with 
a specific G protein.  Indeed, as mentioned, PTX may specifically interfere with the 
coupling of receptors to most members of the Gi/o family (with the exception of Gz).  
As such, the PTX sensitivity of an activated GPCR-induced signal is frequently 
proposed to provide an indication of GPCR-Gi/o interaction (Ruf et al., 2003).  
However, the observation by Shan and colleagues of RTK-induced G protein subunit 
activation (Shan et al., 2006), taken together with the knowledge that GPCRs 
themselves may transactivate RTKs (Delcourt et al., 2007), dictates that such 
sensitivity does not provide direct evidence of GPCR-Gi/o coupling.  Similarly, 
cholera toxin (CTX) may be used to pharmacologically modulate the G proteins of 
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the Gs family (Milligan and Kostenis, 2006).  CTX application results in the ADP 
ribosylation of the Gαs subunits, the subsequent persistent activity of the adenylyl 
cyclases and thus the sustained elevation of intracellular cAMP.  Given that it has 
been demonstrated that the Gβγ complex (Gao and Gilman, 1991, Tang and Gilman, 
1991, Yoshimura et al., 1996, Steiner et al., 2006) is also able to activate adenylyl 
cyclase enzymes, it is not simply sufficient to surmise direct GPCR-Gs interaction 
from studies which observe similar signalling outputs with CTX as with stimulation 
of a given receptor. 
 
Clearly, therefore, the determination of direct GPCR-G protein interaction must rely 
on more than the simple analysis of positive second messenger responses to chemical 
inhibitors.  There are a number of ways by which this can be achieved.  For example, 
specific G protein antibodies have been successfully used to study the specificity of 
direct receptor-G protein interaction with the scintillation proximity assay (DeLapp 
et al., 1999).  Antibodies raised against specific G protein subunits or epitope tags 
have also been used to demonstrate such interaction by coimmunoprecipitation 
(Lachance et al., 1999, Feng et al., 2002).  A more recent approach involves using 
cell lines deficient in specific G protein subunits to study ligand-induced signalling 
(Riobo and Manning, 2005).  This method has the inherent advantage of maintaining 
an intact cell environment but is generally constrained to MEF cells.  In this thesis, I 
have utilised the latter two methodologies discussed. 
 
1.3.4.2 GnRH Receptor Activation of the Heterotrimeric G Proteins 
Activation of multiple heterotrimeric G proteins by the agonist-bound GnRH 
receptor is the subject of much controversy.  Numerous studies infer a direct 
interaction between this GPCR and G proteins of different families (table 1.7 and 
references therein).  However, debatably erroneous conclusions, based on indirect 
second messenger outputs in response to toxin treatments, form the vast majority of 
the published data to date.  For example, GnRH analogue- (leuprolide) induced ERK 
activation has been shown to be sensitive to PTX suggesting the involvement of Gi/o 
in the GnRH-mediated stimulation of ERK (Kimura et al., 1999).  In 2000, Grosse 
and colleagues attempted to directly address this issue by using a non-hydrolysable 
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GTP analogue, [α-32P]GTP azidoanilide, and subsequent immunoprecipitation with 
antisera raised against specific Gα subunits (Grosse et al., 2000).  Their 
investigations revealed exclusive GnRH-induced photolabelling of Gαq/11 in αT31 
and CHO membrane preparations suggesting that the GnRH receptor does not 
interact directly with Gi/o.  These studies emphasise the unresolved nature of the G 
protein coupling selectivity of the mammalian GnRH receptor, a critical issue which 
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Table 1.7 Studies of the G protein coupling profile of the GnRH receptor.  Table compiled from Ruf et al., 2003.  Structure of the 
GnRH receptor stimulated signalling network: insights from genomics.  Front Neuroendocrinol, 24, 181-199 and references shown above. 
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1.3.4.3  Molecular Basis of GPCR-G Protein Coupling Specificity 
Over the past two decades, the G protein coupling profile of many GPCRs has been 
elucidated in considerable detail using various experimental approaches.  One largely 
unsuccessful method used to predict the G protein coupling specificity of a given 
receptor was to analyse the primary sequence of the protein (Wess, 1998).  However, 
the amino acids predicted to determine specific coupling properties are generally not 
well conserved among other receptors that display a similar coupling profile (Wong, 
2003).  Thus, a conserved G protein coupling motif, which directs signalling 
selectivity at given receptors, is not thought to exist.  Instead, evidence suggests that 
such selectivity is dictated by the conformation of the intracellular regions of the 
receptor.  This hypothesis accounts for the observation that different carboxy-
terminal splice variants of the prostaglandin EP3 receptor exhibit different G protein 
coupling profiles (Namba et al., 1993).  Furthermore, it is supported by the 
demonstration that the mutation of Lys583 in ECL3 of the rat LH receptor to Ala, Arg, 
Glu and Leu completely disrupts Gs coupling (Gilchrist et al., 1996).  A slight change 
in a particular receptor conformation may therefore alter the selectivity of G protein 
coupling for a given GPCR and, thus, the efficacy of signalling at a given pathway. 
 
Experimental evidence has shown that ICL2 and ICL3 are thought to be involved in 
determining the selectivity of interaction between a GPCR and G proteins as well as 
the efficiency of G protein activation.  The exchange of ICL3 between different 
chemokine receptors revealed that this loop largely determines Gq coupling 
selectivity (Arai and Charo, 1996).  Additionally, mRNA editing of the serotonin 5-
HT2C receptor results in receptor isoforms which differ in their ICL2 sequences and 
vary considerably in their Gq coupling efficiencies (Burns et al., 1997).  Similarly, 
evidence suggests that ICL1 may also regulate receptor-G protein coupling 
selectivity.  Indeed, Wu and colleagues showed that an amino acid sequence derived 
from ICL1 of the CCKA receptor is able to confer the ability to couple to Gs upon the 
CCKB receptor (Wu et al., 1997).  In the case of the GnRH receptor, it has been 
suggested that ICL1 is involved in the activation of Gs (Arora et al., 1998) while 
ICL2 and ICL3 are important in mediating the activation of Gq/11 (Millar et al., 
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2004).  The receptor domains thought to be important in the coupling of the receptor 
to Gi/o remain undefined. 
 
Although receptor conformation undoubtedly plays a role in defining the selectivity 
of receptor-G protein interaction, it is not the exclusive determinant.  Receptor 
phosphorylation and palmitoylation, interaction of a GPCR with accessory proteins, 
the cellular expression levels of different G protein subunits and the G protein 
structure itself may all contribute to the mediation of such selectivity (Wess, 1998, 
Millar et al., 2004, Morfis et al., 2008).  Evidence indicates that the carboxy-terminal 
portions of the Gα subunit play a key role in dictating the specificity of receptor-G 
protein coupling (Conklin et al., 1993).  In addition, the amino-terminus of the Gα 
subunit and the composition of the Gβγ complex may also participate in coupling 
determination.  Indeed, Figler and colleagues showed that, when the A1 adenosine 
receptor was reconstituted with G protein βγ complexes of defined subunit 
composition, the Gβ1/Gγ1 complex is markedly less effective than either the Gβ1/Gγ2 
or the Gβ1/Gγ3 complex in promoting receptor-G protein coupling (Figler et al., 
1997). 
 
1.3.5  Summary 
Numerous studies infer that the GnRH receptor may have the inherent ability to 
couple to and activate multiple G proteins.  Additionally, other reports postulate 
exclusive interaction of the agonist-bound receptor with G proteins of the Gq/11 
family (Grosse et al., 2000).  When viewed collectively with the potential therapeutic 
value of GnRH, these studies serve to underscore the necessity to fully evaluate the 
intrinsic G protein coupling ability of this GPCR.   
 
1.4  Outline of Thesis 
A desire to finally delineate the intrinsic G protein coupling ability of the activated 
GnRH receptor, in an intact cell environment, represents the underlying motivation 
behind the studies that make up this thesis.  This aspiration stems from my interest in 
defining the mechanism by which GnRH may inhibit the proliferation of 
reproductive cancer cells.   
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In chapter three I provide, in my opinion, convincing evidence to suggest that the 
GnRH receptor does not possess the ability to interact directly with the G proteins of 
the Gi/o or the Gs families.  Additionally, I show that Gq/11 is critical for the induction 
of antiproliferative signalling by GnRH I but that the signalling mechanism involved 
in the stimulation of such an effect is dissimilar to the canonical signalling pathway 
activated by this G protein family.  Instead, I implicate src Tyr kinase and the ERK, 
but neither the JNK nor the P38 MAPKs, in the induction of the GnRH I-mediated 
inhibition of cell growth.   
 
In chapter four, based on my previous observations, I identify a novel GnRH 
receptor-G12/13-mediated signalling pathway.  Initially, I use a variety of second 
messenger systems to associate this signal transduction cascade with GnRH-
mediated signalling.  However, I then confirm, in an intact cell system, that the G12/13 
G protein family may interact directly with this GPCR.  Furthermore, I show that 
GnRH I and GnRH II can induce distinct and dramatic changes in the actin 
cytoskeleton (which are indicative of the differential activation of the Rac and the 
Rho monomeric G proteins).  Based on my experimental data and an abundance of 
published literature, I suggest that these changes reflect the activation of both this 
newly identified signalling cascade and a recently discovered GnRH receptor-
mediated G protein-independent src-induced pathway.  Indeed, I go on to provide 
evidence to confirm that the GnRH receptor may interact with src and that GnRH I 
but not GnRH II may, independently of Gq/11, activate this Tyr kinase.  Finally, I 
propose the involvement of the G12/13 G protein family but not src in the 
transcriptional regulation of LHβ and FSHβ in the pituitary gonadotrope. 
 
Both of the results chapters within this thesis are designed to read independently.  
They contain a short abstract and introduction in an effort to familiarise the reader 
with the details relevant to the appropriate aspect of GPCR-/GnRH receptor-
mediated signalling.  However, it is hoped that, when all the included data is viewed 
collectively, a cohesive and accurate description of GnRH receptor-G protein 
interaction and the subsequent signalling associated with such cellular 
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2.0  Introduction 
This chapter details the materials and the laboratory techniques used in the 
completion of the research presented within this thesis.  All materials used that were 
obtained from external sources and any work not performed by myself has been 
acknowledged.  Any reagents with no stated manufacturer were obtained from Sigma 
(Dorset, UK). 
 
2.1  Materials 
The pMEP4 expression vector was kindly provided by Dr. Keith Leppard, University 
of Warwick, UK.  The MEK1/2 inhibitor PD98059, the JNK inhibitor SP600125, the 
P38 inhibitor SB203580, the PKC inhibitor Ro-32-0432, the Ca2+ chelator BAPTA-
AM, the src Tyr kinase inhibitor PP2 and the PLCβ inhibitor U-73122 were all 
obtained from Calbiochem (Nottingham, UK).  YM-254890 was kindly provided by 
Dr. Masatoshi Taniguchi, Astellas Pharma, Japan.  The Gαq/11, the Gαi1, the Gαi2, the 
Gαi3 the Gα12, the Gα13, the GαqQ209L, the Gαi2Q205L, the GαsQ227L, the 
Gα12Q231L, the Gα13Q226L and the Gαi2G203T cDNAs were all obtained from the 
cDNA Resource Centre (Missouri, USA).  The Gα13G225A cDNA was kindly 
provided by Dr. Stefan Offermanns, University of Heidelberg, Germany and the 
ΔDH-p115 RhoGEF cDNA was kindly provided by Dr. Philip Wedegaertner, 
Kimmel Cancer Centre, USA.  The SRE-luciferase reporter cDNA was kindly 
provided by Dr. Adam Pawson, MRC Human Reproductive Sciences Unit, UK.  The 
LHβ luciferase reporter and the FSHβ luciferase reporter cDNAs and the 
recombinant adenovirus expressing green fluorescent protein (GFP) were all kindly 
provided by Dr. Pamela Brown, MRC Human Reproductive Sciences Unit, UK.  The 
Gαqi5 cDNA and the Gαq/11 knockout MEF cell line were both kindly provided by 
Professor Graeme Milligan, University of Glasgow, UK.  The Gαq/11 knockout MEF 
cell line was originally derived from a combined Gαq/11 double knockout mouse and 
has been previously shown to have absolutely no endogenous Gαq/11 (Offermanns et 
al., 1998, Stevens et al., 2001).  The LβT2 cell line was kindly provided by Dr. 
Pamela Mellon, University of California, USA.  The recombinant adenovirus 
expressing Gαq was kindly provided by Dr. Nicholas Webster, University of 
California, USA.  The pERK1/2, the pJNK, the pP38, the ERK1/2, the psrc and the 
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src antibodies were all obtained from Cell Signalling Technology (Hertfordshire, 
UK).  The Gαq/11, the Gαi/o, the Gα13, the HA agarose conjugate and the PY20 
agarose conjugate antibodies were all obtained from Santa Cruz Biotechnology 
(Heidelberg, Germany).  The HA and the β-actin antibodies were both obtained from 
Abcam (Cambridge, UK).  Activin A was obtained from R&D Systems 
(Minneapolis, USA).   
 
2.2  Transformation of Competent Cells 
XL-10 Gold competent cells (Stratagene, Cheadle, UK) were thawed on ice and 
incubated with 1.5 µl β-mercaptoethanol for 10 minutes.  10 ng plasmid DNA was 
added and the bacteria left on ice for an additional 30 minutes.  After incubation, the 
cells were heat shocked at 42 °C for 35 seconds and immediately placed back on ice.  
450 µl S.O.C. medium (Invitrogen, Paisley, UK) was added and the bacteria shaken 
at 37 °C for 1 hour prior to being streaked out on a Luria Broth- (LB) agar plate 
(containing 100 µg/ml ampicillin) and incubated at 37 °C overnight. 
 
2.3 Preparation of Plasmid DNA 
A single colony transformed bacteria was picked and used to inoculate 5 ml LB 
medium containing 100 µg/ml ampicillin.  The culture was grown at 37 °C overnight 
with constant shaking.  The following evening, 1 ml was used to inoculate 250 ml 
fresh LB medium (containing 100 µg/ml ampicillin) and the culture grown for a 
further 16 hours.  Plasmid DNA was purified using Qiagen maxi-preparation 
columns (Qiagen, Crawley, UK) according to the manufacturers instructions and 
eluted in TE buffer (10 mM Tris (pH 8.0), 1 mM EDTA).  The DNA was examined 
by agarose gel electrophoresis and the concentration and the quality were determined 
using a Nanodrop spectrophotometer (Nanodrop Technologies, Delaware, USA). 
 
2.4  Preparation of Glycerol Stocks 
Glycerol stocks were made by adding 300 µl sterile 80% (v/v) glycerol to 700 µl 
bacterial culture that had been grown overnight.  Vials were inverted to mix the 
glycerol, frozen on dry ice and stored at -80 °C.  To recover the bacteria, a sterile 
inoculating loop was used to scrape the surface of the frozen culture.  The bacteria 
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were streaked out on a LB-agar plate (containing 100 µg/ml ampicillin) and grown at 
37 °C overnight.  A single colony was picked and plasmid DNA prepared as 
described. 
 
2.5  Agarose Gel Electrophoresis 
1% (w/v) agarose gels were prepared in TAE buffer (40 mM Tris, 320 mM acetic 
acid, 1 mM EDTA, pH 7.2).  Plasmid DNA and restriction digests were separated at 
120 V for 40 minutes, stained with ethidium bromide and visualised under ultraviolet 
light using a GeneFlash transilluminator (Syngene Bio Imaging, Cambridge, UK).  
For preparative work, a 366 nm light source was used in order to minimise 
photonicking and dimerisation of DNA.  The DNA was recovered from agarose gel 
slices using a QIAquick gel extraction kit (Qiagen, Crawley, UK) according to the 
manufacturers instructions.   
 
2.6  Restriction Digests 
Double restriction digests of plasmid DNA were performed in a 20 µl final volume 
using 1 unit appropriate enzymes (Promega Madison, USA) in a buffer which was 
chosen to give maximum enzymatic activity.  Digestions were performed at 37 °C 
for between 1 and 3 hours.  DNA was fractioned by agarose gel electrophoresis and 
the required products were recovered as described. 
 
2.7 Ligation of DNA 
Inserts were ligated into linearised vectors with cohesive ends using T4 DNA ligase 
(Promega Madison, USA).  100 ng vector and an appropriate mass insert were made 
up to 8 µl using sterile H20.  1 µl 10 x T4 DNA ligase buffer (300 mM Tris (pH 7.8), 
100 mM MgCl2, 100 mM DTT, 100 mM ATP) and 1 µl T4 DNA ligase were added 
and the reaction allowed to proceed at 12 °C for 16 hours.  Control reactions were set 
up with either vector alone or insert alone.  1 µl ligation mixture was used to 
transform XL-10 Gold competent cells and the transformants were selected on LB-
agar plates (containing 100 µg/ml ampicillin) as described.  Single colonies were 
picked and used to inoculate 5 ml LB medium (containing 100 µg/ml ampicillin) and 
the culture was grown at 37 °C overnight with constant shaking.  The bacteria were 
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harvested by centrifugation at 6,000 x g for 5 minutes and plasmid DNA prepared 
using Qiagen mini-preparation columns (Qiagen, Crawley, UK) according to the 
manufacturers instructions.  Restriction digests were performed as described to 
confirm the presence of DNA inserts and the plasmids sequenced to ensure the 
absence of mutations.  Dideoxy sequencing reactions were carried out at the MRC 
Human Genetics Unit, Edinburgh, UK. 
 
2.8  Cell Culture 
Full length GnRH receptor cDNA was cloned into pMEP4 at Not1 and Xho1 and the 
construct transfected into Gαq/11 knockout MEF cells by electroporation.  Cloned 
cells were selected using hygromycin resistance and screened by radioligand binding.  
Gαq/11 knockout MEF cells stably expressing the GnRH receptor were maintained in 
Dulbeccos Modified Eagles medium (DMEM) supplemented with 10% (v/v) foetal 
calf serum (PAA Laboratories, Somerset, UK), 2 mM glutamine, 50 IU/ml penicillin, 
50 IU/ml streptomycin, 0.5 mg/ml G418 sulphate and 50 μg/ml hygromycin 
(Invitrogen Life Technologies, Paisley, UK) at 37 C in a humidified 5% CO2 
atmosphere.  HEK293 cells stably expressing the GnRH receptor (designated 
SCL60) and BHK cells stably expressing the GnRH receptor and an SRE-luciferase 
reporter were generated previously within our laboratory.  Both cell lines were 
maintained in DMEM supplemented with 10% (v/v) foetal calf serum, 2 mM 
glutamine, 50 IU/ml penicillin, 50 IU/ml streptomycin and 0.5 mg/ml G418 sulphate 
at 37 C in a humidified 5% CO2 atmosphere.  COS7 cells and LβT2 cells were 
maintained in DMEM supplemented with 10% (v/v) foetal calf serum, 2 mM 
glutamine, 50 IU/ml penicillin and 50 IU/ml streptomycin at 37 C in a humidified 
5% CO2 atmosphere.  LβT2 cells were routinely grown on matrigel (BD Biosciences, 
New Jersey, USA) coated cell culture vessels.   
 
All cell lines were routinely passaged twice weekly by enzymatic dispersal with 
trypsin.  Briefly, the medium was removed from confluent cultures and the cells 
washed once in phosphate buffered saline (PBS).  2 ml trypsin was added to each 
162 cm2 cell culture flask (Fisher Scientific, Leicestershire, UK) and the flasks 
returned to the incubator for between 2 and 5 minutes.  After successful dispersal, 8 
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ml growth medium was added in order to quench the trypsin.  All cell lines were 
routinely split 1:3.  Excess dispersed cells were diluted 1:10 in PBS and counted 
using a Nebauer haemocytometer.  All four counting areas were utilised and an 
average taken to give the cell number x 105/ml.  The correct volume cell suspension 
was then seeded onto cell culture dishes for experiments as appropriate. 
 
2.9  Cryopreservation and Resuscitation of Immortalised Cell Lines 
Stocks of each cell line were stored at -196 C under liquid nitrogen in 
cryoprotectant (10% (v/v) dimethylsulphoxide (DMSO), 90% (v/v) foetal calf 
serum).  Cells were recovered from the liquid nitrogen store and warmed rapidly to 
37 C prior to being gently resuspended in growth medium and seeded into cell 
culture flasks.  Frozen stocks were preserved by banking the cells for the first two 
passages after they were resuscitated.  Confluent cultures were passaged as described 
and the cells collected by centrifugation at 500 x g for 3 minutes.  The growth 
medium was decanted and the cell pellet gently resuspended in cryoprotectant, 
aliquoted into vials and frozen at -80 C in a cryo 1 C freezing container (Nalgene, 
Hereford, UK).  After 24 hours, the vials were transferred to liquid nitrogen for long 
term storage. 
 
2.10  Transient Transfection by Adenoviral Infection 
Gαq/11 knockout MEF cells were transfected (for sulforhodamine B (SRB) and trypan 
blue dye exclusion assays only) using a recombinant adenovirus expressing Gαq 
essentially as previously described (Liu et al., 2005).  Briefly, 0.5 x 105 cells/ml were 
seeded onto 12 well cell culture dishes (1 ml/well) and allowed to attach overnight.  
The following day, the growth medium was removed and the cells were infected at a 
multiplicity of infection (MOI) of 90 plaque forming units (PFU)/cell for 16 hours.  
A recombinant adenovirus expressing GFP was used as a control.  To allow protein 
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2.11  Transient Transfection by Electroporation 
COS7 cells and Gαq/11 knockout MEF cells were transfected by electroporation 
essentially as previously described (Lu et al., 2005, Lu et al., 2007).  Briefly, 1.0 x 
105 cells/ml were seeded onto 162 cm2 cell culture flasks (25 ml/flask) and allowed 
to grow for 96 hours prior to transfection.  The cells within each cell culture flask 
were enzymatically dispersed as described and resuspended in 0.7 ml 4 C Optimem 
(Invitrogen Life Technologies, Paisley, UK).  Transient transfections were performed 
by electroporation, using a Bio-Rad Gene Pulser XCell (Bio-Rad Laboratories, 
Hertfordshire, UK), at 230 V/950 μF for COS7 cells and 320 V/500 μF for Gαq/11 
knockout MEF cells with 20 μg plasmid DNA and 0.7 ml cell suspension in each 0.4 
cm electroporation cuvette.  After 10 minutes, the contents of each electroporation 
cuvette were resuspended in growth medium and seeded onto cell culture dishes for 
experiments as appropriate. 
 
2.12  Transient Transfection with Fugene 
LβT2 cells and BHK cells were transfected with Fugene (Roche, Welwyn Garden 
City, UK) using 6 µl Fugene/1 µg plasmid DNA.  6 x 105 cells/ml were seeded onto 
12 well cell culture dishes (1 ml/well) and allowed to attach overnight.  The 
following day, 12 µl Fugene was added to 100 µl 37 C Optimem and the solution 
vortexed for 3 seconds.  5 minutes later, 2 µg plasmid DNA was added and the 
solution vortexed, centrifuged briefly and left for 45 minutes to ensure transfection 
complex formation.  100 µl transfection mix was added directly to the growth 
medium in each well and the dishes swirled to allow complete mixing.  The cells 
were returned to the incubator and routinely harvested for experiments either 48 or 
72 hours after transfection. 
 
2.13  Preparation of Pharmacological Inhibitors and Ligands 
Stock solutions of inhibitors were routinely prepared in DMSO as per the 
manufacturers instructions, aliquoted and stored at -20 C.  Stock solutions of GnRH 
I and GnRH II were prepared in 20% (v/v) propylene glycol, rapidly frozen in a 
cardice bath and stored at -20 C.  On the day of experiments, GnRH aliquots were 
defrosted and diluted in 20% (v/v) propylene glycol and, subsequently, growth 
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medium or buffer to the desired concentration.  All inhibitors and ligands, except for 
U-73122, were subjected to a maximum of two freeze/thaw cycles.  U-73122 was 
freshly prepared for each experiment. 
 
2.14  Radioligand Binding Assay 
Radioligand binding assays were performed on intact cells as previously described 
(Lu et al., 2005, Lu et al., 2007, Coetsee et al., 2008, Stewart et al., 2008, White et 
al., 2008a).  Briefly, Gαq/11 knockout MEF cells, LβT2 cells and SCL60 cells, on 12 
well cell culture dishes, were incubated with 125I-[His5,D-Tyr6]GnRH (100,000 
cpm/0.5 ml/well) and either vehicle (0.2% (v/v) propylene glycol) or various 
concentrations of unlabelled GnRH in a radioligand binding assay buffer (0.1% (w/v) 
bovine serum albumin (BSA), 25 mM 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES), DMEM) for 4 hours at 4 C.  Non-specific binding 
was determined in the presence of 1 µM unlabelled GnRH.  After incubation, the free 
ligand was removed with two rapid washes in cold PBS and the cells solubilised in 
0.5 ml 0.1 M NaOH.  Radioactivity was counted by γ-spectrometry.  For GnRH 
receptor expression level comparison, cells that had been seeded in parallel were 
enzymatically dispersed and counted as described.  Data is presented as 
counts/minute/million cells. 
 
2.15  Preparation of Cellular Extracts 
Appropriately transfected or untransfected Gαq/11 knockout MEF cells, COS7 cells or 
SCL60 cells were seeded onto 100 mm cell culture dishes (at a density of 3 x 105 
cells/ml with 10 ml/dish for SCL60 cells) and allowed to attach overnight.  The 
growth medium was removed and the cells were washed twice in PBS prior to being 
incubated in serum free medium (DMEM supplemented with 2 mM glutamine, 50 
IU/ml penicillin, 50 IU/ml streptomycin and 10 mM HEPES) for 16 hours in the 
presence or absence of chemical inhibitors as described in the figure legends.  GnRH 
stimulations were performed at 37 C in fresh serum free medium in the presence or 
absence of chemical inhibitors as described in the figure legends.  Following 
appropriate GnRH stimulation, the cell monolayers were placed on ice, washed once 
in cold PBS and lysed in a Nonidet P-40 solubilisation buffer (250 mM NaCl, 50 
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mM HEPES, 0.5% (v/v) Nonidet P-40, 10% (v/v) glycerol, 2 mM EDTA, pH 8.0) 
supplemented with 1 mM sodium orthovanodate, 1 mM phenylmethylsulphonyl 
fluoride and 10 μg/ml leupeptin.  The solubilised lysates were clarified by 
centrifugation at 20,000 x g for 15 minutes and the nuclear contents were sheared by 
subsequent sonication.  Sample protein concentrations were measured as described 
and the samples were diluted with sterile H20 to a concentration of 1 mg/ml total 
protein.   
 
2.16  Determination of Protein Concentration 
Protein concentrations were determined using the modified Bradford assay (Bio-Rad 
Laboratories, Hertfordshire, UK).  BSA was used as a standard.  A standard curve (0 
mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.5 mg/ml, 0.75 mg/ml, 1 mg/ml, 1.5 
mg/ml and 2.0 mg/ml) was prepared by the serial dilution of a 10 mg/ml BSA stock 
in 200 µl Bradford dye and an appropriate volume PBS (such that the final volume 
was made up to 1 ml).  5 µl each sample was added to 795 µl PBS and 200 µl 
Bradford dye.  All standards and samples were vortexed and left for 5 minutes.  
Absorbances were measured at 595 nm using a spectrophotometer and a standard 
curve plotted.  The concentration of protein in each sample was calculated from the 
equation of the line. 
 
2.17  Immunoprecipitation 
Proteins were immunoprecipitated from 500 µg cellular extract with 20 µl 
appropriate agarose conjugated antibody slurry.  Briefly, samples were tumbled at 4 
C overnight and immunoprecipitates collected by centrifugation at 20,000 x g for 5 
minutes.  Immune complexes were washed three times in 1 ml Nonidet P-40 
solubilisation buffer supplemented with 1 mM sodium orthovanodate, 1 mM 
phenylmethylsulphonyl fluoride and 10 μg/ml leupeptin to remove contaminating 
proteins.  To allow only specific binding of proteins to the agarose conjugate, cellular 
extracts were routinely cleared with 20 µl appropriate agarose conjugated antibody 
slurry for 2 hours prior to immunoprecipitating.   
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2.18  Western Blotting 
Clarified cellular extracts were mixed with an equal volume 2 x Laemmli sample 
buffer (LSB) (80% (v/v) 10% (w/v) SDS, 5% (v/v) β-mercaptoethanol, 10% (v/v) 
glycerol, 2.5% (v/v) 1M Tris (pH 7.0), 2.5% (v/v) distilled H2O), heated to 100 C 
for 5 minutes and allowed to cool.  Immunoprecipitates were routinely solubilised in 
25 µl LSB, heated to 100 C for 5 minutes and allowed to cool.  Agarose beads were 
pelleted by centrifugation at 20,000 x g for 1 minute.  Proteins were resolved by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) using 
20% Tris-Gly gels (Invitrogen Life Technologies, Paisley, UK).  Electrophoretic 
separation was performed at 45 mA for 1 hour in SDS-PAGE running buffer (25 mM 
Tris, 192 mM glycine, 1% (w/v) SDS). 
 
After electrophoretic separation, proteins were electroblotted on to polyvinylidene 
difluoride (PVDF) membranes (NEN Life Sciences, Buckinghamshire, UK) for 
protein immunoblotting.  PVDF membranes were prepared by washing in 100% 
methanol for 5 minutes followed by several 10 minute washes in distilled H2O.  
Finally, they were equilibrated in semi-dry transfer buffer (20 mM Tris, 192 mM 
glycine, 20% (v/v) methanol, 0.1% (w/v) SDS) for at least 30 minutes.  Six 
thicknesses electrode paper (Bio-Rad Laboratories, Hertfordshire, UK) were soaked 
in semi-dry transfer buffer for at least 10 minutes prior to electroblotting.  Three 
thicknesses electrode paper were placed onto the anode plate of the transfer apparatus 
and the PVDF membrane placed on top.  The Tris-Gly gel was next placed onto the 
stack and another three thicknesses electrode paper placed on top of it.  Air bubbles 
were carefully rolled out with a glass test tube and the cathode plate placed on top.  
Proteins were electroblotted at 25 V for 1 hour. 
 
Following electroblotting, the membranes were rinsed for 10 minutes with TBS-T 
(100 mM Tris (pH 7.0), 150 mM NaCl, 0.05% (v/v) Tween 20, 0.05% (v/v) Nonidet 
P-40) and blocked for at least 1 hour in 10 ml blocking buffer (4% (w/v) BSA, TBS-
T) with gentle shaking.  The blocking buffer was discarded and a primary antibody 
(diluted 1:1000 in 10 ml blocking buffer) applied at 4 C overnight.  Each primary 
antibody was used a maximum of 10 times before being replaced.  PVDF membranes 
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were washed three times in TBS-T for 10 minutes after which an appropriate alkaline 
phosphatase conjugated polyclonal secondary antibody (diluted 1:10,000 in 10 ml 
blocking buffer) was applied for 1 hour.  After three further 10 minute washes in 
TBS-T, the immunoblots were drained and developed with an enzyme linked 
chemifluorescence (ECF) substrate (GE Healthcare, Buckinghamshire, UK) 
according to the manufacturers instructions.  Protein bands were visualised using a 
Typhoon 9200 PhosphorImager (GE Healthcare, Buckinghamshire, UK) and 
quantified with ImageQuant version TL (GE Healthcare, Buckinghamshire, UK). 
 
After visualisation, the immunoblots were routinely washed in 40% (v/v) methanol 
for 30 minutes to remove the precipitated fluorophore and rinsed three times, for 10 
minutes, in TBS-T.  The antibodies were then stripped off by incubating the PVDF 
membrane in 20 ml stripping buffer (25 mM Tris (pH 7.0), 8% (w/v) SDS, 0.72 M β-
mercaptoethanol) at 80 C for 30 minutes.  After a further three 10 minute rinses in 
TBS-T, the PVDF membranes were either blocked prior to being probed with 
another antibody or dried and kept until such times as they were needed.  
Representative immunoblots are presented throughout this thesis. 
 
2.19  Measurement of Intracellular cAMP Accumulation 
Untransfected Gαq/11 knockout MEF cells were seeded onto 12 well cell culture 
dishes (1 ml/well) at a density of 3 x 105 cells/ml and allowed to attach overnight.  
The growth medium was removed and the cells were washed twice in PBS prior to 
being incubated in serum free medium for 16 hours.  GnRH stimulations were 
performed at 37 C in fresh serum free medium after a 30 minute incubation with 1 
mM 3-isobutyl-1-methylxanthine (IBMX).  Following appropriate GnRH 
stimulation, the cell monolayers were placed on ice, washed twice in cold PBS and 
lysed in 0.1 M HCl.  Intracellular cAMP concentrations were determined using an 
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2.20  Measurement of Cell Growth 
The growth medium was removed from appropriately transfected Gαq/11 knockout 
MEF cells and the cells were incubated in fresh growth medium for 16 hours in the 
presence or absence of chemical inhibitors as described in the figure legends.  GnRH 
stimulations were performed at 37 C in fresh growth medium in the presence or 
absence of chemical inhibitors as described in the figure legends.  Following 
appropriate GnRH stimulation, the cell monolayers were placed on ice and an equal 
volume cold 25% (v/v) trichloracetic acid was added directly to the growth medium.  
The cells were fixed at 4 C for at least 1 hour after which cell growth was 
determined using the SRB assay as previously described (Skehan et al., 1990, 
Morgan et al., 2008, White et al., 2008a).  Briefly, the fixed cells were stained with 
0.4% (w/v) SRB in 1% (v/v) acetic acid for at least 30 minutes prior to being washed 
four times in 1% (v/v) acetic acid and allowed to dry.  The protein-bound dye was 
extracted with 10 mM Tris (pH 10.5) and the optical density determined at 540 nm 
using a spectrophotometer. 
 
2.21  Trypan Blue Dye Exclusion 
The growth medium was removed from appropriately transfected Gαq/11 knockout 
MEF cells.  GnRH stimulations were performed at 37 C in fresh growth medium.  
Following appropriate GnRH stimulation, the cell monolayers were placed on ice 
and the media collected.  Samples were subjected to centrifugation at 6,000 x g for 
10 minutes and the supernatant was removed.  The pellets were resuspended in PBS 
and an equal volume 0.4% (v/v) Trypan Blue solution was added.  After 10 minutes, 
the samples were imaged on an Olympus Provis AX70 inverted light microscope 
(Olympus UK, Hertfordshire, UK) to test for dye uptake.   
 
2.22  Dual Light Luciferase Reporter Gene Assay 
BHK cells and LβT2 cells were transfected with Fugene as described.  6 x 105 
cells/ml were seeded onto 12 well cell culture dishes (1 ml/well), allowed to attach 
overnight and transfected with 2 µg/well plasmid DNA and 33 ng/well Renilla 
luciferase (Promega UK, Southampton, UK) to control for transfection efficiency.  
24 hours after transfection, the growth medium was removed and the cells were 
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washed twice in PBS prior to being incubated in serum free medium for 16 hours in 
the presence or absence of chemical inhibitors as described in the figure legends.  
GnRH stimulations were performed at 37 C in fresh serum free medium in the 
presence or absence of chemical inhibitors as described in the figure legends.  
Following appropriate GnRH stimulation, the cell monolayers were placed on ice, 
washed once in cold PBS and lysed in a passive lysis buffer (Promega UK, 
Southampton, UK) with constant shaking.  Luciferase activity was determined using 
a dual light luciferase assay kit (Promega UK, Southampton, UK) and a FLUOstar 
OPTIMA luminometer (BMG Lab Technologies, Aylesbury, UK).  The luciferase 
response was expressed in arbitrary units relative to the activity observed in vehicle 
treated control cells and normalised for Renilla luciferase activity.  It was then 
expressed as a fold over control response as indicated in the figure legends. 
 
2.23  Measurement of Inositol Phosphate Generation 
BHK cells were transfected with Fugene as described.  6 x 105 cells/ml were seeded 
onto 12 well cell culture dishes (1 ml/well), allowed to attach overnight and 
transfected with 2 µg/well plasmid DNA.  24 hours after transfection, the growth 
medium was removed and the cells were washed twice in PBS prior to being 
incubated in inositol free DMEM (Invitrogen, Paisley, UK) supplemented with 2 mM 
glutamine, 50 IU/ml penicillin, 50 IU/ml streptomycin, 1% (v/v) dialysed foetal calf 
serum and 1 µCi/ml myo-D-[3H]inositol (GE Healthcare, Buckinghamshire, UK) for 
16 hours.  Thereafter, the cells were incubated in 0.5 ml buffer A (140 mM NaCl, 20 
mM HEPES, 8 mM glucose, 4 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 1 mg/ml BSA) 
containing 10 mM LiCl at 37 C for 30 minutes.  GnRH stimulations were performed 
at 37 C in fresh buffer A containing 10 mM LiCl for a further 30 minutes.  
Following appropriate GnRH stimulation, the buffer A was removed and the reaction 
terminated by addition of 10 mM formic acid at 4 C for at least 30 minutes.  The 
[3H]inositol phosphates were purified from the formic acid extracts by ion exchange 
chromatography using Dowex AG1-X8 ion exchange resin (Bio-Rad Laboratories, 
Hertfordshire, UK).  The bound [3H]inositol phosphates were eluted with 1 M 
ammonium formate containing 0.1 M formic acid and quantified by liquid 
scintillation spectroscopy. 
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2.24  Immunocytochemistry and Confocal Laser Microscopy 
Gαq/11 knockout MEF cells were seeded onto 8 well chamber slides (0.5 ml/well) at a 
density of 0.5 x 105 cells/ml and allowed to attach overnight.  The growth medium 
was removed and the cells were washed twice in PBS prior to being incubated in 
serum free medium for 16 hours in the presence or absence of chemical inhibitors as 
described in the figure legends.  GnRH stimulations were performed at 37 C in fresh 
serum free medium in the presence or absence of chemical inhibitors as described in 
the figure legends.  Following appropriate GnRH stimulation, the cell monolayers 
were placed on ice, washed once in cold PBS and fixed with cold methanol at -20 C 
for 10 minutes.  The fixed cells were washed twice in PBS, permeabilised with 
immunocytochemistry permeabilisation buffer (10% (v/v) foetal calf serum, 1% 
(w/v) BSA, 0.2% (v/v) Nonidet P-40, PBS) for 30 minutes, washed a further two 
times in PBS and blocked with immunocytochemistry blocking buffer (10% (v/v) 
foetal calf serum, 1% (w/v) BSA, PBS) for 1 hour.  The immunocytochemistry 
blocking buffer was discarded and a primary antibody (diluted 1:100 in 
immunocytochemistry blocking buffer) applied at 4 C overnight.  Each primary 
antibody was freshly prepared for each experiment.  After appropriate incubation, the 
cells were washed three times in PBS prior to the application of an appropriate FITC 
conjugated secondary antibody (diluted 1:200 in immunocytochemistry blocking 
buffer) for 1 hour.  After three further PBS washes, the cells were exposed to DAPI 
(diluted 1:2,000 in PBS) for 5 minutes in order to stain DNA, washed another three 
times in PBS, mounted in Permafluor mounting medium (Immunotech, Marseille, 
France) and left to dry in the dark for at least 48 hours.  Confocal microscopy was 
performed on a Zeiss LSM 510 laser scanning microscope (Carl Zeiss AG, 
Oberköchen, Germany) using a 40 x 1.4 numerical aperture oil immersion lens.  
Images were exported to Adobe Photoshop version 9.0.2 (Adobe Systems Europe, 
Uxbridge, UK).  Representative images are presented throughout this thesis. 
 
2.25  Statistical Analysis 
All experiments were repeated independently at least three times.  In addition, all 
assays were performed in triplicate.  Data are presented as mean values + or ± the 
standard error of the mean (SE).  Statistical significance was set at p<0.05, p<0.01 or 
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p<0.001, indicated by asterisks in figures, and analyses were performed using the 
students t-test.  For agonist dose-response analyses, data representing the mean ± SE 
from at least three independent experiments were plotted and analysed using 
GraphPad Prism 5.0 (GraphPad Software, San Diego, USA).  Sigmoidal dose 
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3.0  Abstract 
GnRH acts on its cognate receptor in pituitary gonadotropes to regulate the 
biosynthesis and the secretion of gonadotropins.  However, it may also inhibit 
cellular growth in reproductive malignancies and, here, the GnRH-mediated 
activation of the MAPK cascades is thought to play a pivotal role.  In extrapituitary 
tissues, GnRH receptor signalling has been postulated to involve the coupling of the 
receptor to different G proteins.  In this chapter, I examined the ability of the GnRH 
receptor to couple directly to Gq/11, Gi/o and Gs, their roles in the activation of the 
MAPK cascades and the subsequent effects on cellular growth.  I show that, in Gαq/11 
knockout cells stably expressing the GnRH receptor, GnRH did not induce detectable 
activation of ERK, JNK or P38.  In contrast to Gαi or chimeric Gαqi5, transfection of 
Gαq cDNA enabled GnRH to induce phosphorylation of all of these proteins.  
Furthermore, no GnRH-mediated cAMP response or inhibition of isoproterenol-
induced cAMP accumulation was observed.  Interestingly, GnRH I stimulated a 
marked reduction in cell growth only in cells expressing Gαq.  This inhibition could 
be significantly rescued by blocking ERK activation with PD98059 whilst the 
inhibition of PKC with Ro-31-8220, the chelation of intracellular Ca2+ with BAPTA-
AM, the inhibition of JNK with SP600125 or the inhibition of P38 with SB203580 
had no effect.  Notably, specific inhibition of src Tyr kinase with PP2 was sufficient 
to completely abrogate the GnRH I-induced antiproliferative response.  I therefore 
provide evidence to suggest that the coupling of the GnRH receptor to Gq/11, but not 
to Gi/o or Gs, and the consequent activation of the src and the ERK pathways (but 
neither the JNK nor the P38 cascades) plays a crucial role in GnRH I-mediated 
antiproliferation.  Based on these and other data, I propose a mechanism whereby 
GnRH I may inhibit cellular growth. 
 
3.1  Introduction 
As well as influencing reproductive behaviour, evidence suggests that GnRH may act 
peripherally to exert a growth regulatory effect on certain cell types.  Indeed, GnRH 
and the GnRH receptor have been found in extrapituitary tissues such as the ovary 
(Oikawa et al., 1990, Fraser et al., 1996) and the mammary gland (Palmon et al., 
1994).  Cancers of the breast (Baumann et al., 1993, Kakar et al., 1994, Mangia et al., 
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2002), ovary (Kakar et al., 1994, Irmer et al., 1995), endometrium (Borri et al., 1998) 
and prostate (Limonta et al., 1999) have also been shown to express both the ligands 
and the receptor.  Several studies, both in vitro and in vivo, have demonstrated that 
the direct application of GnRH analogues to receptor expressing cells results in an 
attenuation of cellular proliferation and the activation of proapoptotic signalling 
mechanisms (Klijn and de Jong, 1982, Dondi et al., 1994, Yano et al., 1992, Yano et 
al., 1994, Jeyarajah et al., 1996, Dondi et al., 1998, Kimura et al., 1999, Kraus et al., 
2004, Maudsley et al., 2004, Gnanapragasam et al., 2005, Morgan et al., 2008, White 
et al., 2008a, White et al., 2008b).  In such GnRH-induced cellular responses, 
activation of the MAPK cascades is sometimes thought to play a fundamental role 
(Kimura et al., 1999, Kraus et al., 2004, Maudsley et al., 2004, Dobkin-Bekman et 
al., 2006, White et al., 2008a).   
 
Several groups have demonstrated that GnRH stimulates the phosphorylation of 
ERK, JNK and P38 in the αT31 and the LβT2 gonadotrope cell lines and a wide 
variety of GnRH receptor transfected cells (Sim et al., 1993, Sim et al., 1995, Reiss 
et al., 1997, Haisenleder et al., 1998, Levi et al., 1998, Roberson et al., 1999, Naor et 
al., 2000, Harris et al., 2002, Maudsley et al., 2004, Dobkin-Bekman et al., 2006, 
White et al., 2008a).  How these cascades are initiated upstream by the activated 
receptor and which of them impinge on cell growth inhibition remains unclear.  It has 
been proposed that, whereas the actions of GnRH at the pituitary are mediated by the 
interaction of the receptor with the G protein subunits of the Gq/11 family and the 
consequent signalling to and the activation of, among other molecules, ERK, JNK 
and P38, the antiproliferative actions of GnRH are best explained via an interaction 
of the receptor with the Gαi/o G protein α subunits.  Indeed, Imai and colleagues 
demonstrated that treatment with PTX of plasma membrane preparations from 
surgically removed ovarian carcinomas and uterine leiomyosarcomas completely 
inhibits the buserelin-mediated stimulation of the phosphotyrosine phosphatases 
(PTPs) (Imai et al., 1996).  The authors further speculated that, as PTP activity has 
been proposed to be involved in the antiproliferative action of dopamine at the D2 
receptor (Florio et al., 1992), this observation may have relevance to the GnRH-
induced inhibition of cell growth.  Additionally, Limonta and colleagues showed that 
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PTX completely abrogates the inhibitory effects of GnRH analogues (zoladex) on 
cellular proliferation in LNCaP and DU145 cells (Limonta et al., 1999).  With 
regards to the involvement of the MAPK cascades in the GnRH-mediated induction 
of cell growth inhibition, Kraus and colleagues implicated the activation of JNK in 
the GnRH analogue- ([D-Trp6]-GnRH) induced antiproliferative effect (Kraus et al., 
2004).  Inhibition of JNK activation in DU145 cells with SP600125 completely 
abrogated the [D-Trp6]-GnRH elicited terminal deoxynucleotidyltransferase-
mediated nick end labelling (TUNEL) response.  Similarly, Maudsley and colleagues 
showed that, depending on the cell line studied, GnRH-induced inhibition of cell 
growth coincided with the activation of either JNK (JEG3) or P38 (BPH1) 
(Maudsley et al., 2004).  Inhibition of the activation of these kinases significantly 
reduced the GnRH I-mediated annexin 5-FITC staining of phosphatidylserine 
expressed on the outer aspect of the plasma membrane.  Interestingly, these results 
are in contrast to those obtained by Kimura and colleagues who showed that, in the 
Caov3 cell line, specific inhibition of the ERK cascade with PD98059 was sufficient 
to completely impede leuprolide-induced antiproliferation (Kimura et al., 1999).  
Viewed collectively, these data suggest that interaction of the GnRH receptor with 
different G proteins may explain the published diversity of the mechanisms involved 
in MAPK activation and the subsequent effects on cellular fate.  However, as 
reviewed in chapter one, this theory is not without opposition and, despite largely 
circumstantial evidence, convincing proof of the activation of multiple G proteins by 
the agonist-bound GnRH receptor is still severely lacking. 
 
To better understand the pathways involved in GnRH-mediated cell growth 
inhibition, I set out to clarify the G protein coupling profile of the GnRH receptor.  I 
provide evidence that the receptor couples to G proteins of the Gq/11 family but not to 
Gi/o or Gs as previously suggested.  I also demonstrate that ERK, JNK and P38 
activation, in response to GnRH treatment, may be mediated by Gq/11 and that Gq/11 
may facilitate the induction of antiproliferative signalling by GnRH I.  Moreover, I 
show that the src and the ERK cascades, but neither the JNK nor the P38 pathways, 
also play a pivotal role in this process. 
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3.2  Results 
3.2.1  GnRH I-Induced MAPK Activation may be Mediated by Gq/11 
In order to facilitate the potential coupling of the GnRH receptor to G proteins other 
than Gq/11, I performed a series of experiments in Gαq/11 knockout MEF cells stably 
expressing the receptor protein.  These cells thus eliminate the possible competition 
from Gq/11 for the binding of this GPCR.  The Gαq/11 knockout MEF cell line 
expresses more receptors per cell than either the SCL60 cells or the LβT2 cells whilst 
the binding affinity of GnRH I is not significantly different (figure 3.1; table 3.1).  
Interestingly, the estimated number of GnRH binding sites on αT31 cells is 
approximately 50% of the number on primary gonadotropes (Kaiser et al., 1997).  
Thus, the Gαq/11 knockout MEF cell model may better reflect the GnRH receptor 
expression levels encountered in vivo.   
 
To elucidate the ability of GnRH to activate ERK, JNK and P38 in these cells, GnRH 
I was applied in both time- and dose-dependent manners.  Stimulation brought about 
no significant increase in the levels of pERK1/2, pJNK1 or pP38 at any time or dose 
tested.  Transient expression of Gαq allowed GnRH I to elicit an increase in ERK1/2 
phosphorylation with a maximal response of 3.0 ± 0.4-fold that of vehicle treated 
controls after 5 minutes stimulation (figure 3.2).  Additionally, JNK1 and P38 
phosphorylation became evident giving maximal responses of 3.7 ± 0.3-fold after 5 
minutes stimulation (figure 3.3) and 3.6 ± 0.2-fold after 30 minutes stimulation 
(figure 3.4) respectively.  Agonist dose-response analysis yielded EC50 values for the 
induction of pERK1/2, pJNK1 and pP38, after 10 minutes stimulation, of 1.0 nM 
(figure 3.5), 3.3 nM (figure 3.6) and 2.4 nM (figure 3.7) GnRH I respectively.   
 
In vector transfected cells, the complete absence of Gαq/11 was verified both by 
western blotting (figure 3.8) and the lack of phosphoinositide (PhI) hydrolysis (figure 
3.9).  When compared to LβT2 cells, the levels of Gαq following transient G protein 
expression were within the physiological range.  Additionally, transient transfection 
of Gαq allowed GnRH I to elicit an Emax PhI response of 17.6 ± 0.5-fold that of 
vehicle treated controls.  In contrast, the Emax PhI response obtained in cells 
transfected with vector was 1.4 ± 0.5-fold.  
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Figure 3.1 Radioligand binding assays depicting the expression levels of the 
GnRH receptor.  Intact Gαq/11 knockout MEF cells, stably expressing the GnRH 
receptor, (▲), SCL60 cells (●) and LβT2 cells (■)were incubated with 125I-[His5,D-
Tyr6]GnRH (100,000 cpm/0.5 ml/well) and either vehicle (0.2% propylene glycol; 
V) or increasing doses of unlabelled GnRH I (0.1 nM, 1 nM, 10 nM, 100 nM and 1 
µM) as indicated for 4 hours at 4°C.  Data are representative of at least three 
independent experiments and the mean counts/minute/million cells (CPM/Million 
cells) ± SE is presented. 
 
Cell Line IC50 (nM) 
Gαq/11 knockout MEF 11.1 ± 2.2 
SCL60 10.1 ± 1.7 
LβT2 10.1 ± 1.3 
 
Table 3.1 GnRH I binding affinities.  Data from at least three independent 
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Figure 3.2 Immunoblots depicting the time dependence of the GnRH I-
induced phosphorylation of ERK1/2.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently transfected with vector (black bars) or Gαq 
(white bars) cDNA were serum starved for 16 hours prior to being treated with 
vehicle (0.2% propylene glycol; V) or 1 µM GnRH I for the indicated times.  
Representative blots are shown.  Data from at least three independent experiments 
were quantified (using ERK1/2 as a loading control) and the mean fold over control 
± SE for the activation of ERK1/2 is presented.  p<0.05 (*) represents statistical 
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Figure 3.3 Immunoblots depicting the time dependence of the GnRH I-
induced phosphorylation of JNK1.  Gαq/11 knockout MEF cells, stably expressing 
the GnRH receptor, transiently transfected with vector (black bars) or Gαq (white 
bars) cDNA were serum starved for 16 hours prior to being treated with vehicle 
(0.2% propylene glycol; V) or 1 µM GnRH I for the indicated times.  Representative 
blots are shown.  Data from at least three independent experiments were quantified 
(using ERK1/2 as a loading control) and the mean fold over control ± SE for the 
activation of JNK1 is presented.  p<0.01 (**) represents statistical significance from 
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Figure 3.4 Immunoblots depicting the time dependence of the GnRH I-
induced phosphorylation of P38.  Gαq/11 knockout MEF cells, stably expressing the 
GnRH receptor, transiently transfected with vector (black bars) or Gαq (white bars) 
cDNA were serum starved for 16 hours prior to being treated with vehicle (0.2% 
propylene glycol; V) or 1 µM GnRH I for the indicated times.  Representative blots 
are shown.  Data from at least three independent experiments were quantified (using 
ERK1/2 as a loading control) and the mean fold over control ± SE for the activation 
of P38 is presented.  p<0.05 (*) and p<0.01 (**) represents statistical significance 
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Figure 3.5 Immunoblots depicting the dose dependence of the GnRH I-
induced phosphorylation of ERK1/2.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently transfected with vector (□) or Gαq (■) 
cDNA were serum starved for 16 hours prior to being treated with vehicle (0.2% 
propylene glycol; V) or increasing doses of GnRH I (0.1 nM, 1 nM, 10 nM, 100 nM 
and 1 µM) as indicated for 10 minutes.  Representative blots are shown.  Data from 
at least three independent experiments were quantified (using ERK1/2 as a loading 
control) and the mean fold over control ± SE for the activation of ERK1/2 is 
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Figure 3.6 Immunoblots depicting the dose dependence of the GnRH I-
induced phosphorylation of JNK1.  Gαq/11 knockout MEF cells, stably expressing 
the GnRH receptor, transiently transfected with vector (□) or Gαq (■) cDNA were 
serum starved for 16 hours prior to being treated with vehicle (0.2% propylene 
glycol; V) or increasing doses of GnRH I (0.1 nM, 1 nM, 10 nM, 100 nM and 1 µM) 
as indicated for 10 minutes.  Representative blots are shown.  Data from at least three 
independent experiments were quantified (using ERK1/2 as a loading control) and 
the mean fold over control ± SE for the activation of JNK1 is presented.  p<0.05 (*) 
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Figure 3.7 Immunoblots depicting the dose dependence of the GnRH I-
induced phosphorylation of P38.  Gαq/11 knockout MEF cells, stably expressing the 
GnRH receptor, transiently transfected with vector (□) or Gαq (■) cDNA were serum 
starved for 16 hours prior to being treated with vehicle (0.2% propylene glycol; V) or 
increasing doses of GnRH I (0.1 nM, 1 nM, 10 nM, 100 nM and 1 µM) as indicated 
for 10 minutes.  Representative blots are shown.  Data from at least three 
independent experiments were quantified (using ERK1/2 as a loading control) and 
the mean fold over control ± SE for the activation of P38 is presented.  p<0.05 (*) 
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Figure 3.8 Immunoblots depicting the relative Gαq expression levels.  Gαq/11 
knockout MEF cells transiently transfected with vector (lane 1) or Gαq (lane 2) 
cDNA and LβT2 cells (lane 3) were serum starved for 16 hours.  Unstimulated cell 
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Figure 3.9 Phosphoinositide hydrolysis assays depicting the functionality of 
transfected Gαq.  Gαq/11 knockout MEF cells, stably expressing the GnRH receptor, 
transiently transfected with vector (□) or Gαq (■) cDNA were labelled overnight with 
1 µCi/ml myo-D-[3H]inositol prior to being treated with vehicle (0.2% propylene 
glycol; V) or increasing doses of GnRH I (0.1 nM, 1 nM, 10 nM, 100 nM and 1 µM) 
as indicated for 30 minutes.  Data are representative of at least three independent 
experiments and the mean counts/minute (CPM) ± SE for phosphoinositide 
hydrolysis is presented.  p<0.001 (***) represents statistical significance from 
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3.2.2  The GnRH Receptor does not Directly Interact with Gi/o or Gs 
Thus far I have confirmed that the transfection of Gαq into the Gαq/11 knockout MEF 
cell model allows the detection of significant GnRH-induced activation of ERK, JNK 
and P38.  Nevertheless, previous studies have argued that these responses may also 
be mediated by the interaction of the GnRH receptor with other G protein α subunits 
(Sim et al., 1995, Kimura et al., 1999, Maudsley et al., 2004).  Although my previous 
results indicate that (in the complete absence of Gαq/11) it was not possible to detect 
significant increases in MAPK activation, I attempted to address this theory.  
Initially, I considered the possibility that the overexpression of Gαi may facilitate 
detectable MAPK signalling.  In contrast to Gαq, transient transfection of Gαi1, Gαi2 
or Gαi3 did not enable GnRH I to significantly increase ERK1/2, JNK1 or P38 
phosphorylation (figure 3.10).  Additionally, I made use of a chimeric G protein α 
subunit; Gαqi5.  The carboxy-terminus of the G protein α subunit has previously been 
shown to play a pivotal role in defining the specificity of receptor-G protein 
interaction (Conklin et al., 1993).  Mutation of the five carboxy-terminal amino acids 
is sufficient to completely switch GPCR coupling selectivity.  The cDNA of Gαqi5 
codes for a G protein α subunit consisting of mainly Gαq.  The five carboxy-terminal 
amino acids have, however, been substituted for those from Gαi2.  This facilitates 
Gi/o-coupled GPCR signalling through PLCβ and, as such, a classical Gαq-mediated 
output is indicative of receptor-Gi/o interaction.  Transient expression of Gαqi5 in the 
Gαq/11 knockout MEF cell line did not enable the activated receptor to elicit any 
increase in ERK1/2, JNK1 or P38 phosphorylation (pERK1/2 - 1.0 ± 0.1-fold; 
pJNK1 - 1.1 ± 0.2-fold; pP38 - 1.0 ± 0.1-fold).   
 
In order to address the possibility that the GnRH receptor does interact with Gi/o, but 
that Gi/o does not activate the MAPK cascades thus making it impossible to identify 
such interaction using MAPK phosphorylation as an output, I assessed the ability of 
GnRH to inhibit intracellular cAMP accumulation.  Stimulation of the Gαq/11 
knockout MEF cells with isoproterenol increased intracellular cAMP levels to 14.7 ± 
0.4-fold that of vehicle treated controls (figure 3.11).  Stimulation with isoproterenol 
and GnRH I together did not significantly affect the cAMP response obtained (15.5 ± 
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Figure 3.10 Immunoblots depicting the lack of effect of transient 
overexpression of Gαi1-i3 or Gαqi5 on the GnRH I-induced phosphorylation of 
ERK1/2, JNK1 and P38.  A; Gαq/11 knockout MEF cells, stably expressing the 
GnRH receptor, transiently transfected with vector, Gαi1, Gαi2, Gαi3 or Gαqi5 cDNA 
were serum starved for 16 hours prior to being treated with vehicle (0.2% propylene 
glycol; V; black bars) or 1 µM GnRH I as indicated for 10 minutes.  Representative 
blots are shown.  Data from at least three independent experiments were quantified 
(using ERK1/2 as a loading control) and the mean fold over control ± SE for the 
activation of ERK1/2 (white bars), JNK1 (light grey bars) and P38 (dark grey bars) is 
presented.  B; Gαq/11 knockout MEF cells transiently transfected with vector, Gαi1, 
Gαi2, Gαi3 or Gαqi5 cDNA were serum starved for 16 hours.  Unstimulated cell 
lysates were collected.  Representative blots are shown. 
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Figure 3.11 cAMP assays depicting the effect of GnRH I and isoproterenol on 
intracellular cAMP accumulation.  Gαq/11 knockout MEF cells, stably expressing 
the GnRH receptor, were serum starved for 16 hours prior to being treated with 
vehicle (0.2% propylene glycol; V), 3 µM isoproterenol (Iso), 1 µM GnRH I or 1 µM 
GnRH I and 3 µM isoproterenol as indicated for 30 minutes after a 30 minute 
incubation with 1 mM IBMX.  Data from at least three independent experiments 
were quantified and the mean fold over control ± SE for the stimulation of 
intracellular cAMP accumulation is presented.  p<0.001 (***) represents statistical 
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3.2.3 Coupling of the GnRH Receptor to Gq/11 and the Activation of 
ERK is Involved in GnRH I-Mediated Cell Growth Inhibition 
Continuous treatment of the Gαq/11 knockout MEF cells with GnRH I resulted in a 
time- and dose-dependent inhibition of cell growth (relative to that of vehicle treated 
controls) only in cells transfected with Gαq (figure 3.12).  In these cells, significant 
growth inhibition was evident on day 1 (cell growth was 94 ± 1%) and increased in a 
time-dependent manner to reach a maximum inhibition on day 4 (cell growth was 70 
± 3%).  A P38 inhibitor, SB203580, (cell growth was 75 ± 2% on day 4) (figure 
3.13) and a JNK inhibitor, SP600125, (cell growth was 64 ± 14% on day 4) (figure 
3.14) were unable to significantly rescue this inhibition but a MEK1/2 inhibitor, 
PD98059, (cell growth was 90 ± 2% on day 4) (figure 3.15) significantly decreased 
the GnRH I-induced effect.  Agonist dose-response analysis yielded an IC50 value for 
the induction of cell growth inhibition on day 4 in cells transfected with Gαq of 4.5 
nM GnRH I (figure 3.16).  Vector transfected control cells showed no significant 
inhibition of growth in response to GnRH I treatment nor did any of the MAPK 
inhibitors have a significant effect.  Trypan blue dye exclusion confirmed that the 
detached cells were dead (as measured by dye uptake when compared to either live 
cell suspensions or vector transfected samples) and that these dead cells were more 
numerous than in the samples from vector transfected controls (figure 3.17). 
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Figure 3.12: Sulforhodamine B assays depicting the time dependence of the 
GnRH I-induced inhibition of cell growth.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently infected with GFP (□) or Gαq (■) were 
incubated in media containing 10% serum prior to being treated with vehicle (0.2% 
propylene glycol; V) or 100 nM GnRH I for the indicated times.  Data from at least 
three independent experiments were quantified and the mean % cell growth ± SE is 
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Figure 3.13: Sulforhodamine B assays depicting the SB203580 insensitivity of 
the GnRH I-induced inhibition of cell growth.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently infected with GFP (□, ○) or Gαq (■, ●) 
were incubated in media containing 10% serum in the presence (○, ●) or absence (□, 
■) of 20 µM SB203580 prior to being treated with vehicle (0.2% propylene glycol; 
V) or 100 nM GnRH I for the indicated times.  Data from at least three independent 
experiments were quantified and the mean % cell growth ± SE is presented.  p<0.001 
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Figure 3.14: Sulforhodamine B assays depicting the SP600125 insensitivity of 
the GnRH I-induced inhibition of cell growth.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently infected with GFP (□, ○) or Gαq (■, ●) 
were incubated in media containing 10% serum in the presence (○, ●) or absence (□, 
■) of 50 µM SP600125 prior to being treated with vehicle (0.2% propylene glycol; 
V) or 100 nM GnRH I for the indicated times.  Data from at least three independent 
experiments were quantified and the mean % cell growth ± SE is presented.  p<0.001 
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Figure 3.15: Sulforhodamine B assays depicting the PD98059 sensitivity of the 
GnRH I-induced inhibition of cell growth.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently infected with GFP (□, ○) or Gαq (■, ●) 
were incubated in media containing 10% serum in the presence (○, ●) or absence (□, 
■) of 50 µM PD98059 prior to being treated with vehicle (0.2% propylene glycol; V) 
or 100 nM GnRH I for the indicated times.  Data from at least three independent 
experiments were quantified and the mean % cell growth ± SE is presented.  p<0.01 
(**) and p<0.001 (***) represents statistical significance from vehicle treated 
controls and from GnRH I treated controls. 
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Figure 3.16: Sulforhodamine B assays depicting the dose dependence of the 
GnRH I-induced inhibition of cell growth.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently infected with GFP (□) or Gαq (■) were 
incubated in media containing 10% serum prior to being treated with vehicle (0.2% 
propylene glycol; V) or increasing doses of GnRH I (0.1 nM, 1 nM, 10 nM, 100 nM 
and 1 µM) as indicated for 4 days.  Data from at least three independent experiments 
were quantified and the mean % cell growth ± SE is presented.  p<0.05 (*), p<0.01 
(**) and p<0.001 (***) represents statistical significance from vehicle treated 
controls. 
 




Figure 3.17 Trypan Blue dye exclusion assays depicting the time dependence 
of the GnRH I-induced cell death.  Gαq/11 knockout MEF cells, stably expressing 
the GnRH receptor, transiently infected with GFP or Gαq were incubated in media 
containing 10% serum prior to being treated with vehicle (0.2% propylene glycol) or 
100 nM GnRH I for the indicated times.  Representative images are shown. 
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3.2.4 GnRH I-Mediated Cell Growth Inhibition Occurs Independently 
of PKC and Ca2+ but Src Plays a Pivotal Role  
Given that my previous results indicate that there exists a crucial role for Gαq/11 in 
the GnRH I-mediated inhibition of cell growth, I attempted to further elucidate the 
signalling pathway involved in such a process.  Activation of the Gαq/11 G protein α 
subunits leads to the rapid and pronounced stimulation of PLCβ (Taylor et al., 1990, 
Lee et al., 1992a).  Subsequently, PIP2 hydrolysis to IP3 occurs with resultant 
elevation of intracellular Ca2+.  Additionally, the same reaction results in the 
formation of DAG, the physiological regulator of PKC activity.  PKC has been 
reported to have an effect on the GnRH-mediated inhibition of cell growth 
(Yamamoto et al., 2001, Kim et al., 2006, Morgan et al., 2008).  The role of Ca2+ in 
this process, however, has not been widely investigated.  In my hands, PKC 
inhibition with Ro-31-8220 (cell growth was 80 ± 4% on day 4) (figure 3.18) or the 
chelation of intracellular calcium with BAPTA-AM (cell growth was 79 ± 2% on day 
4) (figure 3.19) did not in any way influence the GnRH I-induced antiproliferative 
response.  Interestingly, a 5-fold lower concentration of BAPTA-AM has previously 
been shown to completely inhibit the thrombin- or bradykinin-induced increase in 
intracellular Ca2+ in the same cell type (Vogt et al., 2003) and several studies have 
shown significant effects of both of these inhibitors, when used at equimolar 
concentrations, on the GnRH-mediated signalling cascades (Mulvaney and 
Roberson, 2000, Maudsley et al., 2007). 
 
These data indicate that while Gαq/11 is essential for the GnRH I-induced inhibition 
of cell growth to occur, such inhibition does not rely on the canonical signalling 
pathways activated by these G protein α subunits.  A recent study by Voisin and 
colleagues reported similar findings at the orexin OX1 receptor (Voisin et al., 2008).  
The authors demonstrated that orexin-induced apoptosis is mediated by a mechanism 
driven by SHP-2 phosphatase recruitment to the receptor.  This recruitment requires 
Gαq/11 but occurs independently of the activity of PLCβ.  Moreover, the authors 
highlighted a critical role for src in this process.  It was proposed that, while Gαq/11 is 
necessary for the induction of the orexin-mediated proapoptotic response, src-
mediated Tyr phosphorylation of the receptor protein is central to this signalling 
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mechanism.  Upon phosphorylation, the OX1 receptor was shown to recruit and 
associate with SHP-2 directly at a pYxxL motif in the intracellular end of TM7.  This 
association was demonstrated to be critical for the orexin-mediated induction of 
apoptosis to occur.  Given that evidence from our laboratory indicates that GnRH I 
may potently activate SHP-2 in both dose- and time-dependent manners, and that src 
is an absolute requirement for such activation (Coetsee and Lu, unpublished 
observations), I sought to investigate whether src is involved in the regulation of the 
GnRH I-mediated inhibition of cell growth.  Inhibition of src with PP2 was sufficient 
to completely prevent the GnRH I-induced antiproliferation in Gαq/11 knockout MEF 
cells transiently transfected with Gαq.  In Gαq transfected GnRH treated controls, cell 
growth was 81 ± 1% after a 4 day exposure to GnRH I (figure 3.20).  PP2 treatment 
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Figure 3.18: Sulforhodamine B assays depicting the Ro-31-8220 insensitivity of 
the GnRH I-induced inhibition of cell growth.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently infected with GFP (□, ○) or Gαq (■, ●) 
were incubated in media containing 10% serum in the presence (○, ●) or absence (□, 
■) of 100 nM Ro-31-8220 prior to being treated with vehicle (0.2% propylene 
glycol; V) or 100 nM GnRH I for the indicated times.  Data from at least three 
independent experiments were quantified and the mean % cell growth ± SE is 
presented.  p<0.001 (***) represents statistical significance from vehicle treated 
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Figure 3.19: Sulforhodamine B assays depicting the BAPTA-AM insensitivity 
of the GnRH I-induced inhibition of cell growth.  Gαq/11 knockout MEF cells, 
stably expressing the GnRH receptor, transiently infected with GFP (□, ○) or Gαq (■, 
●) were incubated in media containing 10% serum in the presence (○, ●) or absence 
(□, ■) of 50 µM BAPTA-AM prior to being treated with vehicle (0.2% propylene 
glycol; V) or 100 nM GnRH I for the indicated times.  Data from at least three 
independent experiments were quantified and the mean % cell growth ± SE is 
presented.  p<0.001 (***) represents statistical significance from vehicle treated 
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Figure 3.20: Sulforhodamine B assays depicting the PP2 sensitivity of the 
GnRH I-induced inhibition of cell growth.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently infected with GFP (□, ○) or Gαq (■, ●) 
were incubated in media containing 10% serum in the presence (○, ●) or absence (□, 
■) of 10 µM PP2 prior to being treated with vehicle (0.2% propylene glycol; V) or 
100 nM GnRH I for the indicated times.  Data from at least three independent 
experiments were quantified and the mean % cell growth ± SE is presented.  p<0.001 
(***) represents statistical significance from vehicle treated controls and from GnRH 
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3.3  Discussion 
Binding of GnRH to its receptor at the plasma membrane initiates a variety of 
intracellular signalling events with distinct physiological outcomes.  Since the 
original observations of GnRH-induced cell growth inhibition on receptor expressing 
cell lines (Miller et al., 1985), substantial effort has been directed towards delineating 
the precise mechanism(s) involved.  Considerable evidence suggests that the 
signalling cascades involved in GnRH-mediated cell growth inhibition are distinct 
from those involved in regulating gonadotropin secretion (Limonta et al., 2003, 
Maudsley et al., 2004, Millar et al., 2008) and one possibility to explain this 
divergent signalling is to hypothesise the inherent ability of the GnRH receptor to 
directly interact with multiple families of G proteins.  Multiplicity of G protein 
coupling has after all been successfully confirmed for several other GPCRs including 
the β2-adrenergic receptor (Wenzel-Seifert and Seifert, 2000), the muscarinic 
receptors (Akam et al., 2001) and the chemokine CXCR2 receptor (Hall et al., 1999).  
However, circumstantial evidence of such interaction forms the basis of much of the 
literature published to date and the frequently repeated paradigm of the ability of the 
GnRH receptor to directly interact with Gi/o and Gs has led to confusion regarding the 
mechanisms which underpin GnRH-mediated antiproliferation.  To critically address 
this issue, I studied the G protein coupling profile of the GnRH receptor in stably 
transfected MEF cells derived from Gαq/11 knockout mice (Offermanns et al., 1998).  
Additionally, I investigated the roles of the various G proteins in the activation of 
ERK, JNK and P38 and the downstream cellular effects of the activation of these 
MAPK modules. 
 
GnRH-mediated MAPK activation has been extensively studied over the past two 
decades (Sim et al., 1993, Sim et al., 1995, Reiss et al., 1997, Haisenleder et al., 
1998, Levi et al., 1998, Roberson et al., 1999, Naor et al., 2000, Benard et al., 2001, 
Bonfil et al., 2004, Davidson et al., 2004, Kraus et al., 2004, Maudsley et al., 2004, 
Dobkin-Bekman et al., 2006).  Several investigations have shown that 
phosphorylation of these proteins readily occurs upon GnRH stimulation of receptor 
expressing cell lines and that this activation is dependent on the activity of PLCβ and 
PKC.  Indeed, Roberson and colleagues showed that specific depletion of PKC 
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isoforms in αT31 cells blocks the GnRH-induced activation of P38 (Roberson et al., 
1999).  Similarly, Levi and colleagues demonstrated that PKC inhibition with 
GF109203X in the same cell type is sufficient to significantly inhibit GnRH-
mediated JNK activation (Levi et al., 1998).  These studies thus suggest that GnRH-
induced MAPK activation is, at least partially, dependent on Gq/11.  However, the role 
of Gi/o in MAPK activation in response to GnRH has also been the subject of much 
research.  ERK activation in αT31 cells has been suggested to depend on a dual 
mechanism involving PKC and Gi/o (Sim et al., 1995).  Similarly, in Caov3 cells 
(which have been shown to express GnRH receptor mRNA), ERK activation has 
been hypothesised as being mediated by a combination of interactions involving the 
Gαi/o G protein α subunits and the Gβγ complex (Kimura et al., 1999).  Studies using 
PTX have also proposed a role for Gαi/o in the GnRH-induced phosphorylation of 
JNK and P38 (Maudsley et al., 2004).  Interestingly, my data contradicts these 
studies as I have found no evidence to support the theory of GnRH-induced 
activation of these MAPKs by Gi/o, even when artificially overexpressed in the Gαq/11 
knockout MEF cell system.  I have however confirmed that Gq/11-mediated signalling 
plays a pivotal role.  
 
Elegant studies have shown that the expression of Gαqi5 with other GPCRs 
successfully enables Gi/o-coupled receptors to signal through PLCβ and PKC 
(Conklin et al., 1993, Coward et al., 1999).  It follows then that the inability of 
GnRH to induce phosphorylation of ERK, JNK or P38 when Gαqi5 is expressed 
suggests that the GnRH receptor does not directly interact with the G protein α 
subunits of the Gi/o family.  This conclusion is strengthened by the observation that 
GnRH does not inhibit isoproterenol-induced cAMP accumulation.  However, by 
definition, one of the most direct measures of G protein activation by an activated 
receptor is receptor catalysed GDP/GTP exchange.  Other analytical approaches may 
yield indirect results and the notion of GnRH receptor-Gi/o interaction has largely 
been derived from circumstantial evidence using PTX (Hawes et al., 1993, Sim et al., 
1995, Imai et al., 1996, Kimura et al., 1999, Limonta et al., 1999, Maudsley et al., 
2004, Romanelli et al., 2004, Imai et al., 2006).  In this case, recent research from 
our laboratory (White et al., 2008a), taken together with the observations of Grosse 
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and colleagues who reported exclusive GnRH receptor-mediated labelling of Gαq/11 
with [-32P]GTP azidoanilide (Grosse et al., 2000), show definitively that the GnRH 
receptor does not directly couple to Gi/o but does interact with Gq/11.  A report by 
Shah and colleagues using activated G protein subunits as an output support this 
interpretation (Shah et al., 1995).  Here, stimulation of αT31 cells with GnRH 
agonists resulted in the elevated agonist-induced downregulation of Gαq/11.  Gαi/o 
remained unaffected.  Interestingly, it has recently been shown that the G protein α 
subunits can be activated directly by RTKs (Shan et al., 2006).  Thus, it is possible 
that GnRH receptor-mediated RTK transactivation could be responsible for previous 
interpretations implicating a direct interaction of the receptor with Gi/o.   
 
In the early 1990s, Janovick and Conn showed that treatment of rat pituitary cultures 
with CTX increased LH release in response to GnRH treatment and interpreted this 
finding as demonstrating that the GnRH receptor is directly coupled to Gs (Janovick 
and Conn, 1993).  Since then, many other groups have studied this possibility but the 
results are inconclusive.  The cAMP pathway is important for gonadotrope function 
in that it is thought to play a role in the regulation of LHβ gene expression (Starzec et 
al., 1989, Horton and Halvorson, 2004).  However, the involvement of Gs in this 
GnRH-induced signalling cascade is still debated.  Using palmitoylation as a 
measure of G protein activation, it was suggested that there was a direct interaction 
between the GnRH receptor and Gs in rat pituitary cells (Stanislaus et al., 1998b) and 
this hypothesis was recapitulated in the LβT2 cell line using cell permeable peptides 
that uncouple Gαs from the receptor (Liu et al., 2002b).  However, the Gudermann 
group examined the possibility of a direct interaction between the activated receptor 
and Gαs and, in agreement with my findings, failed to detect any Gαs-mediated signal 
transduction in response to GnRH treatment (Grosse et al., 2000).  Additionally, 
Larivière and colleagues recently identified a novel signalling pathway involving 
PKCδ and PKCε which may mediate GnRH-induced activation of a cAMP sensitive 
promoter in LβT2 cells (Lariviere et al., 2007).  These data, viewed collectively with 
my own observations, question the possibility of a direct interaction between the 
GnRH receptor and Gs.  Interestingly, it has also been shown that specific adenylyl 
cyclase isoforms may be activated directly by the Gβγ complex (Gao and Gilman, 
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1991, Tang and Gilman, 1991, Yoshimura et al., 1996, Steiner et al., 2006) or 
independently of G proteins altogether (Feldman and Gros, 2007).  Given that I 
cannot detect any cAMP accumulation in response to GnRH treatment in the Gαq/11 
knockout MEF cell model, taken together with the fact that the β2-adrenergic 
receptor agonist isoproterenol can elicit a marked increase in intracellular cAMP, I 
would suggest that the GnRH receptor does not directly interact with Gs.  
 
The MAPK pathways are evolutionarily conserved kinase cascades that link 
extracellular signals to the machinery that controls fundamental cellular processes 
such as growth, proliferation, differentiation, migration and apoptosis.  Historically, 
ERK signalling was synonymous with cell proliferation (Dhillon et al., 2007) whilst 
the JNK and the P38 pathways were regarded as being stress activated (Yamauchi et 
al., 2001).  Involvement of the JNK and the P38 signalling cascades in the GPCR-
induced inhibition of cell proliferation has been widely documented (Pearson et al., 
2001, Yamauchi et al., 2001, Dhillon et al., 2007, Raman et al., 2007) and here the 
GnRH receptor is no exception (Kraus et al., 2004, Maudsley et al., 2004, Dobkin-
Bekman et al., 2006, Zhang et al., 2006).  In contrast to these data, I showed that P38 
and JNK do not influence GnRH I-induced cell growth inhibition.  Additionally, I 
demonstrated that, in agreement with previous studies (Kimura et al., 1999, Kim et 
al., 2006), the ERK signalling pathway plays a critical role.  
 
ERK has been implicated in cell growth inhibition, cell cycle arrest and the induction 
of proapoptotic signalling in a number of cell types (Goulet et al., 2005, Koike et al., 
2006) and a large body of evidence indicates that the strength and duration of the 
ERK signal is kernel in determining cellular fate (Marshall, 1995, Meloche and 
Pouyssegur, 2007, White et al., 2008b).  Several studies have shown that strong and 
prolonged activation of ERK by constitutively active Ras or Raf leads to arrest in the 
G1 phase of the cell cycle by inducing the expression of cyclin-dependent kinase 
(CDK) inhibitors such as p53 and p21 (Pumiglia and Decker, 1997, Sewing et al., 
1997).  As such, it seems plausible to speculate that continuous exposure of the 
Gαq/11 knockout cells to GnRH I would result in ERK activation of a similar strength 
and duration.  Thus, by inhibiting this pathway, this activation is abolished and the 
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GnRH I-induced inhibition of cell growth is significantly diminished.  Interestingly, 
Zhang and colleagues demonstrated that, in LβT2 cells, p53 is phosphorylated by 
GnRH in a P38-dependent manner (Zhang et al., 2006).  While my results do not 
indicate a role for P38 in GnRH I-mediated cell growth inhibition, it is possible that 
the transformation of the LβT2 cell line with SV40 large T antigen may influence the 
signalling pathways involved.  Indeed, the transformation domains of this 
oncoprotein have been shown to directly interact with a number of intracellular 
proteins including p53 (Ali and DeCaprio, 2001).   
 
The observation that both Gαq and src were necessary for GnRH I to induce a 
significant inhibition of cell growth, but that this inhibition occurred independently 
of PKC and Ca2+, suggests that the GnRH receptor has the ability to modulate the 
activity of other Gq/11-dependent signalling pathways which regulate GnRH I-
mediated antiproliferation.  An attractive candidate which may be involved in such 
signalling events is SHP-2.  Indeed, Coetsee and colleagues have demonstrated that 
GnRH I potently induces the activation of SHP-2 (Coetsee and Lu, unpublished 
observations).  Furthermore, the intracellular domain of TM7 of the GnRH receptor 
possesses a YxxL motif which is known to, when Tyr phosphorylated, form part of 
the consensus sequence involved in the binding of SHPs to immunoreceptors 
(Unkeless and Jin, 1997).  Additionally, SHP-2 has been implicated in the 
bradykinin-induced regulation of cellular proliferation at the B2 receptor (Duchene et 
al., 2002) and both SHP-1 and SHP-2 have been demonstrated to be critical for the 
somatostatin SST2 receptor-induced inhibition of cell growth to occur (Lopez et al., 
2001, Ferjoux et al., 2003).  Interestingly, Ferjoux and colleagues also showed that 
src is central to the initiation of the somatostatin-induced response (Ferjoux et al., 
2003).  Upon SST2 receptor activation, src was demonstrated to Tyr phosphorylate 
the receptor protein (Ferjoux et al., 2003).  Such phosphorylation results in SHP-2 
recruitment to the newly formed SH2 binding domain, consequent activation of the 
phosphatase and subsequent somatostatin-induced cell growth inhibition (Ferjoux et 
al., 2003).  Similarly, SHP-2 activation by GnRH has been shown to be totally 
dependent on src activation (Coetsee and Lu, unpublished observations).  Thus, I 
propose that the GnRH-mediated activation of SHP-2 may be involved in the 
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regulation of the GnRH I-induced antiproliferative response.  Furthermore, it is 
possible to speculate on the signalling pathways that may be important.   
 
Firstly, analogous to the results obtained by Ferjoux and colleagues (Ferjoux et al., 
2003) and Voisin and colleagues (Voisin et al., 2008), it is plausible that src may be 
activated by the Gβγ complex of Gq/11.  Indeed, src has previously been shown to be 
activated downstream of these G protein subunits (Shajahan et al., 2004, Gentili et 
al., 2006).  In this regard, the presence of Gαq/11 would be necessary for dissociation 
of the heterotrimeric complex.  Upon receptor activation and consequent 
dissociation, Gβγ-mediated src activation and resultant Tyr phosphorylation of the 
receptor at the YxxL motif could occur.  Such signalling events could result in SHP-
2 recruitment and activation and, consequently, downstream regulation of the ERK 
cascade.  Indeed, Coetsee and colleagues have shown that a SHP-2 dominant 
negative construct significantly inhibits GnRH-induced ERK activation (Coetsee and 
Lu, unpublished observations) and my results indicate that the GnRH I-mediated 
activation of the ERK cascade is involved in the GnRH I stimulated inhibition of cell 
growth.  In addition, evidence suggests that it is not possible to demonstrate GnRH-
induced SHP-2 activation in the Gαq/11 knockout MEF cell line implying that Gαq/11 
is necessary for such activation to occur (Coetsee and Lu, unpublished observations).   
 
A second possibility to explain my observations is based on a study by Feng and 
colleagues (Feng et al., 2002).  The authors demonstrated that SHP-1-AT2 receptor 
association and consequent SHP-1 activation requires the presence of Gαs but is 
independent of both G protein activation (Gαs was shown to interact with SHP-1 and 
thus act as a scaffold for the phosphatase at this GPCR) and angiotensin-induced AT2 
receptor Tyr phosphorylation.  Interestingly, however, the authors did not investigate 
the role of the Tyr residue in the NPxxY motif of the AT2 receptor and this residue 
has been shown to be critical for SHP-2 activation via the B2 receptor (Duchene et 
al., 2002).  Thus, in the context of my data, upon transfection of Gαq and receptor 
activation, SHP-2 may be expected to associate with both the GnRH receptor and 
Gαq/11.  Such association may mediate GnRH I-induced antiproliferative signalling 
through the ERK cascade.  This association and consequent signalling, however, may 
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still require Tyr phosphorylation of the GnRH receptor which may involve the GnRH 
I-mediated activation of src.  How src could become activated by this GPCR is, in 
the context of these experiments, not clear.   
 
The ability of many hormones and neurotransmitters to evoke diverse physiological 
and pathological responses, by binding to a single cognate receptor, brought about 
the hypothesis that one GPCR may have the inherent ability to activate multiple G 
proteins.  As such, the differential effects of GnRH at central and peripheral sites 
have been proposed to be mediated via interaction of the activated receptor with 
Gq/11, Gi/o and Gs.  In this chapter, I have provided evidence to suggest that the GnRH 
receptor does not couple to G proteins of either the Gi/o or the Gs families, that 
MAPK activation in response to GnRH treatment is entirely dependent, of the G 
protein α subunits tested, on Gαq/11 and that the src and the ERK pathways are 
significantly involved in GnRH I-mediated cell death.  Thus, while I cannot 
completely rule out cell background specific differences, I propose that signal 
transduction that is indicative of coupling to Gi/o or Gs is determined downstream of 
the receptor-G protein interface or is mediated by different signalling mechanisms 
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4.0 Abstract 
Previous studies propose that the GnRH receptor may adopt multiple active 
conformations and modulate the activity of distinct intracellular signalling cascades.  
Furthermore, a large number of Gq/11-coupled GPCRs are known to directly interact 
with G12/13.  In this chapter, given my previous data, I investigated the possibility of 
GnRH-induced activation of the G12/13 G proteins.  Transient transfection of both the 
Gα12 and the Gα13 subunits into Gαq/11 knockout MEF cells resulted in Gq/11-
independent ERK activation.  In BHK cells, which endogenously express both Gq/11 
and G12/13, GnRH I and GnRH II stimulated SRE-luciferase reporter gene activity.  
Both signals were significantly reduced by YM-254890 and Gα13 (Gα13G225A) and 
p115 RhoGEF (ΔDH-p115 RhoGEF) dominant negative mutants.  Transient 
transfection of increasing amounts of Gα13G225A cDNA gradually decreased the 
GnRH stimulation of PhI hydrolysis.  Additionally, the GnRH receptor and both 
endogenous Gα13 and Gα13G225A could be coimmunoprecipitated.  Surprisingly, 
stimulation of Gαq/11 knockout MEF cells with GnRH I promoted the cortical 
polymerisation of actin and the formation of lamellipodia.  In contrast, stimulation 
with GnRH II increased the formation of stress fibres.  Y-27632, a ROCK inhibitor, 
potentiated the GnRH I-induced actin polymerisation and completely abolished the 
GnRH II stimulated response.  A src inhibitor (PP2) markedly inhibited the GnRH I-
induced cytoskeletal change but had no effect on the GnRH II stimulated stress fibre 
formation.  Coimmunoprecipitation confirmed that the GnRH receptor could interact 
with src.  In Gαq/11 knockout MEF cells or SCL60 cells in the presence of YM-
254890, GnRH I but not GnRH II elicited an increase in src Tyr phosphorylation.  
Interestingly, the transcriptional activity of a LHβ and a FSHβ promoter was partially 
inhibited by a PLCβ inhibitor (U-73122) and ΔDH-p115 RhoGEF but not PP2.  U-
73122 and ΔDH-p115 RhoGEF together completely abolished the GnRH I 
stimulated response.  These data therefore suggest that the GnRH receptor can couple 
to G12/13 and that this signalling pathway may play an important role in the regulation 
of the synthesis of the gonadotropins.  In addition, they confirm that the GnRH 
receptor may directly interact with src and suggest that GnRH I but not GnRH II 
may, independently of Gq/11, Tyr phosphorylate and thus activate this Tyr kinase. 
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4.1  Introduction 
Evidence from our laboratory proposes that the GnRH receptor may adopt multiple 
receptor active conformations, which can be induced by the binding of different 
GnRH ligands, and thus differentially activate discrete intracellular signalling 
cascades.  Lu and colleagues showed that individual Ala substitution of Met132, 
Met227, Phe272, Phe276, Ile322 and Tyr323, which lie deep within the TMs and are 
proposed to be remote from the ligand binding site, specifically increases the binding 
affinity of GnRH II but not GnRH I (Lu et al., 2005).  These results therefore suggest 
that the binding of GnRH I and GnRH II facilitates the disruption of different 
combinations of receptor intramolecular constraints and thus induces different 
conformational changes of this GPCR.  Given that the evidence presented within 
chapter three suggests that the GnRH receptor couples to Gq/11, but not to Gi/o or Gs, 
these data propose that it may modulate the activity of other as yet undefined 
signalling pathways.  Taken together with the fact that a large number of Gq/11-
coupled GPCRs are known to also activate G12/13 (Riobo and Manning, 2005), I 
investigated the possible GnRH-mediated activation of the G12/13 G protein family.   
 
The potential activation of G12/13 by GnRH has not been well elucidated.  Grosse and 
colleagues were unable to detect interaction between this GPCR and Gα12 or Gα13 
using [α-32P]GTP azidoanilide and subsequent immunoprecipitation with antisera 
raised against these Gα subunits (Grosse et al., 2000).  However, their assays were 
carried out on plasma membrane preparations of αT31 and CHO cells.  Recent 
evidence suggests that the Gα13 subunits localise exclusively within the cytoplasm of 
COS7 cells and only translocate to the membrane upon GPCR activation (Yamazaki 
et al., 2005).  Additionally, the cellular background in which any experiments are 
performed has been suggested to influence the stoichiometry of GnRH-induced 
signalling, in part by modulating the G protein coupling ability of the GnRH receptor 
(Dobkin-Bekman et al., 2006).  Furthermore, competition among many different G 
proteins for a receptor may give rise to negative results (Riobo and Manning, 2005).  
As discussed in the previous chapter, expression of the GnRH receptor in Gαq/11 
knockout MEF cells eliminates the potential competition from Gq/11.  Thus, the use of 
this cell model may better facilitate the identification of Gq/11-independent signalling 
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pathways.  In this chapter, using Gαq/11 knockout MEF cells and pathway specific 
inhibitors, dominant negative constructs and coimmunoprecipitation assays in other 
cell lines, I show that the GnRH receptor can directly activate G12/13.  Furthermore, 
the evidence gained during the completion of these studies confirms previous work 
from our laboratory indicating that the GnRH receptor may interact with src Tyr 
kinase and provides data to suggest that GnRH I but not GnRH II may induce Gq/11-
independent src activation. 
 
4.2  Results 
4.2.1 GnRH I Stimulates Gq/11-Independent ERK Activation  
The data presented within chapter three indicates that no GnRH-induced pERK1/2 
response was evident in the Gαq/11 knockout MEF cell line which stably expresses 
the GnRH receptor.  In order to eliminate the possibility that this result was due to a 
low endogenous cellular expression of G12/13, or the sensitivity of the western 
detection system, I transiently transfected independently both Gα12 and Gα13 into 
these cells.  Overexpression of Gα12 or Gα13 resulted in hitherto indemonstrable ERK 
activation in the absence of Gαq.  For cells transfected with Gα12, pERK1/2 was 
significantly maximally increased 1.9 ± 0.1-fold above that of vehicle treated 
controls 5 minutes post-stimulation (figure 4.1).  Similarly, Gα13 transfection elicited 
a significant maximal pERK1/2 response of 2.0 ± 0.0-fold 5 minutes after GnRH I 
application.  Consistent with my previous data, no significant increase in ERK 
activation was observed in vector transfected control cells at any time point tested.   









































































Figure 4.1 Immunoblots depicting the time dependence of the GnRH I-
induced phosphorylation of ERK1/2.  Gαq/11 knockout MEF cells, stably 
expressing the GnRH receptor, transiently transfected with vector (A; grey bars), 
Gα12 (B; white bars) or Gα13 (C; black bars) cDNA were serum starved for 16 hours 
prior to being treated with vehicle (0.2% propylene glycol; V) or 1 µM GnRH I for 
the indicated times.  Representative blots are shown.  Data from at least three 
independent experiments were quantified (using ERK1/2 as a loading control) and 
the mean fold over control ± SE for the activation of ERK1/2 is presented.  p<0.05 
(*) represents statistical significance from vehicle treated controls. 
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4.2.2 GnRH Stimulates SRE-Promoted Reporter Gene Activity 
Arguably one of the most common methodologies used to study the activation of G 
proteins of the G12/13 family is to observe the SRE-driven transcriptional response 
(Riobo and Manning, 2005).  This technique does not provide definitive answers 
regarding direct GPCR-G protein interaction but it does provide an indication of 
GPCR ligand-induced G12/13 activation.  A number of studies have used 
constitutively active Gα mutants to verify that G12/13 stimulates SRE-promoted 
transcription (Fromm et al., 1997, Mao et al., 1998a, Shi et al., 2000, Suzuki et al., 
2003, Vazquez-Prado et al., 2004).  Similarly, I utilised GTPase deficient G protein α 
subunits to validate this method as a means of studying the possibility of GnRH-
induced G12/13-mediated signalling.  Only constitutively active Gαq (GαqQ209L), 
Gα12 (Gα12Q231L) or Gα13 (Gα13Q226L) could provoke significant increases in the 
SRE-luciferase signal and elicited responses of 2.7 ± 0.5-fold, 1.5 ± 0.1-fold and 2.2 
± 0.3-fold that of vector transfected controls respectively (figure 4.2).  Gαi2 
(Gαi2Q205L) and Gαs (GαsQ227L) were completely without effect (1.0 ± 0.1-fold 
and 1.0 ± 0.2-fold respectively). 
 
SRE-luciferase reporter gene assays revealed that both GnRH I and GnRH II were 
able to induce a SRE-driven transcriptional response.  GnRH I elicited a significant 
increase in luciferase activity of 7.7 ± 0.3-fold that of vehicle treated controls (figure 
4.3; table 4.1).  GnRH II, however, provoked a much lower luciferase response of 3.8 
± 0.3-fold.  These data are inconsistent with the GnRH-induced Gq/11-mediated 
stimulation of PhI hydrolysis.  In this case, both GnRH ligands stimulate a similar 
maximal activity (Lu et al., 2007).  Dose-respone data obtained after initial 
submission of this thesis also revealed that the luciferase output stimulated by both 
GnRH I and GnRH II is maximal at the 1 μM concentration used.  Thus, in order to 
clarify the signalling cascades involved, signalling pathway specific inhibitors and 
dominant negative constructs were utilised.  The transcriptional signal induced by 
both GnRH ligands was significantly inhibited by YM-254890 (GnRH I - 2.8 ± 0.1-
fold; GnRH II - 1.5 ± 0.1-fold) (figure 4.4; table 4.1).  Notably, however, the 
luciferase response elicited by either GnRH was still significantly increased above 
basal values and YM-254890 completely inhibits Gαq/11-mediated signalling at the 
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100 nM concentration used (figure 4.5).  PTX had no significant effect on the 
luciferase readout obtained in response to either GnRH I or GnRH II (GnRH I - 8.4 ± 
1.3-fold; GnRH II - 3.4 ± 0.5-fold) (figure 4.6; table 4.1).  A dominant negative Gα13 
mutant (Gα13G225A) (GnRH I - 5.2 ± 0.2-fold; GnRH II - 2.4 ± 0.1-fold) (figure 4.7; 
table 4.1) and a dominant negative p115 RhoGEF mutant (ΔDH-p115 RhoGEF) 
(GnRH I - 5.3 ± 0.2-fold; GnRH II - 2.1 ± 0.2-fold) (figure 4.8; table 4.1) 
significantly inhibited the luciferase signals obtained after stimulation with either 
GnRH.  Importantly, ΔDH-p115 RhoGEF has been demonstrated to inhibit the Gα13-
induced SRE luciferase response but not that mediated by Gαq (Mao et al., 1998b).  
Interestingly, under all the conditions tested, a difference in the maximal SRE-
luciferase signal induced by both GnRHs still existed.  Transient expression of ΔDH-
p115 RhoGEF and subsequent incubation with YM-254890 completely inhibited the 
luciferase response obtained after stimulation with GnRH II (1.0 ± 0.1-fold) (figure 
4.9; table 4.1).  In contrast, GnRH I still displayed the ability to induce SRE-driven 
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Figure 4.2 SRE-luciferase reporter gene assays depicting the GTPase 
deficient Gα subunit-induced stimulation of SRE-promoted transcriptional 
activity.  BHK cells, stably expressing a SRE-luciferase reporter, transiently 
transfected with vector, GαqQ209L, Gαi2Q205L, GαsQ227L, Gα12Q231L or 
Gα13Q226L cDNA were serum starved for 40 hours.  Luciferase activity was 
expressed in arbitrary units and normalised for Renilla luciferase activity.  Data from 
at least three independent experiments were quantified and the mean fold over 
control ± SE for the activation of SRE-luciferase is presented.  p<0.05 (*) represents 
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Figure 4.3 SRE-luciferase reporter gene assays depicting the GnRH-induced 
stimulation of SRE-promoted transcriptional activity.  BHK cells, stably 
expressing the GnRH receptor and a SRE-luciferase reporter, were serum starved for 
16 hours prior to being treated with vehicle (0.2% propylene glycol; V), 1 µM GnRH 
I or 1 µM GnRH II as indicated for 24 hours.  Luciferase activity was expressed in 
arbitrary units and normalised for Renilla luciferase activity.  Data from at least three 
independent experiments were quantified and the mean fold over control ± SE for the 
activation of SRE-luciferase is presented.  p<0.001 (***) represents statistical 
significance from vehicle treated controls. 
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Figure 4.4 SRE-luciferase reporter gene assays depicting the YM-254890 
sensitivity of the GnRH-induced stimulation of SRE-promoted transcriptional 
activity.  BHK cells, stably expressing the GnRH receptor and a SRE-luciferase 
reporter, were serum starved for 16 hours in the presence (white bars) or absence 
(black bars) of 100 nM YM-254890 prior to being treated with vehicle (0.2% 
propylene glycol; V), 1 µM GnRH I or 1 µM GnRH II as indicated for 24 hours.  
Luciferase activity was expressed in arbitrary units and normalised for Renilla 
luciferase activity.  Data from at least three independent experiments were quantified 
and the mean fold over control ± SE for the activation of SRE-luciferase is presented.  
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Figure 4.5 Phosphoinositide hydrolysis assays depicting the YM-254890 
sensitivity of the GnRH-induced stimulation of phosphoinositide hydrolysis.  
BHK cells, stably expressing the GnRH receptor, were labelled overnight with 1 
µCi/ml myo-D-[3H]inositol in the presence or absence of 100 nM YM-254890 as 
indicated prior to being treated with 1 µM GnRH I (black bars) or 1 µM GnRH II 
(white bars) for 30 minutes.  Data from at least three independent experiments were 
quantified and the mean % maximum ± SE for phosphoinositide hydrolysis is 
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Figure 4.6 SRE-luciferase reporter gene assays depicting the PTX 
insensitivity of the GnRH-induced stimulation of SRE-promoted transcriptional 
activity.  BHK cells, stably expressing the GnRH receptor and a SRE-luciferase 
reporter, were serum starved for 16 hours in the presence (white bars) or absence 
(black bars) of 200 ng/ml PTX prior to being treated with vehicle (0.2% propylene 
glycol; V), 1 µM GnRH I or 1 µM GnRH II as indicated for 24 hours.  Luciferase 
activity was expressed in arbitrary units and normalised for Renilla luciferase 
activity.  Data from at least three independent experiments were quantified and the 
mean fold over control ± SE for the activation of SRE-luciferase is presented.  For 
ease of presentation, statistical analysis is shown in table 4.1. 
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Figure 4.7 SRE-luciferase reporter gene assays depicting the Gα13G225A 
sensitivity of the GnRH-induced stimulation of SRE-promoted transcriptional 
activity.  BHK cells, stably expressing the GnRH receptor and a SRE-luciferase 
reporter, transiently transfected with vector (black bars) or Gα13G225A (white bars) 
cDNA were serum starved for 16 hours prior to being treated with vehicle (0.2% 
propylene glycol; V), 1 µM GnRH I or 1 µM GnRH II as indicated for 24 hours.  
Luciferase activity was expressed in arbitrary units and normalised for Renilla 
luciferase activity.  Data from at least three independent experiments were quantified 
and the mean fold over control ± SE for the activation of SRE-luciferase is presented.  
For ease of presentation, statistical analysis is shown in table 4.1. 
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Figure 4.8 SRE-luciferase reporter gene assays depicting the ΔDH-p115 
RhoGEF sensitivity of the GnRH-induced stimulation of SRE-promoted 
transcriptional activity.  BHK cells, stably expressing the GnRH receptor and a 
SRE-luciferase reporter, transiently transfected with vector (black bars) or ΔDH-
p115 RhoGEF (white bars) cDNA were serum starved for 16 hours prior to being 
treated with vehicle (0.2% propylene glycol; V), 1 µM GnRH I or 1 µM GnRH II as 
indicated for 24 hours.  Luciferase activity was expressed in arbitrary units and 
normalised for Renilla luciferase activity.  Data from at least three independent 
experiments were quantified and the mean fold over control ± SE for the activation 
of SRE-luciferase is presented.  For ease of presentation, statistical analysis is shown 
in table 4.1. 
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Figure 4.9 SRE-luciferase reporter gene assays depicting the ΔDH-p115 
RhoGEF and YM-254890 sensitivity of the GnRH-induced stimulation of SRE-
promoted transcriptional activity.  BHK cells, stably expressing the GnRH 
receptor and a SRE-luciferase reporter, transiently transfected with vector (black 
bars) or ΔDH-p115 RhoGEF (white bars) cDNA were serum starved for 16 hours in 
the presence (white bars) or absence (black bars) of 100 nM YM-254890 prior to 
being treated with vehicle (0.2% propylene glycol; V), 1 µM GnRH I or 1 µM GnRH 
II as indicated for 24 hours.  Luciferase activity was expressed in arbitrary units and 
normalised for Renilla luciferase activity.  Data from at least three independent 
experiments were quantified and the mean fold over control ± SE for the activation 
of SRE-luciferase is presented.  For ease of presentation, statistical analysis is shown 





Negative Construct SRE-Luciferase Response 
(Fold) 
Significant Increase Above 
Control?† 
Significant Inhibition?‡ 
- 7.7 ± 0.3 *** - 
YM-254890 2.8 ± 0.1 ** *** 
PTX 8.4 ± 1.3 ** ns 
Gα13G225A 5.2 ± 0.2 ** * 
ΔDH-p115 RhoGEF 5.3 ± 0.2 ** * 
ΔDH-p115 RhoGEF +  
YM-254890 




Negative Construct SRE-Luciferase Response 
(Fold) 
Significant Increase Above 
Control?† 
Significant Inhibition?‡ 
- 3.8 ± 0.3 *** - 
YM-254890 1.5 ± 0.1 * *** 
PTX 3.4 ± 0.5 * ns 
Gα13G225A 2.4 ± 0.1 ** * 
ΔDH-p115 RhoGEF 2.1 ± 0.2 * * 
ΔDH-p115 RhoGEF +  
YM-254890 
1.0 ± 0.1 ns ** 
 
Table 4.1 Statistical analysis of SRE-luciferase reporter gene assays depicting the chemical inhibitor and dominant negative 
construct (in)sensitivity of the GnRH-induced stimulation of SRE-promoted transcriptional activity.  Data from at least three 
independent experiments were quantified and the mean fold over control ± SE for the activation of SRE-luciferase is presented.  p<0.05 
(*), p<0.01 (**) and p<0.001 (***) represents statistical significance from vehicle treated controls (†) and from GnRH treated controls (‡). 
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4.2.3 The GnRH Receptor Directly Interacts with the G12/13 G Proteins 
Thus far I have provided evidence to suggest that GnRH may mediate G12/13-
dependent signalling.  These data, however, are based on distal phosphorylation and 
transcriptional signalling events and rely heavily on the use of chemical inhibitors.  
With this in mind, I sought to provide more upstream evidence to support my 
hypothesis that the GnRH receptor couples to G12/13.  Dominant negative constructs 
have previously been used in competitive binding experiments to elucidate the ability 
of a given GPCR to directly activate multiple G protein families.  Indeed, a dominant 
negative Gαs mutant was sufficient to significantly inhibit the thyroid-stimulating 
hormone receptor-mediated stimulation of PhI hydrolysis by competing with native 
Gq/11 for activation by the receptor (Cleator et al., 2004).  In contrast, it had no effect 
on the α1B-adrenergic receptor-induced PhI response as this GPCR does not interact 
with Gs.  These observations therefore support the proposition that, while not a direct 
measure, this technique gives a strong indication of interaction between a GPCR and 
specific G proteins.  In the case of the GnRH receptor, transient transfection of 
increasing amounts of Gα13G225A significantly decreased the PhI response 
provoked by both GnRH I and GnRH II in a concentration-dependent manner (figure 
4.10).  Conversely, and in agreement with the data presented within chapter three, a 
Gαi2 dominant negative (Gαi2G203T) had no effect on the PhI response obtained 
after stimulation with either GnRH ligand.   
 
Gα13G225A is thought to bind tightly to G12/13-coupled GPCRs in order to exert a 
dominant negative phenotype (Gohla et al., 1999, Orth et al., 2005).  Indeed, 
analogous mutation of Gαs (GαsG226A) results in a G protein subunit mutant that is 
incapable of undergoing the conformational change necessary for GTP-induced G 
protein α subunit dissociation from the Gβγ complex (Miller et al., 1988, Lee et al., 
1992b).  Thus, I hypothesised that the GnRH receptor may form a stable complex 
with this mutant Gα subunit such that constitutive physical association between the 
receptor and Gα13G225A should be detectable.  Several studies have used 
coimmunoprecipitation in order to elucidate direct GPCR-G protein interaction.  
However, an inherent difficulty with such an approach is the transient nature of these 
contacts.  In agreement with this, previous reports reveal that coimmunoprecipitation 
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of the β2-adrenergic receptor (Lachance et al., 1999) and the angiotensin AT2 
receptor (Feng et al., 2002) with Gαs allows only the weakest of signals 
corresponding to this α subunit to be detected.  Such fundamental experimental 
problems may be overcome by utilising a dissociation defective mutant Gα subunit.  
Indeed, as dissociation of the heterotrimeric complex is prevented in response to 
basal receptor signalling, direct GPCR-G protein interaction should become more 
readily detectable.  Cotransfection of the human influenza hemagglutinin (HA) 
tagged GnRH receptor and Gα13G225A into COS7 cells revealed that both proteins 
could be coimmunoprecipitated in an easily detectable manner (figure 4.11).  Vector 
transfected controls reinforced the specificity of this detection method as no specific 
bands were present in this lane.  Additionally, in agreement with the studies 
discussed previously, a weak band corresponding to endogenous Gα13 was present in 
samples transfected with only the HA tagged GnRH receptor.  These data, viewed 









































Figure 4.10 Phosphoinositide hydrolysis assays depicting the Gα13G225A sensitivity of the GnRH-induced stimulation of 
phosphoinositide hydrolysis.  BHK cells, stably expressing the GnRH receptor, transiently transfected with vector, 0.1 µg/well 
Gα13G225A, 0.5 µg/well Gα13G225A, 2.0 µg/well Gα13G225A or 2.0 µg/well Gαi2G203T cDNA were labelled overnight with 1 µCi/ml 
myo-D-[3H]inositol prior to being treated with 1 µM GnRH I (black bars) or 1 µM GnRH II (white bars) for 30 minutes.  The amount of 
cDNA transfected remained constant.  Data from at least three independent experiments were quantified and the mean % maximum ± SE 
for phosphoinositide hydrolysis is presented.  p<0.01 (**) and p<0.001 (***) represents statistical significance from GnRH treated 
controls. 
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Figure 4.11 Coimmunoprecipitation assays depicting a direct interaction 
between the GnRH receptor and Gα13.  COS7 cells, transiently transfected with 
vector, HA tagged GnRH receptor or HA tagged GnRH receptor and Gα13G225A 
cDNA were serum starved for 16 hours prior to being lysed and incubated with an 
anti-HA agarose conjugate slurry with constant agitation at 4°C for 16 hours.  The 
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4.2.4 GnRH Stimulates Cytoskeletal Reorganisation 
A number of studies indicate that the G12/13 G proteins can mediate actin stress fibre 
formation in a Rho-dependent manner (Buhl et al., 1995, Gohla et al., 1999).  
Additionally, evidence suggests that they are not involved in the positive regulation 
of Rac (Gratacap et al., 2001).  In order to investigate the possibility of GnRH-
mediated Gq/11-independent actin reorganisation, I studied the cytoskeletal 
rearrangement induced by GnRH in the Gαq/11 knockout MEF cell model.  Following 
stimulation with either GnRH I or GnRH II, marked changes in cellular phenotype 
relative to that of vehicle treated controls were observed.  β-actin 
immunocytochemical studies revealed that GnRH I induced both actin 
polymerisation at the cell cortex and lamellipodia formation (figure 4.12), both of 
which are accepted indicators of the activation of Rac (Ridley et al., 1992).  In 
contrast, GnRH II stimulated stress fibre formation, a marker of Rho activation 
(Ridley and Hall, 1992).  In an effort to elucidate the signalling cascades involved, 
pathway specific inhibitors were utilised.  Microinjection of the ROCK catalytic 
domain into Swiss 3T3 cells has been shown to result in the formation of stress fibres 
(Amano et al., 1997).  Additionally, ROCK has previously been demonstrated to be 
central to the G12/13-Rho-dependent induction of stress fibre formation (LePage et al., 
2003).  Y-27632, a ROCK inhibitor, completely inhibited the GnRH II-induced 
response.  In contrast, it had the opposite effect on that elicited by GnRH I.  In this 
case, the GnRH I stimulated actin polymerisation and lamellipodia formation were 
potentiated.  Indeed, increased β-actin staining at the cell periphery and more 
pronounced lamellipodial extensions were apparent. 
 
The observation that GnRH I induced Rac activation is consistent with a previous 
study (intriguingly, however, it is inconsistent with the G12/13-mediated activation of 
Rho).  Davidson and colleagues demonstrated that GnRH I induced the alteration of 
cellular morphology and the de novo generation of polymerised actin structures 
(Davidson et al., 2004).  Furthermore, the authors suggested that this effect was 
independent of the classical GnRH receptor-Gq/11 signalling pathway.  Specific 
inhibition of src with PP2 was sufficient to completely prevent the GnRH I-induced 
response.  How the GnRH I-bound GnRH receptor activated Rac remained 
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undefined.  These data, taken together with the now established link between src and 
Rac (Servitja et al., 2003, Kawakatsu et al., 2005, Zhou et al., 2007, Dise et al., 2008) 
and the fact that previous work from our laboratory indicates that the GnRH receptor 
may interact with src (Coetsee and Lu, unpublished observations), prompted me to 
investigate the possible involvement of this Tyr kinase in the GnRH-mediated 
regulation of the actin cytoskeleton.  Inhibition of src with PP2 resulted in a marked 
induction of actin stress fibre formation after stimulation with GnRH I (figure 4.11).  
In contrast, PP2 application had no effect on the GnRH II-induced response.  
Application of both Y-27632 and PP2 prevented any apparent change in the 
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Figure 4.12 Immunocytochemistry depicting the Y-27632 and the PP2 
sensitivity of the GnRH-induced alteration in the organisation of the actin 
cytoskeleton.  Gαq/11 knockout MEF cells, stably expressing the GnRH receptor, 
were serum starved for 16 hours in the presence or absence of 25 µM Y-27632, 10 
µM PP2 or 25 µM Y-27632 and 10 µM PP2 prior to being treated with vehicle (0.2% 
propylene glycol), 1 µM GnRH I or 1 µM GnRH II as indicated for 60 minutes.  
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4.2.5 GnRH I but not GnRH II Directly Activates Src Independently of 
Gq/11 
The immunocytochemical data described previously suggests that src is, 
independently of Gq/11, involved in the activation of Rac in response to GnRH I but 
not GnRH II.  Indeed, inhibition of src with PP2 was sufficient to completely prevent 
the GnRH I-induced cortical localisation of actin and the formation of lamellipodia.  
In contrast, PP2 application had no effect on the response stimulated by GnRH II.  
Others within our group have previously shown that the GnRH receptor may interact 
with src (Coetsee and Lu, unpublished observations) and, initially, I sought to 
confirm these results.  Transient transfection of the HA tagged GnRH receptor into 
COS7 cells revealed that both the receptor protein and src could be 
coimmunoprecipitated (figure 4.13).  No specific bands were present in controls 
transfected with vector only. 
 
Src activation events enable autophosphorylation of a Tyr residue within the kinase 
domain of the protein (Boggon and Eck, 2004).  To investigate whether GnRH I and 
GnRH II could mediate the Gq/11-independent activation of src, and in keeping with 
the work of Davidson and colleagues (Davidson et al., 2004), I examined src 
activation in SCL60 cells in the presence and absence of YM-254890.  Prior to 
commencing these studies, I attempted to analyse the GnRH-induced src activation 
in the Gαq/11 knockout MEF cell model.  In this cell line, however, significant Tyr 
phosphorylation of src was undetectable in response to either GnRH ligand.  The 
western blots subjectively indicate that, relative to vehicle treated controls, src is Tyr 
phosphorylated only in response to GnRH I.  The data sets are not, however, 
statistically significant when compared to either each either or cells treated only with 
vehicle (GnRH I - 1.8 ± 0.4-fold; GnRH II - 1.2 ± 0.3-fold) (figure 4.14).  
Nevertheless, these results do not preclude the above hypothesis as the sensitivity of 
the assay with regards to this cell line may be solely responsible.  The use of the 
SCL60 cellular background also provides a positive control allowing confirmation of 
previous observations which suggest that src may be activated downstream of Gq/11 
(Nagao et al., 1998) and therefore by both GnRH ligands.  Stimulation with both 
GnRH I and GnRH II induced significant increases in pY416-src giving responses of 
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2.8 ± 0.2-fold and 2.4 ± 0.2-fold that of vehicle treated controls respectively (figure 
4.15; table 4.2).  Specific inhibition of the Gαq/11 signalling pathway with YM-
254890 was sufficient to significantly reduce the levels of pY416-src detected in 
response to both GnRHs.  When compared to vehicle treated controls, however, a 
significant increase in phosphorylated src could still be detected in response to 
stimulation with GnRH I but not with GnRH II (GnRH I - 1.5 ± 0.1-fold; GnRH II - 
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Figure 4.13 Coimmunoprecipitation assays depicting an interaction between 
the GnRH receptor and src.  COS7 cells, transiently transfected with vector (lane 
1) or HA tagged GnRH receptor (lane 2) cDNA were serum starved for 16 hours 
prior to being lysed and incubated with an anti-HA agarose conjugate slurry with 
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Figure 4.14 Immunoblots depicting the GnRH-induced phosphorylation of 
src.  Gαq/11 knockout MEF cells, stably expressing the GnRH receptor, were serum 
starved for 16 hours prior to being treated with vehicle (0.2% propylene glycol; V), 1 
µM GnRH I (I) or 1 µM GnRH II (II) as indicated for 10 minutes.  Representative 
blots are shown.  Data from at least three independent experiments were quantified 
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Figure 4.15 Immunoblots depicting the YM-254890 sensitivity of the GnRH-
induced phosphorylation of src.  SCL60 cells, stably expressing the GnRH 
receptor, were serum starved for 16 hours in the presence (white bars) or absence 
(black bars) of 100 nM YM-254890 prior to being treated with vehicle (0.2% 
propylene glycol; V), 1 µM GnRH I (I) or 1 µM GnRH II (II) as indicated for 10 
minutes.  Representative blots are shown.  Data from at least three independent 
experiments were quantified and the mean fold over control ± SE for the activation 





















GnRH I 2.8 ± 0.2 * ** * 
GnRH II 2.4 ± 0.2 * ** ns 
 
Table 4.2 Statistical analysis of immunoblots depicting the U-73122 
sensitivity of the GnRH-induced phosphorylation of src.  Data from at least three 
independent experiments were quantified and the mean fold over control ± SE for the 
phosphorylation of src is presented.  p<0.05 (*), p<0.01 (**) and p<0.001(***) 
represents statistical significance from vehicle treated controls (†) and from GnRH 
treated controls (‡). 
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SRE-luciferase assays described earlier in this chapter demonstrated that GnRH I and 
GnRH II have the ability to induce significantly different levels of SRE-driven 
transcriptional activity (figure 4.3; table 4.1).  Additionally, the data recently 
illustrated propose that src may associate with the GnRH receptor and may be, 
independently of Gq/11, activated by GnRH I.  Furthermore, they indicate that src 
activation may subsequently be involved in the activation of Rac.  Interestingly, 
constitutively active Rac has been shown to potently activate SRE-luciferase (Kim 
and Kim, 1997).  These data therefore suggest that the difference in the SRE-
luciferase response induced by both GnRH ligands may be due to interaction of the 
GnRH receptor with src and consequent GnRH I-induced, Gq/11-independent, 
stimulation of Rac activity.  In line with this proposal, inhibition of src with PP2 
significantly decreased the SRE-mediated transcriptional signal in response to GnRH 
I but not to GnRH II (GnRH I - 5.3 ± 0.2-fold; GnRH II - 3.3 ± 0.4-fold) (figure 4.16; 
table 4.3).   
 
I have previously shown that transient transfection of ΔDH-p115 RhoGEF and 
subsequent inhibition with YM-254890 completely inhibited the GnRH II-induced 
transcriptional signal (1.0 ± 0.1-fold) (figure 4.9; table 4.1).  In contrast, that 
mediated by GnRH I remained significantly increased above vehicle treated controls 
(1.8 ± 0.0-fold).  To investigate if src is involved in the residual GnRH I-induced 
signal, the effect of PP2 application was analysed.  Transient transfection of ΔDH-
p115 RhoGEF and subsequent inhibition with both YM-254890 and PP2 was 
sufficient to completely inhibit the SRE-driven transcription induced by stimulation 
with either GnRH ligand (GnRH I – 0.9 ± 0.1-fold; GnRH II - 1.1 ± 0.1-fold) (figure 
4.17; table 4.3).   
 
At the Gq/11 signalling pathway, both GnRHs are known to induce similar maximal 
responses (Lu et al., 2007).  Consistent with these observations, inhibition of both the 
Gα13-p115 RhoGEF- and the src-mediated signalling pathways revealed that GnRH I 
and GnRH II were able to induce SRE-luciferase responses of similar levels (GnRH I 
- 2.6 ± 0.1-fold; GnRH II - 2.3 ± 0.2-fold) (figure 4.18; table 4.3).  Additionally, no 
significant difference existed between the GnRH II-induced SRE-mediated 
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transcriptional response in cells inhibited with ΔDH-p115 RhoGEF or ΔDH-p115 
RhoGEF and PP2 together (2.1 ± 0.2-fold and 2.3 ± 0.2-fold respectively).  These 
data, viewed collectively, propose that GnRH I but not GnRH II may, independently 
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Figure 4.16 SRE-luciferase reporter gene assays depicting the PP2 sensitivity 
of the GnRH-induced stimulation of SRE-promoted transcriptional activity.  
BHK cells, stably expressing the GnRH receptor and a SRE-luciferase reporter, were 
serum starved for 16 hours in the presence (white bars) or absence (black bars) of 10 
µM PP2 prior to being treated with vehicle (0.2% propylene glycol; V), 1 µM GnRH 
I or 1 µM GnRH II as indicated for 24 hours.  Luciferase activity was expressed in 
arbitrary units and normalised for Renilla luciferase activity.  Data from at least three 
independent experiments were quantified and the mean fold over control ± SE for the 
activation of SRE-luciferase is presented.  For ease of presentation, statistical 
analysis is shown in table 4.3. 
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Figure 4.17 SRE-luciferase reporter gene assays depicting the ΔDH-p115 
RhoGEF, YM-254890 and PP2 sensitivity of the GnRH-induced stimulation of 
SRE-promoted transcriptional activity.  BHK cells, stably expressing the GnRH 
receptor and a SRE-luciferase reporter, transiently transfected with vector (black 
bars) or Gα13G225A (white bars) cDNA were serum starved for 16 hours in the 
presence (white bars) or absence (black bars) of 100 nM YM-254890 and 10 µM PP2 
prior to being treated with vehicle (0.2% propylene glycol; V), 1 µM GnRH I or 1 
µM GnRH II as indicated for 24 hours.  Luciferase activity was expressed in 
arbitrary units and normalised for Renilla luciferase activity.  Data from at least three 
independent experiments were quantified and the mean fold over control ± SE for the 
activation of SRE-luciferase is presented.  For ease of presentation, statistical 
analysis is shown in table 4.3. 
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Figure 4.18 SRE-luciferase reporter gene assays depicting the ΔDH-p115 
RhoGEF and PP2 sensitivity of the GnRH-induced stimulation of SRE-
promoted transcriptional activity.  BHK cells, stably expressing the GnRH 
receptor and a SRE-luciferase reporter, transiently transfected with vector (black 
bars) or Gα13G225A (white bars) cDNA were serum starved for 16 hours in the 
presence (white bars) or absence (black bars) of 10 µM PP2 prior to being treated 
with vehicle (0.2% propylene glycol; V), 1 µM GnRH I or 1 µM GnRH II as 
indicated for 24 hours.  Luciferase activity was expressed in arbitrary units and 
normalised for Renilla luciferase activity.  Data from at least three independent 
experiments were quantified and the mean fold over control ± SE for the activation 
of SRE-luciferase is presented.  For ease of presentation, statistical analysis is shown 







Negative Construct SRE-Luciferase Response 
(Fold) 
Significant Increase Above 
Control?† 
Significant Inhibition?‡ 
- 7.7 ± 0.3 *** - 
PP2 5.3 ± 0.2 ** * 
ΔDH-p115 RhoGEF + YM-
254890 + PP2 
0.9 ± 0.1 ns *** 




Negative Construct SRE-Luciferase Response 
(Fold) 
Significant Increase Above 
Control?† 
Significant Inhibition?‡ 
- 3.8 ± 0.3 *** - 
PP2 3.3 ± 0.4 * ns 
ΔDH-p115 RhoGEF + YM-
254890 + PP2 
1.1 ± 0.1 ns ** 
ΔDH-p115 RhoGEF + PP2 2.3 ± 0.2 * *** 
 
Table 4.3 Statistical analysis of SRE-luciferase reporter gene assays depicting the chemical inhibitor and dominant negative 
construct (in)sensitivity of the GnRH-induced stimulation of SRE-promoted transcriptional activity.  Data from at least three 
independent experiments were quantified and the mean fold over control ± SE for the activation of SRE-luciferase is presented.  p<0.05 
(*), p<0.01 (**) and p<0.001 (***) represents statistical significance from vehicle treated controls (†) and from GnRH treated controls (‡). 
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4.2.6 G12/13 is Involved in LHβ and FSHβ Gene Transcription 
In an effort to clarify a physiological role for these novel GnRH-induced signalling 
pathways, I investigated their possible involvement in GnRH stimulated LHβ and/or 
FSHβ gene transcription.  GnRH I elicited significant increases in LHβ- and FSHβ-
promoted luciferase activity (LHβ - 20.9 ± 3.1-fold; FSHβ - 3.7 ± 0.3-fold) (figure 
4.19; table 4.4).  The luciferase response obtained in both cases was significantly 
decreased, although not to basal levels, after inhibition of PLCβ with U-73122 (LHβ 
- 7.4 ± 0.3-fold; FSHβ - 1.9 ± 0.0-fold) (figure 4.20; table 4.4) or transient 
transfection of ΔDH-p115 RhoGEF (LHβ - 11.7 ± 1.9-fold; FSHβ - 1.8 ± 0.1-fold) 
(figure 4.21; table 4.4).  Transient transfection of ΔDH-p115 RhoGEF and 
subsequent incubation with U-73122 was sufficient to completely inhibit both 
luciferase signals obtained after GnRH I stimulation (LHβ - 0.9 ± 0.1-fold; FSHβ - 
0.9 ± 0.1-fold) (figure 4.22; table 4.4).  Additionally, PP2 was completely without 
effect (LHβ - 19.4 ± 4.5-fold; FSHβ - 3.8 ± 0.4-fold) (figure 4.23; table 4.4).  These 
results suggest that GnRH-induced G12/13-mediated signalling but not GnRH-induced 
Gq/11-independent src-mediated signalling may be involved in the transcriptional 
regulation of these gonadotropins. 
 









































































































Figure 4.19 LHβ- and FSHβ-luciferase reporter gene assays depicting the 
GnRH I-induced stimulation of LHβ- and FSHβ-promoted transcriptional 
activity.  LβT2 cells, stably expressing the GnRH receptor, transiently transfected 
with a LHβ- (A) or a FSHβ- (B) luciferase reporter were serum starved for 16 hours 
prior to being treated with vehicle (0.2% propylene glycol; V) or 1 µM GnRH I as 
indicated for 6 hours (A) or 8 hours (B) in the presence (B) or absence (A) of 25 
ng/ml activin A.  Luciferase activity was expressed in arbitrary units and normalised 
for Renilla luciferase activity.  Data from at least three independent experiments 
were quantified and the mean fold over control ± SE for the activation of LHβ-
/FSHβ-luciferase is presented.  p<0.005 (**) represents statistical significance from 












































































































Figure 4.20 LHβ- and FSHβ-luciferase reporter gene assays depicting the U-
73122 sensitivity of the GnRH I-induced stimulation of LHβ- and FSHβ-
promoted transcriptional activity.  LβT2 cells, stably expressing the GnRH 
receptor, transiently transfected with a LHβ- (A) or a FSHβ- (B) luciferase reporter 
were serum starved for 16 hours in the presence (white bars) or absence (black bars) 
of 10 µM U-73122 prior to being treated with vehicle (0.2% propylene glycol; V) or 
1 µM GnRH I as indicated for 6 hours (A) or 8 hours (B) in the presence (B) or 
absence (A) of 25 ng/ml activin A.  Luciferase activity was expressed in arbitrary 
units and normalised for Renilla luciferase activity.  Data from at least three 
independent experiments were quantified and the mean fold over control ± SE for the 
activation of LHβ-/FSHβ-luciferase is presented.  For ease of presentation, statistical 
analysis is shown in table 4.4. 
 








































































































Figure 4.21 LHβ- and FSHβ-luciferase reporter gene assays depicting the 
ΔDH-p115 RhoGEF sensitivity of the GnRH I-induced stimulation of LHβ- and 
FSHβ-promoted transcriptional activity.  LβT2 cells, stably expressing the GnRH 
receptor, transiently transfected with a LHβ- (A) or a FSHβ- (B) luciferase reporter 
and vector (black bars) or ΔDH-p115 RhoGEF (white bars) cDNA were serum 
starved for 16 hours prior to being treated with vehicle (0.2% propylene glycol; V) or 
1 µM GnRH I as indicated for 6 hours (A) or 8 hours (B) in the presence (B) or 
absence (A) of 25 ng/ml activin A.  Luciferase activity was expressed in arbitrary 
units and normalised for Renilla luciferase activity.  Data from at least three 
independent experiments were quantified and the mean fold over control ± SE for the 
activation of LHβ-/FSHβ-luciferase is presented.  For ease of presentation, statistical 
analysis is shown in table 4.4. 








































































































Figure 4.22 LHβ- and FSHβ-luciferase reporter gene assays depicting the U-
73122 and ΔDH-p115 RhoGEF sensitivity of the GnRH I-induced stimulation of 
LHβ- and FSHβ-promoted transcriptional activity.  LβT2 cells, stably expressing 
the GnRH receptor, transiently transfected with a LHβ- (A) or a FSHβ- (B) luciferase 
reporter and vector (black bars) or ΔDH-p115 RhoGEF (white bars) cDNA were 
serum starved in the presence (white bars) or absence (black bars) of 10 µM U-73122 
for 16 hours prior to being treated with vehicle (0.2% propylene glycol; V) or 1 µM 
GnRH I as indicated for 6 hours (A) or 8 hours (B) in the presence (B) or absence 
(A) of 25 ng/ml activin A.  Luciferase activity was expressed in arbitrary units and 
normalised for Renilla luciferase activity.  Data from at least three independent 
experiments were quantified and the mean fold over control ± SE for the activation 
of LHβ-/FSHβ-luciferase is presented.  For ease of presentation, statistical analysis is 
shown in table 4.4. 








































































































Figure 4.23 LHβ- and FSHβ-luciferase reporter gene assays depicting the PP2 
insensitivity of the GnRH I-induced stimulation of LHβ- and FSHβ-promoted 
transcriptional activity.  LβT2 cells, stably expressing the GnRH receptor, 
transiently transfected with a LHβ- (A) or a FSHβ- (B) luciferase reporter were 
serum starved for 16 hours in the presence (white bars) or absence (black bars) of 10 
µM PP2 prior to being treated with vehicle (0.2% propylene glycol; V) or 1 µM 
GnRH I as indicated for 6 hours (A) or 8 hours (B) in the presence (B) or absence 
(A) of 25 ng/ml activin A.  Luciferase activity was expressed in arbitrary units and 
normalised for Renilla luciferase activity.  Data from at least three independent 
experiments were quantified and the mean fold over control ± SE for the activation 
of LHβ-/FSHβ-luciferase is presented.  For ease of presentation, statistical analysis is 





Negative Construct Luciferase Response (Fold) 
Significant Increase Above 
Control?† 
Significant Inhibition?‡ 
- 20.9 ± 3.1 ** - 
U-73122 7.4 ± 0.3 ** * 
ΔDH-p115 RhoGEF 11.7 ± 1.9 ** * 
0.9 ± 0.1 ns ** ΔDH-p115 RhoGEF + U-73122 




Negative Construct Luciferase Response (Fold) 
Significant Increase Above 
Control?† 
Significant Inhibition?‡ 
- 3.7 ± 0.3 ** - 
U-73122 1.9 ± 0.0 ** ** 
ΔDH-p115 RhoGEF  1.8 ± 0.1 * ** 
0.9 ± 0.1 ns *** ΔDH-p115 RhoGEF + U-73122 
PP2 3.8 ± 0.4 * ns 
 
Table 4.4 Statistical analysis of LHβ- and FSHβ-luciferase reporter gene assays depicting the chemical inhibitor and dominant 
negative construct (in)sensitivity of the GnRH I-induced stimulation of LHβ- and FSHβ-promoted transcriptional activity.  Data 
from at least three independent experiments were quantified and the mean fold over control ± SE for the activation of LHβ-/FSHβ-
luciferase is presented.  p<0.05 (*), p<0.01 (**) and p<0.001 (***) represents statistical significance from vehicle treated controls (†) and 
from GnRH treated controls (‡). 
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4.3  Discussion 
Evidence suggests that the GnRH receptor may adopt multiple active conformations 
and thereby activate discrete intracellular signalling cascades (Lu et al., 2005).  The 
data presented within chapter three, however, do not support the proposal that these 
cascades may be initiated by the GnRH-mediated activation of Gi/o or Gs.  
Additionally, a large number of Gq/11-coupled GPCRs also interact with G12/13 (Riobo 
and Manning, 2005).  Thus, in this chapter, the potential of GnRH to induce G12/13 
activation was investigated.  The results presented herein indicate for the first time 
that the GnRH receptor can directly interact with the G proteins of the G12/13 family 
and consequently initialise a variety of cellular responses.  Additionally, the data 
gained during the completion of these studies confirm that the receptor may interact 
with src Tyr kinase and propose that GnRH I, but not GnRH II, can induce src 
activation.  Finally, these results imply that the GnRH receptor-mediated activation 
of G12/13 but not src plays an important role in the regulation of the synthesis of the 
gonadotropins. 
 
Activation of the ERK cascade by GnRH has been well investigated although the 
precise upstream mechanism involved is controversial and has been suggested to 
vary between cell types (Sim et al., 1995, Naor et al., 2000, Benard et al., 2001, Liu 
et al., 2002a, Davidson et al., 2004, Kraus et al., 2004, Caunt et al., 2006, Maudsley 
et al., 2007).  G12/13-mediated MAPK activation has also been the subject of much 
research (Orth et al., 2005, Honma et al., 2006, Mariggio et al., 2006, Buch et al., 
2008, White et al., 2008a).  Honma and colleagues recently demonstrated that the 
Gα13-p115 RhoGEF signalling pathway is involved in U46619-induced ERK 
activation in 1321N1 human astrocytoma cells (Honma et al., 2006).  Similarly, 
Mariggio and colleagues showed that Gα13 stimulates ERK phosphorylation in 
response to both thrombin and ATP (Mariggio et al., 2006).  Consistent with these 
data, my results suggest the involvement of the G proteins of the G12/13 family in 
GnRH-induced ERK activation.  Indeed, transfection of either Gα12 or Gα13 into 
Gαq/11 knockout MEF cells was sufficient to elicit an increase in ERK 
phosphorylation in response to GnRH stimulation.  For a number of reasons, the 
observation that such an increase was not evident in vector transfected controls does 
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not preclude the above interpretation.  For example, the sensitivity of the western 
detection system may not be high enough to detect GnRH-induced Gq/11-independent 
ERK activation in this cell line.  Additionally, the cellular abundance of G12/13 may 
be relatively low.  As such, although this assay by itself does not constitute definitive 
proof of GnRH receptor-G12/13 interaction, it seems plausible to speculate that GnRH 
may induce G12/13 activation.  Interestingly, Liu and colleagues showed that, in LβT2 
cells, GnRH elicited robust increases in ERK phosphorylation (Liu et al., 2002a).  
While this response could be significantly diminished by the inhibition of PKC, 
significant ERK activation after GnRH stimulation was still detectable.  Furthermore, 
either the chelation of intracellular Ca2+ or the blockade of Ca2+ influx had only a 
very minor effect.  Thus, these data support the involvement of Gq/11-independent 
signalling pathways in the GnRH stimulated activation of ERK.   
 
One of the classical responses induced by the activation of either Gα12 or Gα13 is the 
stimulation of SRE-driven transcription.  In agreement with Mao and colleagues 
(Mao et al., 1998a), I showed that constitutively active Gαq/11, Gα12 and Gα13, but not 
Gαi/o or Gαs, could induce a SRE-luciferase response.  As such, an observed increase 
in the luciferase signal in response to GnRH stimulation may be as a result of the 
GnRH receptor-mediated activation of Gαq/11, Gα12 or Gα13.  As expected, specific 
inhibition of Gαq/11 with YM-254890 markedly decreased the SRE-luciferase 
response obtained after stimulation with either GnRH ligand.  However, in 
agreement with the PMT-mediated data obtained by Orth and colleagues (Orth et al., 
2005), complete inhibition of the luciferase signal by YM-254890 was not evident.  I 
and others have shown that this compound, when used at a 100 nM concentration, 
completely prevents Gαq/11-induced signalling (Orth et al., 2005).  These data 
therefore suggest the involvement of Gq/11-independent pathways in the GnRH-
induced stimulation of SRE-luciferase.  Specific inhibition of the Gα13-mediated 
cascades with Gα13G225A or ΔDH-p115 RhoGEF was sufficient to decrease the 
luciferase response provoked by both GnRH I and GnRH II.  Significantly, p115 
RhoGEF has been demonstrated to be involved in only the Gα13-Rho-induced 
stimulation of SRE-luciferase activity (Mao et al., 1998b).  Furthermore, an 
expression vector carrying only the RGS domain of this protein has been shown to 
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inhibit the SRE-luciferase response induced by Gα13Q226L but not that mediated by 
GαqQ209L (Chikumi et al., 2002).  These results therefore suggest that the GnRH-
induced SRE-driven transcription at least in part relies on the activity of the Gα12/13 G 
protein α subunits.  The observation that PTX had no effect on GnRH-induced SRE-
promoted transcription was predictable for two reasons.  Firstly, the data within 
chapter three indicate that the GnRH receptor does not couple to Gi/o.  Additionally, 
my results, in keeping with previous observations, reveal that Gαi/o is not capable of 
inducing SRE-driven transcription (Fromm et al., 1997, Mao et al., 1998a).  
Interestingly, recent evidence suggests that the signalling cascades induced by the 
activation of Gαz, a member of the Gi/o family of G proteins, attenuate the Rho-
mediated stimulation of SRE-luciferase (Dutt et al., 2004).  
 
The Gα13G225A-mediated inhibition of the GnRH-induced stimulation of PhI 
hydrolysis suggests that this dominant negative mutant Gα subunit binds tightly to 
the GnRH receptor thereby competitively inhibiting its interaction with Gq/11.  
Indeed, the observation that Gαi2G203T was unable to provoke any such inhibition 
supports the proposal that the interaction between the GnRH receptor and 
Gα13G225A is direct.  These data therefore indicate that, in addition to Gq/11, the 
GnRH receptor can directly interact with G12/13.  Additional support for this 
conclusion exists in the observation that transient transfection of this dominant 
negative G protein α subunit into COS7 cells allowed an increased amount of Gα13 to 
be coimmunoprecipitated with the HA tagged GnRH receptor.  Furthermore, even 
without Gα13G225A transfection, Gα13 and the GnRH receptor could be 
coimmunoprecipitated.  Analogous to these findings, coimmunoprecipitation 
experiments in HEK293 cells heterologously expressing the D5 dopamine receptor 
revealed that both Gα12 and Gα13 directly interact with this GPCR (Zheng et al., 
2003).  Similarly, Gαs could be coimmunoprecipitated with the β2-adrenergic 
receptor (Lachance et al., 1999) and the angiotensin AT2 receptor (Feng et al., 2002).  
My data therefore extend the number of GPCRs known to directly interact with 
G12/13. 
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Perhaps the most intriguing finding from the results described within this chapter 
was the observation that GnRH I and GnRH II were capable of inducing distinct 
Gq/11-independent changes in cellular morphology.  Cytoskeletal reorganisation in 
response to the activation of the G12/13 G proteins has been well described (Buhl et 
al., 1995, Fromm et al., 1997, Gohla et al., 1999, Nielsen et al., 2005, Honma et al., 
2006, Wang et al., 2006, Yanagida et al., 2007).  The members of this family are 
known to act as potent stimulators of the Rho monomeric G proteins and in doing so 
mediate the formation of intracellular stress fibres (Buhl et al., 1995).  Furthermore, 
evidence suggests that ROCK plays a key role in the induction of this phenotypic 
response (LePage et al., 2003).  The observation that GnRH II induced pronounced 
stress fibre formation in Gαq/11 knockout cells therefore suggests, in agreement with 
the other data presented within this chapter, that this ligand induces G12/13 activation 
and consequently stimulates Rho-ROCK signalling.  This conclusion is strengthened 
by the observation that Y-27632 completely inhibited the GnRH II-mediated 
response.  However, GnRH I induced the formation of a cellular morphology 
indicative of the activation of Rac (Ridley et al., 1992).  Published evidence proposes 
that the G12/13 G protein family is not involved in the positive regulation of Rac 
(Gratacap et al., 2001) and may even negatively regulate the activity of this 
monomeric G protein.  Sugimoto and colleagues demonstrated that the specific 
inhibition of either Gα12 or Gα13 with respective carboxy-terminal peptides abolishes 
the sphingosine-1-phosphate- (S1P) induced S1P2-mediated inhibition of Rac 
(Sugimoto et al., 2003).  Similarly, Yamaguchi and colleagues showed that 
expression of Gα12Q231L in PC12 cells significantly inhibits nerve growth factor-
induced Rac activation (Yamaguchi et al., 2001).  Significantly, in the latter study 
mentioned, Y-27632 completely abolished the Rho-mediated effect.  Consistent with 
these data, Y-27632 application resulted in the potentiation of the GnRH I-induced 
response thereby suggesting an increase in Rac activity.  These results therefore 
imply that GnRH I has the ability to stimulate the activity of Rac in a Gq/11-
independent manner and that this pathway may be inhibited by ROCK.  This 
suggestion is consistent with a previous study in which inhibition of ROCK with Y-
27632 was shown to potentiate the S1P-induced src-mediated activation of Rac 
(Vouret-Craviari et al., 2002).  GnRH II, in contrast, appears to have no such ability 
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to activate Rac as Y-27632 only served to completely inhibit the response obtained 
after stimulation. 
 
The observation that GnRH I could induce cytoskeletal changes indicative of the 
activation of Rac begged the question of how this monomeric G protein was 
stimulated.  Gq/11-coupled GPCRs have previously been reported to be central 
mediators of the stimulation of Rac activity (Gratacap et al., 2001).  Given that my 
data indicate that the GnRH I-induced stimulation of Rac occurs independently of 
Gq/11, I hypothesised that src may be involved in the regulation of this monomeric G 
protein.  In support of this proposal, Davidson and colleagues showed that GnRH I-
induced cytoskeletal remodelling was dependent on the activation of both src and 
Rac (Davidson et al., 2004) and a wealth of evidence indicates that this Tyr kinase 
both positively regulates Rac and negatively regulates Rho (Brandt et al., 2002, 
Vouret-Craviari et al., 2002, Servitja et al., 2003, Kawakatsu et al., 2005, Kai et al., 
2007, Zhou et al., 2007, Dise et al., 2008).  Inhibition of src with PP2 altered only the 
cytoskeletal reorganisation induced by stimulation with GnRH I.  Specifically, PP2 
application resulted in the GnRH I-mediated formation of intracellular stress fibres.  
These data therefore have four related implications.  Firstly, they indicate that src is 
involved in the stimulation of Rac activity in response to GnRH I; inhibition of src 
completely inhibited the cellular phenotypic change indicative of Rac activation.  
Secondly, they suggest that, in addition to inducing the activation of Rac, GnRH I 
may activate the G12/13-Rho-ROCK-mediated pathway.  Support for this 
interpretation comes from the fact that, upon inhibition of the src-mediated activation 
of Rac, GnRH I may still induce G12/13-Rho-ROCK signalling.  Consequently, 
morphological changes indicative of such activation become apparent.  Thirdly, they 
support the suggestion that GnRH II may not activate Rac; inhibition of src had no 
apparent effect on the cellular phenotype obtained in response to stimulation with 
this ligand.  Finally, they imply that, in agreement with the later data presented 
within this chapter which will shortly be discussed, the lack of such an activation 
ability is due to the inability of GnRH II to, independently of Gq/11, activate src.   
 
Chapter Four                                                                                                             GnRH Receptor Activation of the G12/13 G Proteins 
 178
Src has been shown to associate directly with the intracellular domains of certain 
GPCRs.  The β3-adrenergic receptor is one such example.  Cao and colleagues 
demonstrated that ligand binding to this receptor induces the formation of a complex 
between src and the GPCR and that this complex can be coimmunoprecipitated in the 
absence or presence of arrestins (Cao et al., 2000).  Protein interaction studies 
revealed that the receptor interacts with the SH3 domain of src via PxxP motifs in 
ICL3 and the carboxy-terminal tail.  Similarly, Liu and colleagues showed that the 
P2Y2 receptor binds the src SH3 domain via PxxP motifs in the carboxy-terminal tail 
(Liu et al., 2004).  Recent studies, however, suggest that the SH3 domain containing 
proteins may bind peptide sequences that lack this canonical motif.  In particular, 
experimental evidence has demonstrated that the (R/K)xx(K/R) sequence may 
instead be necessary for SH3 domain interaction (Liu et al., 2003, Jia et al., 2005).  
Importantly, the GnRH receptor possesses three (R/K)xx(K/R) motifs in ICL1 (figure 
1.10).  Thus, it is possible that, upon GnRH I-mediated receptor activation, the SH3 
domain of src associates with the putative SH3 binding sites of this GPCR.  Indeed, 
coimmunoprecipitation of src and the HA tagged receptor protein suggests, in 
agreement with previous research from our laboratory (Coetsee and Lu, unpublished 
observations), the formation of a tight complex between these proteins. 
 
In 1998, Levi and colleagues demonstrated that GnRH increases src activity in αT31 
cells (Levi et al., 1998).  This increase was shown to be only partially sensitive to 
PKC inhibition, results which imply that src activation in part relies on signalling 
initiated by Gq/11.  Later, Davidson and colleagues performed similar experiments in 
SCL60 cells (Davidson et al., 2004).  GnRH I-induced src phosphorylation was 
shown to occur independently of PLCβ, PKC and intracellular Ca2+ release.  These 
data therefore indicate that, while there appears to be a Gq/11-dependent component of 
GnRH-mediated src activation, such signalling is not the exclusive determinant.  The 
data described within this chapter support this concept.  Indeed, significant Tyr 
phosphorylation of src in response to GnRH I stimulation was still detectable after 
complete inhibition of the Gαq/11-mediated signalling pathway with YM-254890.  In 
contrast, and in agreement with the data described so far, no such phosphorylation 
was evident after stimulation with GnRH II.  The studies in the MEF cells provide 
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additional support for this conclusion.  Although not statistically significant, these 
data suggest that, in the complete absence of Gq/11, only GnRH I may Tyr 
phosphorylate src. 
 
LiSS at the GnRH receptor is further supported by the observation that GnRH I and 
GnRH II induced different maximal levels of SRE-driven transcription.  As with 
Rho, Rac is known to be a central mediator of SRE transcriptional activity (Hill et 
al., 1995).  Indeed, transfection of a dominant negative Rac mutant into rat2 
fibroblasts was sufficient to significantly inhibit TNFα-induced SRE-luciferase 
activation (Kim et al., 1999).  Similarly, Rac has been shown to be necessary for the 
full induction of the EGF-mediated SRE-luciferase response (Kim and Kim, 1997) 
and EGF is known to activate Rac through a pathway involving src (Dise et al., 
2008).  My data also indicate that PP2 had a significant effect on the GnRH I- but not 
the GnRH II-induced SRE response.  Thus, viewed collectively with the observation 
that src is involved in the activation of Rac, these findings provide evidence to 
support my proposal that only GnRH I has, independently of Gq/11, the ability to 
activate src.  Consistent with my results, PP2 has been shown to impede SRE-driven 
transcription in PC12 cells in response to both norepinephrine and nerve growth 
factor (Minneman et al., 2000).  Interestingly, the latter of these ligands has been 
shown to potently induce Rac activation in the same cell type (Yamaguchi et al., 
2001).   
 
According to the conclusions I have drawn, specific inhibition of both the G12/13- and 
the src-mediated pathways should only allow signalling induced by either ligand to 
be promulgated through Gq/11.  At the Gq/11 activated signalling cascade, both GnRH 
ligands have been shown to induce PhI responses with comparable Emax values (Lu et 
al., 2007).  Similarly, my work has shown that transfection of ΔDH-p115 RhoGEF 
and subsequent application of PP2 was sufficient to induce luciferase responses of 
similar values after stimulation with either GnRH ligand.  By themselves, these data 
indicate that either the G12/13 or the src activated signalling mechanism is responsible 
for mediating the larger GnRH I-induced SRE-luciferase response.  However, given 
that specific inhibition of the G12/13 pathway had a significant effect on the SRE-
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driven transcriptional output induced by both the GnRH ligands, taken together with 
the fact that PP2 only significantly affected such signalling induced by GnRH I, I 
propose that these data provide further evidence to support my interpretations that 
only GnRH I activates src and thus the downstream signalling cascades associated 
with this Tyr kinase in a Gq/11-independent manner.  Additionally, inhibition of both 
the Gq/11 and the G12/13 activated cascades completely inhibited the GnRH II-induced 
SRE response.  Such inhibition in response to GnRH I stimulation required the extra 
inhibition of src. 
 
As described in chapter one, GnRH stimulated LHβ and FSHβ gene transcription are 
highly regulated processes.  The results detailed within this chapter suggest that 
GnRH receptor-G12/13-mediated signalling may play a role in such regulation.  While 
this has never been investigated, it is entirely possible for a number of reasons.  With 
regards to LHβ, Salisbury and colleagues demonstrated that maximal activity of this 
gene requires β-catenin (Salisbury et al., 2007) and Gardner and colleagues showed 
that GnRH stimulates β-catenin nuclear accumulation (Gardner et al., 2007).  
Interestingly, Meigs and colleagues demonstrated that constitutively active Gα12/13 
induces β-catenin nuclear translocation (Meigs et al., 2001).  Secondly, GnRH 
stimulates LHβ gene expression through the transcriptional regulation of EGR1 
(Salisbury et al., 2007) which binds to and activates the LHβ promoter by acting in 
combination with SF1 (Duan et al., 2002).  Significantly, the 5’ flanking sequence of 
the EGR1 gene has been cloned from several species revealing the presence of 
multiple SREs (Duan et al., 2002) and an EGR1 promoter may itself be activated by 
Gα13Q226L (Vara Prasad and Dhanasekaran, 1999).  Thirdly, I and others have 
shown that GnRH Receptor-G12/13-induced signalling activates the ERK cascade 
(Buch et al., 2008) and ERK has shown to be involved in the GnRH-induced 
stimulation of LHβ reporter activity (Harris et al., 2002).  Finally, it has been 
demonstrated that Gα13 endogenously expressed in HeLa cells can be 
coimmunoprecipitated with Pro rich Tyr kinase 2 (Pyk2) in an activation-dependent 
manner and that Gα13Q226L has the ability to stimulate Pyk2 kinase activity (Shi et 
al., 2000).  Significantly, Maudsley and colleagues identified a novel GnRH 
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activated Pyk2-dependent signal transduction pathway that regulates EGR1 
activation of the LHβ promoter (Maudsley et al., 2007).   
 
In the case of FSHβ, the situation is more complex (due primarily to our lack of 
understanding of the molecular mechanisms underlying the transcriptional activity of 
this gene).  Perhaps ERK may play a role in the possible G12/13-mediated 
transcriptional regulation as this MAPK is known to be involved in the GnRH-
mediated induction of FSHβ synthesis (Bonfil et al., 2004).  Additionally, my data, in 
agreement with previous findings (Orth et al., 2005), indicate that GnRH-G12/13-
induced signalling may activate ERK. 
 
The involvement of src in the transcriptional regulation of LHβ and FSHβ is 
controversial.  Maudsley and colleagues showed that PP2 inhibits the GnRH-induced 
LHβ luciferase response (Maudsley et al., 2007).  Clearly, these data are at odds with 
my observations and this discrepancy may be due to a number of reasons.  For 
example, in the study mentioned the authors did not make use of serum deprivation 
prior to GnRH stimulation (Maudsley et al., 2007).  Thus, GnRH-independent 
stimulation of LHβ, which may involve src, could account for our dissimilar data.  
Interestingly, a recent study by Roby and colleagues demonstrated that serum LH 
and FSH in day 40 and day 52 mice does not differ between wild-type and src 
knockout animals (Roby et al., 2005). 
 
Taken together, the results within this chapter constitute the first successful 
observations of direct interaction between the GnRH receptor and the G12/13 G 
proteins.  Additionally, they confirm that the receptor may directly interact with src 
Tyr kinase and suggest that GnRH I but not GnRH II may mediate src Tyr 
phosphorylation and thus activation.  Using a range of cellular backgrounds, I have 
shown that the coupling of the receptor to these discrete signalling pathways may 
induce a variety of cellular responses including MAPK activation, gene transcription 
and cytoskeletal reorganisation.  These studies therefore provide a basis for further 
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5.0  Final Discussion 
GnRH is the central regulator of the mammalian reproductive system in that it 
governs the biosynthesis and the release of LH and FSH (Cheng and Leung, 2005, 
Pawson and McNeilly, 2005).  Several studies have demonstrated that it may also 
inhibit cellular growth and upregulate proapoptotic signalling mechanisms (Klijn and 
de Jong, 1982, Dondi et al., 1994, Yano et al., 1992, Yano et al., 1994, Jeyarajah et 
al., 1996, Dondi et al., 1998, Kimura et al., 1999, Kraus et al., 2004, Maudsley et al., 
2004, Gnanapragasam et al., 2005, Morgan et al., 2008, White et al., 2008a, White et 
al., 2008b).  The latter action of GnRH has frequently been proposed to be mediated 
by the coupling of the GnRH receptor to G proteins of the Gi/o family (Imai et al., 
1996, Kimura et al., 1999, Limonta et al., 1999, Maudsley et al., 2004).  
Additionally, this GPCR has been proposed to couple to both Gq/11 and Gs (Liu et al., 
2002b) or exclusively to Gq/11 (Grosse et al., 2000).  These data therefore serve to 
highlight the unresolved nature of the ability of the GnRH receptor to interact with 
multiple G proteins.  This thesis has addressed this issue in detail using, 
predominantly, a cell line derived from Gαq/11 knockout mice (Offermanns et al., 
1998).  The use of this cell model may therefore promote the identification of GnRH-
induced Gq/11-independent signalling pathways. 
 
The data presented provides strong evidence to suggest that the GnRH receptor does 
not couple to the G proteins of the Gi/o family.  Indeed, the observation that, even 
when Gαqi5 was expressed, GnRH did not induce significant phosphorylation of 
ERK, JNK or P38 dictates that this GPCR does not interact with Gi/o.  This 
conclusion is strengthened by the observation that Gq/11-mediated signalling can 
clearly facilitate the GnRH-induced activation of all the MAPKs studied.  Thus, the 
activation of a Gi/o-coupled GPCR in cells expressing Gαqi5 should result in the 
phosphorylation of these proteins.  My interpretations are consistent with previous 
studies which investigated the most proximal step in GnRH-induced G protein 
activation; GDP/GTP exchange (Grosse et al., 2000, White et al., 2008a).  
Conversely, they are not easily reconcilable with several investigations that use PTX 
as a method to infer GnRH receptor-Gi/o interaction (Sim et al., 1995, Imai et al., 
1996, Kimura et al., 1999, Limonta et al., 1999, Maudsley et al., 2004).  
Chapter Five                                                                                                                                                                                                            Final Discussion 
                                                                                                                                                   184 
Nevertheless, as described in chapter one, while positive responses to chemical 
inhibitors provide useful preliminary indications of GPCR-G protein interaction, they 
are by themselves not sufficient to accurately interpret experimental data. 
 
The observation that GnRH did not induce any increase in cAMP suggests that the 
GnRH receptor does not couple to Gs.  It would seem improbable that this assay was 
too insensitive to detect any such increase given the 14.7 ± 0.4-fold response elicited 
by isoproterenol.  It is plausible to speculate that the Gβγ complex-mediated 
inhibition of adenylyl cyclase isoforms may mask any GnRH receptor-Gs-mediated 
cAMP increase.  However, given that the Gβγ complex also stimulates the activity of 
certain adenylyl cyclase isoforms and thus increases cAMP levels (Gao and Gilman, 
1991, Tang and Gilman, 1991, Yoshimura et al., 1996), this would appear unlikely.  
These data therefore provide evidence to indicate that GnRH receptor-Gs interaction 
may not occur.  This conclusion is supported by a previous investigation which 
utilised direct analytical techniques to analyse GnRH-induced G protein activation 
(Grosse et al., 2000).  In this study, the authors could obtain no evidence to indicate 
that the GnRH receptor couples to Gs.  Additionally, unpublished work from our 
laboratory indicates that GnRH may not induce a CRE-mediated transcriptional 
response suggesting that, even at the most distal level, activation of Gs by the GnRH 
receptor is undetectable (Rischitor and Pawson, unpublished observations). 
 
My finding that the GnRH receptor directly interacts with the G12/13 G proteins is one 
that has not been widely investigated.  Nevertheless, the fact that, in contrast to 
Gαi2G203T, Gα13G226A could competitively inhibit the GnRH-induced PhI 
hydrolysis suggests that the GnRH receptor may directly interact with these G 
protein α subunits.  Coimmunoprecipitation of both endogenous Gα13 and 
Gα13G225A with the HA tagged GnRH receptor provide support for this 
interpretation.  Additionally, my results imply that coupling of the receptor to G12/13 
may be functionally important in the synthesis of the gonadotropins.  A more 
detailed analysis is, however, required in order to elucidate the precise mechanism 
involved.  Interestingly, Enomoto and colleagues recently revealed that GnRH 
induced Rho-dependent stress fibre formation in DU145 cells (Enomoto et al., 2006).  
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Moreover, I have shown that, in agreement with previous investigations (Buhl et al., 
1995, LePage et al., 2003), GnRH-induced activation of G12/13 regulates the 
formation of stress fibres in a manner dependent on the activation of Rho and 
consequently ROCK.  Thus, perhaps the GnRH-mediated activation of G12/13 is 
involved in the phenotypic change observed in the investigation highlighted.  
Additionally, the G12/13 G proteins are highly implicated in cellular migration and 
invasion (Offermanns et al., 1997, Kelly et al., 2006a, Kelly et al., 2006b, Kelly et 
al., 2007, Worzfeld et al., 2008).  Cheung and colleagues recently showed that low 
doses of GnRH stimulated Caov3 and OVCAR3 cellular motility and invasion 
(Cheung et al., 2006).  GnRH receptor activation of the G12/13 G proteins may, in this 
case, be functionally important.   
 
One of the main aims of this thesis was to clarify the possible mechanisms 
underlying the ability of GnRH I to induce the inhibition of cellular growth.  In this 
regard, a thorough elucidation of the G protein coupling ability of the GnRH receptor 
was necessary.  My results clearly show that Gq/11 is an absolute requirement for 
GnRH I-induced antiproliferation.  It came as a surprise, therefore, that the inhibition 
of PKC or the chelation of intracellular Ca2+ had no significant effect.  Based on both 
my later data (which indicate that, in the presence of Gq/11, src is important in the 
GnRH I stimulated antiproliferative response) and previous research within our 
group (Coetsee and Lu, unpublished observations), I proposed that SHP-2 may be 
involved in this process.  In this regard, Tyr phosphorylation of the GnRH receptor is 
likely to be necessary as the pYxxL motif is known to provide a docking site for 
SHPs (Unkeless and Jin, 1997).  Src activation is known to result in the Tyr 
phosphorylation of certain GPCRs such as the OX1 receptor (Voisin et al., 2008) and 
the somatostatin SST2 receptor (Ferjoux et al., 2003).  Additionally, Coetsee and 
colleagues have demonstrated that GnRH receptor Tyr phosphorylation is highly 
correlated with src association (Coetsee and Lu, unpublished observations).  In the 
context of my data, however, the question of how src is activated in response to 
GnRH I stimulation still remained.   
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There are a number of pathways which may induce the Tyr phosphorylation and thus 
the activation of src.  Based on the observations presented within chapter four, src 
activation may occur downstream of Gq/11 and, in response to GnRH I stimulation, 
independently of these G proteins.  Src has also been shown to become activated 
downstream of the Gβγ complex (Shajahan et al., 2004, Gentili et al., 2006).  With 
reference to the antiproliferative effects of GnRH I, it would appear that the Gαq/11-
induced activation of src does not play a major role; inhibition of the Gαq/11-mediated 
signalling pathway had no effect on the antiproliferative response obtained.  The 
same conclusion may be reached for the possible GnRH I-induced src activation 
downstream of the Gβγ complex.  Indeed, the data in chapter four indicate that 
GnRH II does not, independently of Gq/11, result in src activation.  However, 
activation of G12/13, which can be induced by GnRH II, will result in Gβγ release.  
These data therefore suggest that the Gβγ complex, in response to GnRH stimulation, 
does not induce src activation.  Coimmunoprecipitation studies revealed that src 
forms a tight and constitutive complex with the GnRH receptor.  Taken together with 
the presence of three putative SH3 binding domains in ICL1, it is conceivable that 
src may, in response to GnRH I stimulation, bind to and become activated directly by 
this GPCR.  Presumably, GnRH I binding facilitates receptor conformational 
changes such that the (R/K)xx(K/R) motifs become accessible. 
 
Given that GnRH I stimulation can result in src activation independently of Gq/11, 
that src association is known to correlate with the Tyr phosphorylation of the GnRH 
receptor (Coetsee and Lu, unpublished observations) and that the pYxxL motif is a 
docking site for SHPs (Unkeless and Jin, 1997), SHP-2 may be expected to interact 
with this GPCR after GnRH I stimulation.  Such interaction may control the duration 
and signalling intensity of ERK, a MAPK that I have shown is important in the 
GnRH I stimulated inhibition of cell growth.  A key unresolved issue, however, is 
where Gq/11 fits into this scheme.  Based on research performed within our 
laboratory, and similar to the data obtained by Feng and colleagues (Feng et al., 
2002), I propose that Gq/11 acts more as a scaffold for the binding of SHP-2 to the 
GnRH receptor.  In this regard, the presence but not the activation of these G proteins 
would be necessary.  Perhaps the YxxL motif in the Gαq/11 subunits plays a role in 
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this scaffolding complex as SHP-2 has two distinct SH2 domains and the 
engagement of both is known to be necessary for maximum phosphatase activity 
(Neel et al., 2003).  In support of this suggestion, Coetsee and colleagues have 
demonstrated that SHP-2 activation requires the presence of Gq/11 (Coetsee and Lu, 
unpublished observations).  Additionally, these investigators have shown that GnRH 
I stimulation of Gq/11-uncoupled GnRH receptor mutants results in robust SHP-2 
activation and that Gq/11 and SHP-2 may be coimmunoprecipitated (Coetsee and Lu, 
unpublished observations). 
 
The proposal described above highlights a potential mechanism whereby GnRH I 
may induce cell growth inhibition.  Nevertheless, it is difficult to reconcile with 
certain previous studies.  For example, complete inhibition of Gq/11-induced 
signalling with YM-254890 is known to completely inhibit the GnRH I-induced 
antiproliferative response in SCL60 cells (White et al., 2008a).  Additionally, in the 
same cell type, the specific inhibition of PKC has been shown to have the same 
effect (Morgan et al., 2008) and GnRH II has been postulated to be more potent in 
inducing antiproliferation than GnRH I (Lopez de Maturana et al., 2008).  Recent 
investigations have highlighted the importance of cellular context in this GnRH-
induced response (Morgan et al., 2008).  Thus, the data discussed previously may 
provide an additional pathway whereby GnRH I may inhibit cell growth.  I would 
argue, however, that it is highly unlikely to be the only cascade involved in the 
regulation of such a process. 
 
The results presented within this thesis have provided strong evidence to indicate that 
the GnRH receptor does not couple to the G proteins of either the Gi/o or the Gs 
families.  In doing so, they have highlighted a crucial role for Gq/11 in the GnRH I-
induced inhibition of cell growth.  Additionally, I have identified a novel GnRH 
receptor-G12/13 signalling pathway, proposed a role for this pathway in the GnRH-
mediated regulation of the gonadotropins and provided evidence to support the 
concept of LiSS.  GnRH continues to offer the promise of extra therapeutic value.  In 
order to exploit such potential, however, it is essential that the signalling pathways 
initiated downstream of receptor activation are accurately delineated.  Perhaps the 
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studies detailed herein may help refocus the field and aid in the translation of basic 
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7.0  Appendices 
The information contained within these appendices is pertinent to the data presented 
within this thesis.  The first details the abbreviations and the one letter codes of the 
amino acids used throughout the text and the second the publications completed or 
contributed to during the course of this PhD. 
 
7.1  Amino Acid Abbreviations and One Letter Codes 
The abbreviations and the one letter codes of the amino acids used throughout the 
text are shown in table 7.1. 
 
Amino Acid Abbreviation One Letter Code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic Acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
 
Table 7.1 Amino acid abbreviations and one letter codes. 
 
7.2  Publications 
The publications completed or contributed to during the course of this PhD are 
shown on the following pages.  Permission has been granted by all the authors and 
the respective editorial offices allowing the inclusion of the manuscripts within this 
thesis. 
 
Structural Determinants for Ligand-Receptor Conformational
Selection in a Peptide G Protein-coupled Receptor*
Received for publication, November 8, 2006, and in revised form, April 18, 2007 Published, JBC Papers in Press, April 23, 2007, DOI 10.1074/jbc.M610413200
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Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, United Kingdom and §The University of Cape Town,
Cape Town 7925, South Africa
G protein coupled receptors (GPCRs) modulate the majority
of physiological processes through specific intermolecular
interactions with structurally diverse ligands and activation of
differential intracellular signaling. A key issue yet to be resolved
is howGPCRs developed selectivity and diversity of ligand bind-
ing and intracellular signaling during evolution. We have
explored the structural basis of selectivity of naturally occurring
gonadotropin-releasing hormones (GnRHs) from different spe-
cies in the single functional human GnRH receptor. We found
that the highly variable amino acids in position 8 of the naturally
occurring isoforms ofGnRHplay a discriminating role in select-
ing receptor conformational states. The human GnRH receptor
has a higher affinity for the cognate GnRH I but a lower affinity
for GnRH II andGnRHs from other species possessing substitu-
tions for Arg8. The latter were partial agonists in the human
GnRH receptor. Mutation of Asn7.45 in transmembrane domain
(TM) 7 had no effect on GnRH I affinity but specifically
increased affinity for other GnRHs and converted them to full
agonists. Usingmolecularmodeling and site-directedmutagen-
esis, we demonstrated that the highly conserved Asn7.45 makes
intramolecular interactions with a highly conserved Cys6.47 in
TM 6, suggesting that disruption of this intramolecular interac-
tion induces a receptor conformational change which alloster-
ically alters ligand specific binding sites and changes ligand
selectivity and signaling efficacy. These results reveal GnRH
ligand and receptor structural elements for conformational
selection, and support co-evolution of GnRH ligand and recep-
tor conformations.
Gprotein-coupled receptors (GPCRs)2 constitute the largest
family of signaling molecules in the mammalian genome. Over
800 GPCRs have been identified in the human genome (1).
GPCRs bind a variety of structurally diverse ligands ranging
fromphotons, ions, bioamines, lipids, nucleotides, and peptides
to large polypeptide hormones at the extracellular surface.
They activate a number of different intracellular effector pro-
teins including G proteins or non-G proteins which participate
in themajority of physiological processes. About 50%of current
clinical drugs target GPCRs, and these receptors thus remain a
major avenue for future drug development.
The 7-TMGPCRs are presumed to have evolved froma com-
mon ancestor (2), and are thought to share important structural
and functional characteristics (3–5), but have undergone spe-
cialization tomirror the nature of their cognate ligands. It is not
clear, however, howGPCRs developed ligand selectivity to cog-
nate ligands during evolution. We hypothesized that GPCR
binding specificity is not only determined by ligand contact
residues but also by receptor conformations specified by recep-
tor intramolecular interactions. There is also increasing evi-
dence that ligands can selectively stabilize different receptor
active conformations thereby mediating ligand-induced selec-
tive signaling (LiSS) (6–9). Selection of signaling by analogues
clearly has potential for future drug development with novel
activities and reduced side-effects. Hence, delineation of recep-
tor allosteric communication networks which couple selective
ligand structural elements to specific receptor conformational
changes is fundamental to understanding LiSS (10).
Although only one functionalmember of the GnRH receptor
and two isoforms of GnRH ligands (GnRH I and GnRH II) (Fig.
1A) exist in humans, coexistence of multiple types of GnRH
ligands and receptors was identified in themajority of chordate
and vertebrate species (6). The humanGnRH receptor has high
affinity for GnRH I (Fig. 1, A and B) but a 10-fold lower affinity
for GnRH II, which differs by three amino acids (Fig. 1A). In
contrast, the marmoset and macaque type II GnRH receptors
have a high affinity for GnRH II but a much lower affinity for
GnRH I (11). The human type II GnRH receptor has been
silenced by stop codons and frameshift deletions (6, 12), sug-
gesting that the single subtype of the human GnRH receptor
mediates actions of both ligands. The ligand binding sites iden-
tified in the human GnRH receptor for the conserved N- and
C-terminal amino acids of GnRHs (Fig. 1C) are almost fully
conserved among all GnRH receptors (6). This implies that the
evolutionarily variable residues in position 5, 7, and 8 of the
jawed vertebrate GnRHs confer ligand binding and functional
selectivity (6, 13). We have recently revealed that mutations in
the single subtype of the human GnRH receptor remote from
* This work was supported by the Medical Research Council, United Kingdom
(to Z. L. L., M. C., C. D. W., and R. P. M.) and the Medical Research Council of
South Africa, Commonwealth Scholarship and Ardana (to M. C.). The costs
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2 The abbreviations used are: GPCRs, G protein-coupled receptors; TM, trans-
membrane domain; GnRH, gonadotropin-releasing hormone; LiSS, ligand-
induced selective signaling; PhI, phosphoinositide; BSA, bovine serum
albumin; DMEM, Dulbecco’s modified Eagle’s medium; mAChR, muscarinic
acetylcholine receptor; PDB, Protein Data Bank.
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ligand binding sites have differential effects on the binding
affinity of the two endogenous ligands (10), implying differen-
tial ligand-receptor conformational selections. Herewe present
studies supporting the hypothesis that changes in the GnRH
receptor conformation occurred coincident with amino acid
changes of GnRH ligands, which modify ligand structure/con-
formation, i.e. there was a reciprocal structural/conformational
selection between ligands and receptors during evolution.
Our preliminary screening mutagenesis of putative TM
interacting residues revealed candidates which appeared func-
tionally important for ligand binding and receptor activation
for further studies. Here we report that the highly conserved
Asn7.45 in TM 7 makes intramolecular interactions with a
highly conservedCys6.47 in TM6which plays an important role
in control of receptor conformational states of the human
GnRH receptor, involved in binding selectivity and signaling
efficacy of GnRH analogues, which differ by only one amino
acid in position 8.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis and Receptor Expression—A PCR
method was used to construct mutant receptors of N7.45A,
C6.47A, and C6.47Y. The mutant receptor DNAs cloned into
the pcDNA I expression vector were validated by di-deoxy
sequencing. Wild-type and mutant receptors were transiently
expressed in COS-7 cells by transfection using a Bio-Rad Gene
Pulser at 230V and 960microfarads with 20g of DNA/0.4-cm
cuvette (1  107 cells; 0.7 ml). After transfection, cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal calf serum, antibiotics, and 2 mM
glutamine (complete DMEM) in the absence or presence of 1
M IN3 (a membrane-permeant non-peptide GnRH receptor
antagonist). Cells were washed four times, each wash lasted for
30min,with 2%Me2SO, 0.1%BSA/Hepes/DMEMat 37 °C after
a 48-h incubation. The cells were then incubatedwith complete
DMEM overnight (18 h), and were washed again as above
prior to assaying. This allowed complete removal of IN3 from
pretreated cells before assaying (10).
Ligand Binding—Radioligand binding assays were per-
formed on intact cells 72 h after transfection (10). Transfected
cells in 12-well culture plates were washed as above and then
incubated with 125I-[His5,D-Tyr6]GnRH (100,000 cpm/0.5
ml/well) and various concentrations of unlabeled GnRH
ligands in 0.1% BSA/Hepes/DMEM for 4 h at 4 °C. Nonspecific
binding was determined in the presence of 1 M unlabeled
GnRH I. After incubation, the cells were rapidly washed with 1
ml ice-cold phosphate-buffered saline (pH 7.4) twice and solu-
bilized in 0.5 ml of 0.1 M NaOH. Radioactivity was counted by
-spectrometry. All experiments were performed in triplicate
and repeated at least three times.
PhI Hydrolysis—Assays for ligand stimulation of inositol
phosphate production were previously described (10). Trans-
fected COS-7 cells were seeded onto 12-well plates in the
absence or presence of 1 M concentration of IN3. After 48 h,
IN3 was washed off as above and labeled overnight with 1
Ci/ml myo-D-[3H]inositol in inositol-free DMEM containing
1% dialyzed fetal calf serum. Before conducting PhI assay, the
cells were washed again as above. Cells were then preincubated
with 0.5 ml of buffer A (140 mM NaCl, 20 mM HEPES, 8 mM
glucose, 4 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 1 mg/ml BSA)
containing 10mMLiCl at 37 °C for 30min, followed by addition
of GnRHs for an additional 30 min. The stimulation was termi-
nated by removal of the medium and addition 0.5 ml of 10 mM
FIGURE 1. Structures of GnRHs and the human GnRH receptor. A, primary
structures of GnRH I, GnRH II, and GnRHs from other species with Arg8 substi-
tution. The N-terminal amino acids (pGlu1-His2-Trp3-Ser4) and C-terminal
amino acids (Pro9-Gly10-NH2) of the decapeptide ligands are highly con-
served over 600 million years of the chordate evolution and are important for
ligand binding (see below) and receptor activation (6). B, an NMR structure of
GnRH I (PDB code: 1YY1) showing a II conformation. C, a homology model
of the 7-TM domains of the human GnRH receptor in the inactive state. The
ligand binding residues for GnRH I are labeled in black. pGlu1 is proposed to
interact with Asn5.39; His2 with Asp2.61/Lys3.32; Tyr5 with Tyr6.58; Arg8 with
Asp7.32; and Gly10NH2 with Asn
2.65. These interactions can all be satisfactorily
accommodated when GnRH in the II conformation is docked to the recep-
tor (not shown for clarity) (6, 10). There is no intermolecular interaction
between Tyr8 of GnRH II and Asp7.32 (green) that interacts with Arg8 of GnRH I
(green) (41). The most highly conserved (80 –100%) residues in the 7 TM
domains among rhodopsin-like family of GPCRs are colored blue.
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formic acid. The [3H]inositol phosphates were isolated from
the formic acid extracts using Dowex AG 1-X8 ion exchange
resin and collected with 1 M ammonium formate containing 0.1
M formic acid and quantified by liquid scintillation counting.
Comparative Modeling of the GnRH Receptor andMolecular
Dynamics (MD) Simulations—Initial homology models of the
human GnRH receptor in the inactive or active state were built
on the crystal structures of bovine rhodopsin (14, 15) (PDB
codes 1U19 and 2I37) using a similar method as previously
described (10, 16, 17), with the “MODELLER” module within
DS Modeling (version 1.6, Accelrys, San Diego, CA). Although
there are concerns in regard to the use of the rhodopsin struc-
ture as a template to model other GPCRs due to low sequence
similarities among the rhodopsin-like family of GPCRs,
sequence analysis suggested that GPCRs share a similar
arrangement of the 7-TM domains. This is also because of the
presence of a few, but significantly conserved residues and
motifs in each of the 7-TMdomains (4, 18, 19). The amino acids
possessing 80–100% conservation are Asn1.50, Leu2.46, Asp/
Asn2.50, Cys3.25, Glu/Asp3.49, Arg3.50, Trp4.50, Phe6.44, Trp/
Phe6.48, Pro6.50, Pro7.50, and Tyr7.53 (4, 18) (Fig. 1C). Molecular
modeling of GPCRs has recently been extensively reviewed by
Fanelli and De Benedetti (18) in which they suggest that com-
parativemodeling of the 7-TMbundle of GPCRs using rhodop-
sin structure as a template is likely to produce reliable results.
The use of rhodopsin to comparatively model the mammalian
GnRH receptor has been validated by the authors (6, 10) and
also by independent groups using extensive site-directed
mutagenesis studies and peptide (20, 21) and non-peptide
docking supported by 76 mutations (22). The MODELLER-
generated models with the highest values of the three-dimen-
sional profile score, computed by means of the module of “ver-
ify protein” in the DS modeling, were selected for further
refinement. The models incorporating all previously experi-
mentally identified amino acid interactionswere subjected to in
vacuo energy minimization and MD simulations by means of
the CHARMM program (23), using a setup similar to that
described for the modeling of the closely-related oxytocin
receptor (24). Harmonic restraints of 2.5 kcal/mol/Å2 on the
receptor backbone atoms except for the second extracellular
loop and the experimentally identified disulfide-bonded N-ter-
minal domain (25) were applied to allow small conformational
changes of the receptor during theMDsimulationswithout loss
of the overall receptor topology (26). Minimizations were car-
ried out by using 1500 steps of steepest descent followed by a
conjugate gradient minimization, until the root-mean-square
gradients was less than 0.001 kcal/mol/Å. A distance-depend-
ent dielectric term (  4r) and a 12 Å non-bonded cut-off
distance were chosen. The systemwas heated to 300 Kwith 5 K
rise, every 100 steps per 6000 steps, by randomly assigning
velocities from the Gaussian distribution. After heating, the
system was allowed to equilibrate for 34 ps. Finally, a produc-
tion phase was carried out involving a 100 ps simulation using
anNVTensemble at 300K, with a time steps of 1 fs. Themodels
wereminimized as above and used for the comparative analysis.
Materials—GnRH I and GnRH II were purchased from
Sigma and Bachem. [His5,D-Tyr6]GnRH, [His5]GnRH,
[Trp7]GnRH, [Tyr8]GnRH, chicken GnRH I ([Gln8]GnRH),
frog GnRH ([Trp8]GnRH), and seabream GnRH ([Ser8]GnRH)
were synthesized in our laboratory as previously described (10).
IN3, (2S)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-
2-oxoethyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]-N-(2-
pyridin-4-ylethyl) propan-1-amine was obtained fromMERCK
(10).
Data Analysis—Binding curves were fitted to the Hill equa-
tion or to the one-site model using Sigmaplot 9.0 (SPSS) yield-
ing an IC50 value. The receptor expression levels were calcu-
lated as percentage of the wild-type control included in each
transfection. PhI dose-response curves were fitted to a four-
parameter logistic function, yielding a basal activity, a maxi-
mum response (Emax), an EC50 value and a slope factor.
RESULTS
Mutation of Asn7.45 to Ala Induces a Receptor Conforma-
tional Instability That Is Rescued by a Membrane-permeant
Non-peptide GnRH Antagonist—Mutation of Asn7.45 to Ala
completely abolished receptor expression on cell surfaces when
transiently transfected into COS-7 cells, as measured by ligand
binding assays with a hydrophilic peptide agonist 125I-[His5,D-
Tyr6]GnRH on intact cells (Fig. 2A, inset). Themutant receptor
also gave undetectable PhI responses.3 To investigate if a cell
membrane-permeant non-peptide GnRH antagonist, IN3,
could rescue the mutant receptor by chaperoning it to the cell
surface, the wild-type and mutant receptor transfected COS-7
cells were preincubated with 1 M IN3 for 48 h. After washing
out the IN3 as described previously (10), the expression level of
the mutant receptor was measured by radioligand binding giv-
ing 40% of the wild-type level (Fig. 2A, inset). The action of the
chaperone ligand IN3 on receptor expression was observed not
only in the mutant GnRH receptor but also in the wild-type
receptor (Fig. 2A, inset). Pretreatment of the receptor-trans-
fected COS-7 cells with IN3 had no effect on GnRH ligand
binding affinity in the wild-type receptor after washout (Fig.
2A). This result suggests that the membrane-permeant non-
peptide GnRH antagonist IN3 can bind with the newly synthe-
sized receptor inside of cells, and alter receptor conformations
from an unstable to a more stable state.
Effect ofMutation of Asn7.45 to Ala on Receptor Binding Affin-
ity of GnRH Analogues—The mutation N7.45A had little effect
on binding affinity of GnRH I (Fig. 2B) and [His5,D-Tyr6]GnRH,
which we conventionally use as a radioligand (Fig. 2A), but
increased affinity of themutant receptor for GnRH II by 8-fold,
as compared with the affinity of the wild-type receptor for
GnRH II (Fig. 2B and Table 1). There are three amino acid
differences between GnRH I and GnRH II in which Tyr5, Leu7,
and Arg8 of GnRH I are replaced by His5, Trp7, and Tyr8 in
GnRH II (Fig. 1A). We examined the effect of mutation of
Asn7.45 to Ala on the binding affinity of GnRH I analogues with
single amino acid substitutions (His5, Trp7, or Tyr8). Themuta-
tion N7.45A had no significant effect on the receptor binding
affinity for [His5]GnRH and [Trp7]GnRH, but increased recep-
tor binding affinity for [Tyr8]GnRH by 14-fold (Fig. 2C and
Table 1).
3 Z. L. Lu, unpublished observation.
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The binding of GnRH I, which contains Arg8, to the wild-
type human GnRH receptor was characterized by one-site
binding isotherms (nH  0.86) with an IC50 at 2.6 nM. The
binding affinities of the wild-type human GnRH receptor for
GnRHs from other species which only have one amino acid
difference in position 8, including chicken GnRH I
([Gln8]GnRH), frog GnRH ([Trp8]GnRH), and seabream
GnRH ([Ser8]GnRH) (Fig. 1A) were much lower than GnRH I
with IC50 values at 80 nM, 111nM, and 684nM (Fig. 2D andTable
1). Interestingly, mutation of Asn7.45 to Ala also increased the
mutant receptor affinity for chicken GnRH I ([Gln8]GnRH),
frog GnRH ([Trp8]GnRH), and seabream GnRH ([Ser8]GnRH)
by 10-fold as was seen for [Tyr8]GnRH (Fig. 2D and Table 1).
Effect of Mutation of Asn7.45 to Ala on the GnRH Ligand-
elicited PhI Turnover—When the N7.45A mutant receptor
expression was rescued, GnRHs were able to elicit a functional
response. Interestingly, GnRH I and GnRH II elicited a maxi-
mum phosphoinositide (PhI) response in the N7.45A mutant
receptor of 110–122% that of the wild-type receptor (Fig. 3A)
even though its expression was only 40% of the wild-type level,
suggesting increased signaling efficacy. In parallel with the
increased GnRH II binding affinity, the mutant receptor was
also more potent in eliciting PhI response, leading to a 3-fold
decrease in the EC50 value as compared with the wild-type
receptor (Fig. 3A and Table 2).
Activation of GnRH receptors from different species by their
cognate ligands can selectively couple to different members of
the G protein family such as Gq/11, Gs, and Gi/o. The human
GnRH receptor preferentially couples to Gq/11, although cou-
pling toGs andGi/o was reported in certain cell types (6). GnRH
I elicits a robust PhI response fromCOS-7 cells transfectedwith
the human GnRH receptor, giving a maximum response five
times the basal activity and an EC50 value of 0.2 nM (Fig. 3, A
and B). Chicken GnRH I ([Gln8]GnRH), frog GnRH I
([Trp8]GnRH), and seabream GnRH I ([Ser8]GnRH) were able
to activate Gq/11-mediated PhI turnover in the human GnRH
receptor with increased EC50 values (Table 2). However, all of
them acted as partial agonists giving reduced Emax responses at
44–83% of that elicited by GnRH I (Fig. 3B and Table 2). Most
interestingly, all of them became full agonists in the N7.45A
mutant receptor, even though the expression is only 40% of the
wild-type, yielding Emax responses equal to or greater than that
elicited by GnRH I in the wild-type receptor with little or only a
small effect on the signaling potency (EC50 value) (Fig. 3B and
Table 2).
FIGURE 2. Competitive binding of GnRH analogues at wild-type and N7.
45A mutant receptors. The wild-type and N7.45A mutant receptor trans-
fected COS-7 cells were preincubated with or without 1 M IN3 for 48 h. The
IN3 was washed off prior to binding assays. A, homologous binding of [His5,D-
Tyr6]GnRH, mutation of Asn7.45 to Ala led to an undetectable GnRH ligand
binding, which was rescued by IN3 preincubation of the transfected cells
(inset). There was no difference in the GnRH binding affinity between the IN3
pretreated and the untreated cells of wild-type receptors. F, wild-type; E,
wild-type with IN3 pretreatment; , N7.45A with IN3 pretreatment. B, com-
petitive binding of GnRH I (F and E) and GnRH II (f and ) at the wild-type
and N7.45A mutant receptors. C, competitive binding of GnRH I analogues
with single amino acid substitution of GnRH II in GnRH I at position 5, 7, or 8 at
the wild-type and N7.45A mutant receptors, [His5]GnRH (F and E);
[Trp7]GnRH (f and ); [Tyr8]GnRH ( and ). D, binding of GnRHs from
different species with Arg8-substitution. GnRH I (F and E); chicken GnRH I
([Gln8]GnRH) (f and ); frog GnRH ([Trp8]GnRH) ( and ); seabream GnRH
([Ser8]GnRH) (Œ and ‚). - - - - - -, wild-type; - - - -, N7.45A. Arrows indicate shift
in affinity of the mutant receptor for Arg8-substituted GnRHs at the N7.45A
mutant receptor.
Structural Determinants for Ligand-Receptor Conformational Selection
17924 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282 • NUMBER 24 • JUNE 15, 2007
 at E
dinburgh U









Identification of the Asn7.45-interacting Residue in the
Human GnRH Receptor—In the refined GnRH receptor
homologymodel in the inactive state, built on the crystal struc-
ture of bovine rhodopsin in the dark state (14), Asn7.45 faces
toward Cys6.47. Mutation of Cys6.47 to Ala or to Tyr (a naturally
occurring mutant in human infertility) led to undetectable
ligand binding and PhI responses. This phenotype is similar to
that of N7.45A. Themutant receptor expression of C6.47A and
C6.47Y at the cell surface was rescued by IN3 pretreatment,
giving 38 and 18% that of the wild-type (Fig. 4B, inset). As with
N7.45A, the mutations C6.47A and C6.47Y led to 3–5-fold
increases in GnRH II binding affinity as compared with the
wild-type receptor (Fig. 4A andTable 1). Bothmutant receptors
showed an increased signaling efficacy for GnRH II, yielding
Emax responses greater than that of the wild-type with
decreased EC50 values (Fig. 4B and Table 2).
DISCUSSION
GPCRs for peptide ligands are frequently present as a variety
of subtypes encoded by distinct genes. The presence ofmultiple
isoforms of peptide ligands which preferentially bind to the
cognate receptor subtypes implies co-evolution of peptide
ligands and receptors. The conventional wisdom in regard to
ligand binding and effector coupling selectivity is that receptor
subtypes incorporate changes in binding site residues for ligand
selectivity and changes in intracellular domains for coupling
selectivity. Our studies here have shown an important role of
receptor conformations in determining ligand binding selectiv-
ity and signaling efficacy in the human GnRH receptor.
Mutation of Asn7.45 to Ala led to
undetectable ligand binding andPhI
responses, which were rescued by a
membrane-permeant, non-peptide
GnRH antagonist, IN3 (Fig. 2, A
and B), suggesting that the side
chain of Asn7.45 makes intramo-
lecular interactions which are
important for receptor folding.
Disruption of the intramolecular
interactions appears to cause
receptor conformational changes
which can be modulated by the
pharmacological chaperon, facili-
tating mutant receptor trafficking
to the cell surface and indicating a
ligand influence on receptor con-
formations. The pharmacological chaperoning effects of IN3
have been extensively studied by Conn and co-workers (27–30)
in which IN3 has been shown to increase protein expression
levels of mutant receptors on the cell membranes and to facili-
tate trafficking of the misfolded mutant receptors from endo-
plasmic reticulum (ER) to the cell surfaces. Membrane-per-
meant antagonists have also been extensively used to rescue
receptor expression of structurally unstable mutants on cell
surfaces in other GPCRs (31–39).
ThemutationN7.45A had no or only amarginal effect on the
receptor binding affinity for GnRH I, [His5]GnRH and
[Trp7]GnRH, but markedly increased receptor binding affinity
for GnRH II and [Tyr8]GnRH (Fig. 2, B and C). This is consist-
ent with our previous suggestion that Tyr8 in GnRH II is
involved in receptor conformational selection (10). An alloste-
ric effect of Asn7.45 mutation on ligand binding affinity was also
observed in the M1 muscarinic acetylcholine receptor
(mAChR), which increased receptor binding affinity not only
for agonists, but also for certain antagonists (16).
The conformation of the wild-type human GnRH receptor
has apparently evolved for high affinity binding to mamma-
lian GnRH I, which contains Arg8 and therefore has a lower
affinity for the second endogenous ligand, GnRH II, possess-
ing Tyr8 (Fig. 2B) and GnRHs from other species, which only
have one amino acid difference in position 8, including
chicken GnRH I ([Gln8]GnRH), frog GnRH ([Trp8]GnRH),
and seabream GnRH ([Ser8]GnRH) (Fig. 2D). Most interest-
ingly, mutation of Asn7.45 to Ala also markedly increased the
FIGURE 3. GnRHs elicited PhI responses at wild-type and N7. 45A mutant receptors. A, GnRH I (F and E)
and GnRH II (f and ) stimulated PhI responses. B, PhI responses elicited by GnRHs from other species with
Arg8-substitution, F, GnRH I; f and , chicken GnRH I ([Gln8]GnRH);  and , frog GnRH ([Trp8]GnRH); Œ and
‚, seabream GnRH ([Ser8]GnRH). - - - - - -, wild-type; - - - -, N7.45A.
TABLE 1
The binding of GnRH analogues to wild-type and mutant human GnRH receptors
Ligand binding were conducted as described under “Experimental Procedures.” Values are mean  S.E. from three or more independent experiments. The competing
radioligand was 125I-His5,D-Tyr6GnRH.
Binding affinity (IC50)
GnRH I GnRH II Tyr8GnRH Gln8GnRH Trp8GnRH Ser8GnRH
nM nM nM nM nM nM
Wild-type 2.6  0.2 29  2 222  13 80  6 111  8 684  43
Wild-type  IN3a 2.5  0.3 28  3 211  23 94  10 107  5 621  30
N7.45Aa 1.5  0.2 3.7  0.5 16  3 8.1  2.2 12  1 48  3
C6.47Aa 3.2  0.1 9.6  0.7
C6.47Ya 2.8  0.3 5.2  0.6
a With IN3 pretreatment.
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mutant receptor affinity for chicken GnRH I, frog GnRH,
and seabream GnRH, as that of GnRH II and [Tyr8]GnRH.
These results indicate an important role of receptor confor-
mations in determining ligand binding selectivity developed
during evolution, which can be manipulated by mutation-
induced receptor conformational changes without alteration
of the side chains of the ligand binding sites. These results
support our proposal of co-evolution of ligand-receptor con-
formations. A single amino acid in position 8 of GnRHs acts
as a structural determinant for receptor binding selectivity.
We propose that ligands might exert a directive role in the
evolution of receptor structure including primary and terti-
ary structures accounting for the origin of receptor specific-
ity and diversity, consistent with the proposal that neu-
ropeptide genes arose before the corresponding receptor
genes and that their receptors might have evolved as targets
for extant peptide ligands (40).
ChickenGnRH I ([Gln8]GnRH), frog GnRH I ([Trp8]GnRH),
and seabreamGnRH I ([Ser8]GnRH), whose side chains at posi-
tion 8 appear to be able tomakeH-bonds with receptor contact
residues, act as partial agonists in the wild-type human GnRH
receptor (Fig. 3B). Most interestingly, all of them became full
agonists in the N7.45A mutant receptor. We propose that
GnRHs from different species that differ by only one amino
acid in position 8 can selectively stabilize different receptor
active conformations with different signaling efficacy. We
envisage this occurs through common and differential
receptor intramolecular and receptor-ligand intermolecular
interactions. Arg8 of GnRH I (Fig. 1B) has been shown to
interact with Asp7.32 (Fig. 1C), but
this is not the case for Tyr8 of
GnRH II (41). There is increasing
evidence that different ligands can
induce different receptor confor-
mations with different signaling
capability (42, 43) and in such a
way, some partial agonists and
even some inverse agonists
become full agonists in activating
different signaling pathways (44–
46). Interestingly, agonists differ-
ing by only a single hydroxyl group
can lead to differential signaling in
a Drosophila octopamine/tyra-
mine receptor (47). Apparently,
high affinity ligand binding can be achieved not only by opti-
mization of ligand binding sites, but also by inducing ligand-
specific receptor intramolecular contacts that stabilize each
binding partner (48), hence creating a ligand-specific recep-
tor conformation which can be facilitated by weakening the
receptor constraint networks. Recent studies have clearly
shown that partial agonists stabilize a receptor conformation
differing from that of full agonists in other GPCRs (49–51).
The marked loss of receptor binding (undetectable) without
loss of binding affinity (determined after rescue with IN3) and
the increases of signaling efficacy of the mutation of Asn7.45 to
Ala indicate that the side chain of Asn7.45makes intramolecular
interactions, forming part of the receptor constraint network.
To identify the residues interacting with Asn7.45, we mutated
residues (Glu2.53, Ser3.35, Cys6.47, Trp6.48 (52), Thr6.49, and
Asp7.49), which potentially interact with Asn7.45, predicted by
molecular modeling. Only Cys6.47 mutants gave a similar phe-
notype of unchanged binding affinity for GnRH I but increased
binding affinity for GnRH II (Fig. 4) to the N7.45Amutant. Our
molecular modeling has shown that the side chain of Asn7.45
can make an intramolecular interaction with Cys6.47 in the
inactive state of the receptor (Fig. 5, A and B). The model was
validated by accommodation of all experimentally identified
receptor intramolecular interactions (10, 53–56) and the exper-
imentally identified GnRH ligand-receptor intermolecular
interactions (Fig. 1C) (6, 10). We therefore propose that the
residues of Asn7.45 and Cys7.49 form part of the intramolecular
constraint network involved in the stabilization of different
FIGURE 4. Binding and PhI assays of GnRH II at wild-type, C6.47A and C6.47Y mutant receptors.
A, competitive binding showing an increased affinity of the mutant receptors for GnRH II. B, PhI assay of GnRH
II. F, wild-type; f, C6.47A; , C6.47Y. Inset shows the mutant receptor expressions relative to the wild-type level.
TABLE 2
Receptor expression and functional responses of the wild-type and mutant GnRH receptors
Measurements of the receptor expression levels on cell surfaces (Bmax) using radioligand binding assay onwhole cells, and PhI responses were conducted as described under
“Experimental Procedures.” The Bmax and the maximum PhI responses (Emax) were expressed relative to a wild-type control in each transfection. Values are mean  S.E.
from three or more independent experiments.
PhI responses
Bmax
GnRH I GnRH II Gln8GnRH Trp8GnRH Ser8GnRH
EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax
% nM % nM % nM % nM % nM %
Wild-type 100 0.2  0.1 100 6.9  1.4 100 10  2 83  9 4.6  0.6 53  6 48  6 44  5
N7.45Aa 40  4 0.2  0.1 110  13 2.2  0.4 122  7 5.1  1.7 132  12 8.5  0.3 104  5 50  4 102  4
C6.47Aa 38  3 0.1  0.1 122  8 1.8  0.9 131  9
C6.47Ya 18  3 0.2  0.1 102  7 2.2  1.2 115  6
a With IN3 pretreatment.
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receptor conformations which have preferential engagement
with partial and full agonists. Partial agonists may only break
part of the intramolecular constraint network. Mutations of
Cys6.47 in the 2 adrenergic receptor (57) and Asn7.45 in the
histamine H1 receptor (58) lead to constitutive activation of
the receptors, indicating an important role of this residue in the
receptor conformational switch. We have built a model of the
human GnRH receptor in an active conformational state using
the crystal structure of a photoactivated deprotonated interme-
diate of bovine rhodopsin (15) as a template. In the model, the
intramolecular interactions between Cys6.47 and Asn7.45, and
between Met3.43 and Phe6.40, which we identified previously
(10), are disrupted due to amotion of themiddle section of TM
3, as seen as a disorder of the helix (Fig. 5C), and a slight out-
wardmovement of TM6 followed by a small clockwise rotation
(viewed from the extracellular surface) of the intramolecular
segment by using Pro6.50 as a hinge
(59) (Fig. 5C). Consistent with the
mutagenesis results, our molecu-
lar modeling also indicates that
these intramolecular interactions
are involved in receptor confor-
mational transition. Interestingly,
no constitutive activity in any
mutations of the human GnRH
receptor was observed, unlike the
2 (57) and H1 (58) receptors. This
indicates that weakening the
intramolecular interactions in the
human GnRH receptor is not suf-
ficient to obtain an active confor-
mation, but rather modifies recep-
tor conformational states which
are, at least, allosterically involved
in ligand binding selectivity and
signaling efficacy. We propose
that GnRH ligand-induction of
new receptor intra- and intermo-
lecular interactions might be a
fundamental component for
GnRH receptor activation, rather
than a ligand-induced disruption
of the receptor intramolecular
constraint networks, which we
proposed as a mechanism of the
M1 mAChR activation (16). This
may provide an explanation for
the distinct pharmacological pro-
files of GnRH analogues in stimu-
lating pituitary gonadotropin and
inhibiting cancer cell proliferation
(6). Of the endogenous ligands
GnRH I is more potent in stimu-
lating gonadotropins (6) but
GnRH II has greater antiprolifera-
tive potency (60). Interestingly,
the presence of Asp7.49, located
one helix below Asn7.45 in the
GnRH receptor because of a reciprocal exchange of the
highly conserved Asp2.50-Asn7.49 pair in other GPCRs pre-
vents the GnRH receptor from coupling to phospholiphase D
via small G proteins (61), supporting our conclusion that
residues within this region play an important role in the
stabilization of different receptor conformations, and
account for ligand binding and signaling selectivity.
In conclusion, our molecular modeling and mutagenesis
studies have indicated that the side chains of the highly con-
served Asn7.45 and Cys6.47 make intramolecular contacts in the
inactive state (Fig. 5, A and B) which form part of the receptor
allosteric network, coupling to specific structural elements of
theGnRH analogues. Thismay underlie different receptor acti-
vation mechanisms, creating different receptor active confor-
mations with potential ligand selective signaling described for
these ligands. The identification of structural elements for
FIGURE 5. Homology models of human GnRH receptor in inactive and active conformations. A, stereo view
of the 7-TM domains of the human GnRH receptor. The model was derived from the crystal structure of bovine
rhodopsin in the inactive state (see “Experimental Procedures”). The model reveals the hydrogen bond inter-
action between Cys6.47 and Asn7.45. The previously experimentally identified hydrogen bonds (green dash lines)
between Asp2.61 and Lys3.32 (56), between Asp3.49 and Arg3.50 (55), and between Asn1.50, Asn2.50, and Asp7.49
(53, 54) and the hydrophobic interactions between Met3.43 and Phe6.40 (and surrounding residues Met5.54,
Phe6.44, and Ile7.32) (10) among the 7-TM domains, which validate our GnRH receptor model, were also shown.
The GnRH receptor binding residues Asp2.61, Trp2.64, Asn2.65, Lys3.32, Asn5.39, Tyr6.58,and Asp7.32 (see Fig. 1C) are
also included. B, intramolecular interactions between Cys6.47 and Asn7.45. The side chains of Cys6.47 and Asn7.45
form part of allosteric intramolecular communication networks that confer GnRH ligand binding selectivity
and signaling efficacy. Two previously identified residues (Met3.43 and Phe6.40) whose mutations have no effect
on GnRH I binding affinity, but specifically increase affinity for GnRH II and [Tyr8]GnRH are also shown (10). C, a
GnRH receptor model in the active conformation, in which there are no intramolecular interactions between
Cys6.47 and Asn7.45 and between Met3.43 and Phe6.40. TM 3 is shown in orange, TM 6 in blue, and TM 7 in olive
green in B and C.
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ligand and receptor conformational selection could have
implications for the development of novel ligands that selec-
tively activate one signaling pathway, bypassing others, and
hence with improved pharmacological specificity and pro-
files. Our studies also support our proposal that ligand bind-
ing selectivity is determined not only by ligand binding res-
idues, but also by receptor conformation. The conformation
of GPCRs has been specialized during evolution by forming a
complex receptor intramolecular interaction network. This
accounts for selective binding of the cognate ligands and G
proteins. The highly conserved amino acids appear to form
part of the allosteric network which might serve as con-
straints for receptor inactive states. Mutation of a residue
within the allosteric network can alter receptor binding
selectivity of ligands and G proteins through subtle receptor
conformational changes, which might be one of the mecha-
nisms of development of ligand binding and signaling selec-
tivity and diversity of GPCRs during evolution.
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GnRH acts on its cognate receptor in pituitary go-
nadotropes to regulate the biosynthesis and secre-
tion of gonadotropins. It may also have direct ex-
trapituitary actions, including inhibition of cell
growth in reproductive malignancies, in which
GnRH activation of the MAPK cascades is thought
to play a pivotal role. In extrapituitary tissues,
GnRH receptor signaling has been postulated to
involve coupling of the receptor to different G pro-
teins. We examined the ability of the GnRH recep-
tor to couple directly to Gq/11, Gi/o, and Gs, their
roles in the activation of the MAPK cascades, and
the subsequent cellular effects. We show that in
Gq/11-negative cells stably expressing the GnRH
receptor, GnRH did not induce activation of ERK,
jun-N-terminal kinase, or P38 MAPK. In contrast to
Gi or chimeric Gqi5, transfection of Gq cDNA
enabled GnRH to induce phosphorylation of ERK,
jun-N-terminal kinase, and P38. Furthermore, no
GnRH-mediated cAMP response or inhibition of
isoproterenol-induced cAMP accumulation was ob-
served. In another cellular background, [35S]GTPS
binding assays confirmed that the GnRH receptor
was unable to directly couple to Gi but could di-
rectly interact with Gq/11. Interestingly, GnRH stim-
ulated a marked reduction in cell growth only in cells
expressing Gq, and this inhibition could be signifi-
cantly rescued by blocking ERK activation. We there-
fore provide direct evidence, in multiple cellular
backgrounds, that coupling of the GnRH receptor to
Gq/11, but not to Gi/o or Gs, and consequent ac-
tivation of ERK plays a crucial role in GnRH-mediated
cell death. (Molecular Endocrinology 22: 2520–2530,
2008)
MAMMALIAN HYPOTHALAMIC GnRH (termedGnRH-I) is a decapeptide hormone that plays
key roles in the regulation of reproduction. It is syn-
thesized in the hypothalamus and transported in the
hypothalamo-hypophyseal portal circulation to the an-
terior pituitary. Here it binds to its cognate receptor, a
member of the seven-transmembrane G protein-cou-
pled receptor (GPCR) superfamily, and stimulates the
biosynthesis and secretion of LH and FSH (1). As well
as having a key role in reproductive behavior, evidence
suggests that GnRH may act peripherally, via an au-
tocrine/paracrine mechanism, to exert a growth-regu-
latory effect on certain cell types (2). Indeed, GnRH
and the GnRH receptor have been found in extrapitu-
itary tissues such as the ovary (3) and the mammary
gland (4). Cancers of the breast (5–7), ovary (6, 8),
endometrium (9), and prostate (10) have also been
shown to express both the ligand and the receptor.
Additionally, several studies, both in vitro and in vivo,
have demonstrated that direct application of GnRH
analogs to receptor-expressing cancer cells results in
an attenuation of cellular proliferation and activation of
proapoptotic signaling mechanisms (11–19). In many of
these cases, activation of the MAPK signaling cascades
is thought to play a fundamental role (16, 17, 20, 21).
Several groups have demonstrated that GnRH stim-
ulates phosphorylation of ERK, jun-N-terminal kinase
(JNK), and P38, three prominent members of the
MAPK superfamily, in T3-1 and LT2 gonadotrope
cell lines and a wide variety of GnRH receptor trans-
fected cells (21–25). How these cascades are initiated
upstream by the activated receptor and which of them
impinge on cell growth inhibition remains unclear. It
has been proposed that whereas the actions of GnRH
at the pituitary are mediated by interactions of the
receptor with G proteins of the Gq/11 subfamily and
consequent signaling to and activation of, among
other molecules, ERK, JNK and P38 (21, 24, 26), the
antiproliferative actions of GnRH are best explained
via an interaction of the receptor with Gi/o (17, 27–30).
Resultant induction of apoptosis coincident with phos-
phorylation of JNK (16) or other members of the MAPK
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Abbreviations: GPCR, G protein-coupled receptor; JNK,
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pholipase C; SPA, scintillation proximity assay.
Molecular Endocrinology is published monthly by The
Endocrine Society (http://www.endo-society.org), the
foremost professional society serving the endocrine
community.
0888-8809/08/$15.00/0 Molecular Endocrinology 22(11):2520–2530
Printed in U.S.A. Copyright © 2008 by The Endocrine Society
doi: 10.1210/me.2008-0122
2520
 at Univ of Edinburgh FAST Er on October 28, 2008 mend.endojournals.orgDownloaded from 
superfamily (17, 20) has also been observed. It is plau-
sible to speculate that interaction of the receptor with
different G proteins may explain the published diver-
sity of the mechanisms involved in MAPK activation
and the subsequent effects on cellular fate. This hy-
pothesis, however, is not uncontested (26). Indeed,
despite circumstantial evidence, direct proof of the
activation of multiple G proteins by the agonist-bound
GnRH receptor is still missing.
To better understand the pathways involved in
GnRH-mediated cell growth inhibition, we set out to
study the G protein coupling profile of the GnRH re-
ceptor. We provide direct evidence, in multiple cellular
backgrounds, that the receptor couples to G proteins
of the Gq/11 subfamily but not to Gi/o or Gs as
previously suggested. We also demonstrate that ERK,
JNK, and P38 activation in response to GnRH treat-
ment may be mediated by the activation of Gq/11.
Furthermore, we show that Gq/11 may facilitate the
induction of proapoptotic signaling by GnRH and that
the ERK cascade, but neither the JNK nor the P38
pathway, plays a pivotal role.
RESULTS
GnRH-Stimulated MAPK Phosphorylation May Be
Mediated by Gq/11
To facilitate potential coupling of the GnRH receptor to
G proteins other than Gq/11, we stably transfected the
receptor into Gq/11-negative MEF cells. These cells
thus eliminate potential competition from Gq/11 for
binding of the receptor. The MEF S19 cell line ex-
presses more receptors per cell than either the SCL60
or the LT2 cells, although the binding affinity of
GnRH-I is not significantly different (MEF S19, 11.1 
2.2 nM; SCL60, 10.1  1.7 nM; and LT2, 10.1  1.3
nM) (Fig. 1). The higher expression of the GnRH recep-
tor in these cells is reflected by their larger size. In
addition, the estimated number of GnRH receptor
binding sites on T3-1 cells is approximately 50% of
the number on primary gonadotropes (31). Thus, the
MEF S19 cells may better reflect GnRH receptor ex-
pression levels encountered in vivo. To elucidate the
ability of GnRH to activate ERK, JNK, and P38 in these
cells, GnRH-I was applied in both a time- and dose-
dependent manner (Fig. 2, A and B, respectively).
GnRH-I stimulation brought about no significant in-
crease in the levels of pERK1/2, pJNK1, or pP38 at any
time or dose tested when compared with vehicle-
treated controls. Transient expression of Gq allowed
GnRH-I to elicit an increase in ERK1/2 phosphoryla-
tion with a maximal response of approximately 3-fold
that of controls after 5 min stimulation. Additionally,
JNK1 and P38 phosphorylation became evident, giv-
ing maximal responses of approximately 3.5-fold that
of controls after 5 min stimulations and 30 min stim-
ulations, respectively. Agonist dose-response analysis
yielded EC50 values for the induction of pERK1/2,
pJNK1, and pP38 after 10 min stimulation of 0.95,
3.32, and 2.36 nM GnRH-I, respectively. In untrans-
fected cells, the complete absence of Gq/11 was ver-
ified both by Western blotting and lack of phospho-
inositide hydrolysis (Fig. 2, C and D, respectively).
Additionally, when compared with LT2 cells, the lev-
els of Gq/11 after transient G protein transfection were
within the physiological range.
The GnRH Receptor Does Not Directly Interact
with Gi/o or Gs
Thus far we have confirmed that transfection of Gq
allows the detection of significant activation of ERK,
JNK, and P38 in response to GnRH treatment. Never-
theless, several studies have argued that these re-
sponses may also be mediated by interactions of the
GnRH receptor with other G proteins. Although the
above results indicate that in the complete absence of
Gq/11, it was not possible to detect significant in-
creases in MAPK activation when compared with con-
trol cells, we attempted to address this theory. Initially,
we considered the possibility that transient overex-
pression of Gi could facilitate detectable MAPK sig-
naling. In contrast to Gq, transient transfection of
each of the three subtypes of Gi did not enable
GnRH-I to significantly increase ERK1/2, JNK1. or P38
phosphorylation when compared with controls (Fig.
3A). Additionally, we made use of a chimeric G protein,
Gqi5. The C terminus of the G protein -subunit has
been shown to play a pivotal role in defining the spec-
ificity of receptor-G protein interactions. Mutation of
the last five C-terminal amino acids is sufficient to
completely switch receptor coupling selectivity (32).
Fig. 1. GnRH Receptor Expression in the MEF S19, SCL60,
and LT2 Cell Lines as Measured by Radioligand Binding
Intact MEF S19 (), SCL60 (E), and LT2 () cells were
incubated with 125I-labeled [His5,D-Tyr6] GnRH (100,000 cpm/
0.5 ml  well) and either vehicle (0.2% propylene glycol) or
various concentrations of unlabeled GnRH-I as indicated for
4 h at 4 C. After incubation, cells were rapidly washed twice
with cold PBS and solubilized in 0.1 M NaOH. Radioactivity
was counted by -spectrometry. Data are representative of
at least three independent experiments and the mean
counts per minute per million cells (CPM/million cells)  SE
is presented.
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Fig. 2. Immunoblots Depicting the Time and Dose Dependence of GnRH-I-Induced, Gq-Mediated Phosphorylation of ERK1/2,
JNK1, and P38
A, Time course of GnRH-I-stimulated MAPK phosphorylation. MEF S19 cells transiently transfected with vector or Gq cDNA
were serum starved for 16 h before being treated with vehicle (0.2% propylene glycol; V) or 1 M GnRH-I for the indicated times.
Representative blots are shown. Data from at least three independent experiments were quantified (using total ERK1/2 as a
loading control), and the mean fold over control  SE for the activation of ERK1/2 (black bars), JNK1 (white bars), and P38 (gray
bars) in cells transfected with vector (middle panel) or Gq (bottom panel) cDNA is presented below the corresponding blots.
*, P  0.05, representing statistical significance from vehicle-treated controls. B, Dose response of GnRH-I-stimulated MAPK
phosphorylation. MEF S19 cells transiently transfected with vector or Gq cDNA were serum starved for 16 h before being treated
with vehicle (0.2% propylene glycol; V) or increasing doses of GnRH-I (0.1, 1, 10, and 100 nM and 1 M) as indicated for 10 min.
Representative blots are shown. Data from at least three independent experiments were quantified (using total ERK1/2 as a
loading control), and the mean fold over control  SE for the activation of ERK1/2 (E and F), JNK1 ( and ), and P38 (‚ and
Œ) in cells transfected with vector (open symbols) or Gq (filled symbols) cDNA is presented below the corresponding blots. *, P 
0.05, representing statistical significance from vehicle-treated controls. C, Immunoblots depicting the relative expression of Gq.
MEF S19 cells transiently transfected with vector (lane 1) or Gq (lane 2) cDNA and LT2 cells (lane 3) were serum starved for
16 h. Unstimulated cell lysates were collected and used to verify transfection efficiency and relative G protein expression level.
Representative blots are shown. D, Phosphoinositide hydrolysis assays depicting the functionality of transfected Gq. MEF S19
cells transiently transfected with vector () or Gq (f) cDNA were labeled overnight with 1 Ci/ml myo-D-[
3H]inositol before being
treated with vehicle (0.2% propylene glycol; V) or increasing doses of GnRH-I (0.1, 1, 10, and 100 nM and 1 M) as indicated for
30 min. The [3H]inositol phosphates were processed as described in Materials and Methods and quantified by liquid scintillation
counting. Data are representative of at least three independent experiments, and the mean counts per minute (CPM)  SE is
presented. ***, P  0.001, representing statistical significance from vehicle-treated controls.
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The cDNA of Gqi5 codes for a G protein -subunit
consisting of mainly Gq. The last five C-terminal
amino acids have, however, been substituted for the
corresponding amino acids from Gi2. This facilitates
Gi/o-coupled GPCR signaling through phospholipase
C (PLC), and as such, a classical Gq-mediated
output becomes indicative of receptor coupling to
Gi/o. Transient expression of Gqi5 in the MEF S19
cell line did not enable the activated receptor to elicit
a significant increase in ERK1/2, JNK1, or P38 phos-
phorylation when compared with control cells. Trans-
fected cells showed significantly increased expression
of Gi1–3 and Gqi5 (Fig. 3B).
To address the possibility that the GnRH receptor
does interact with Gi/o but that Gi/o does not activate
the MAPK cascades thus making it impossible to identify
such interactions using MAPK phosphorylation as an
output, we assessed the ability of GnRH to increase
GTPS binding to Gi and to inhibit intracellular cAMP
accumulation. Furthermore, for the GTPS experiments,
we used a different cell line to investigate cell-type-spe-
cific differences. Stimulation of SCL60 cells with GnRH-I
had no effect on GTPS binding to Gi (Fig. 4). In con-
trast, stimulation of CHO-M2 cells with carbachol signif-
icantly increased GTPS-Gi binding, thereby providing
a positive control for the Gi-GTPS assay system. Stim-
ulation of SCL60 cells with GnRH-I significantly in-
creased GTPS binding to Gq/11 to approximately
1.5-fold that of controls. Moreover, stimulation of
MEF S19 cells with isoproterenol increased intracel-
lular cAMP levels to approximately 15-fold that of
vehicle-treated controls. Costimulation of the same
cells with isoproterenol and GnRH-I did not signifi-
cantly affect the cAMP response obtained (Fig. 5).
Significantly, stimulation with GnRH-I alone did not
induce any increase in intracellular cAMP. Similar
Fig. 4. Scintillation Proximity Assays Quantifying Receptor-
Mediated Activation of Gq/11 and Gi
Freshly prepared SCL60 (gray and white bars) and
CHO-M2 (black bars) membranes were incubated in a GTPS
assay buffer in the presence of vehicle (0.2% propylene
glycol), 1 M GnRHI, or 10 M carbachol and 200 pM
[35S]GTPS for 1 h at 25 C. Thereafter, antibodies against
Gi1/2 and Gi3 (gray and black bars) or Gq/11 (white bars)
and anti-IgG-coated SPA beads were added and pro-
cessed as described in Materials and Methods. Data from
at least three independent experiments were quantified,
and the mean fold over control  SE for GTPS bound is
presented. **, P  0.01; and ***, P  0.001, representing
statistical significance from vehicle-treated controls.
Fig. 3. Immunoblots Depicting the Lack of Effect of Tran-
sient Overexpression of Gi1–3 or Gqi5 on GnRH-I-Induced
Phosphorylation of ERK1/2, JNK1, and P38
A, MEF S19 cells transiently transfected with vector, Gi1,
Gi2, Gi3, or Gqi5 cDNA were serum starved for 16 h before
being treated with vehicle (0.2% propylene glycol; V) or 1 M
GnRH-I for 10 min. Representative blots are shown. Data
from at least three independent experiments were quantified
(using total ERK1/2 as a loading control), and the mean fold
over control  SE for the activation of ERK1/2 (black bars),
JNK1 (white bars), and P38 (dark gray bars) relative to vehicle-
treated controls (light gray bars) is presented below the cor-
responding blots. B, MEF S19 cells transiently transfected
with vector, Gi1, Gi2, Gi3, or Gqi5 cDNA were serum
starved for 16 h. Unstimulated cell lysates were collected and
used to verify transfection efficiency and relative G protein
expression level. Representative blots are shown.
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results were observed in COS-7 cells transiently
expressing the GnRH receptor (White, C. D., and
Z.-L. Lu, unpublished observations).
Coupling of the GnRH Receptor to Gq/11 and
Consequent Activation of the ERK Pathway
Play a Crucial Role in GnRH-Mediated Cell
Growth Inhibition
Continuous treatment of MEF S19 cells with GnRH-I
resulted in a time- and dose-dependent inhibition of
cell growth relative to vehicle-treated controls only in
cells transfected with Gq (Fig. 6A). In these cells,
significant growth inhibition was evident on d 1 (cell
growth was 93.7  1.2% that of controls) and in-
creased in a time-dependent manner to reach a max-
imal inhibition on d 4 (cell growth was 69.8  2.8%
that of controls). SB203580 (a P38 inhibitor) and
SP600125 (a JNK inhibitor) were unable to significantly
rescue this inhibition, but PD98059 (a MAPK kinase-
1/2 inhibitor) significantly decreased the GnRH-I-in-
duced effect (cell growth was 90.4  1.5% that of
controls on d 4). Agonist dose-response analysis
yielded an IC50 value for the induction of cell growth
inhibition on d 4 of 4.54 nM GnRH-I (Fig. 6B). Vector-
transfected control cells showed no significant inhibi-
tion of growth in response to GnRH-I treatment, nor
did any of the MAPK inhibitors have a significant ef-
fect. Similar results were obtained in the SCL60 cell
line (Fig. 6C). Continuous treatment with GnRH-I re-
sulted in a time- and dose-dependent inhibition of cell
growth relative to vehicle-treated controls. Significant
growth inhibition was evident on d 1 (cell growth was
87.6  0.4% that of controls) and increased in a time-
dependent manner to reach a maximal inhibition on d 4
(cell growth was 57.3  1.2% that of controls).
SB203580 and SP600125 were unable to significantly
rescue this inhibition, but PD98059 significantly de-
creased the GnRH-I-induced effect (cell growth was
81.0  1.5% that of controls on d 4). Agonist dose-
response analysis yielded an IC50 value for the induction
of cell growth inhibition on d 4 of 6.21 nM GnRH-I (Fig.
6D). YM-254890 (a Gq/11 inhibitor) completely elimi-
nated the GnRH-I-induced inhibition of cell growth.
Trypan blue exclusion confirmed that detached cells
were dead (as measured by dye uptake when compared
with either live cell suspensions or vector-transfected
samples), and these dead cells were more numerous
than in samples from vector-transfected controls (White,
C. D., and Z.-L. Lu, unpublished observations).
DISCUSSION
Binding of GnRH to its receptor at the plasma mem-
brane initiates a variety of intracellular signaling events
with distinct physiological outcomes. Since the origi-
nal observations of GnRH-induced cell growth inhibi-
tion on receptor-expressing cell lines (33), substantial
effort has been directed toward delineating the precise
mechanisms involved. Considerable evidence sug-
gests that the signaling cascades involved in GnRH-
mediated cell growth inhibition are distinct from those
involved in regulating gonadotropin secretion (17, 30,
34), and one possibility to explain this divergent sig-
naling is to hypothesize the inherent ability of the re-
ceptor to directly interact with multiple classes of G
proteins. Multiplicity of G protein coupling has after all
been successfully confirmed for several other GPCRs
(35). However, as yet, no group has provided direct
evidence of such interactions, and the frequently re-
peated paradigm of the ability of the GnRH receptor to
directly interact with Gi/o and Gs has led to confusion
regarding the mechanisms by which GnRH can inhibit
cell growth. To critically address this issue, we studied
the G protein coupling profile of the GnRH receptor in
stably transfected HEK293 cells and MEF cells derived
from Gq/11 knockout mice (36, 37). Additionally, we
investigated the roles of the various G proteins in the
activation of ERK, JNK, and P38 and the downstream
cellular effects of activation of these MAPK modules.
GnRH-mediated activation of ERK, JNK, and P38
has been extensively studied over the past two de-
cades (21, 24). We and others have shown that phos-
phorylation of these proteins readily occurs upon
GnRH stimulation of receptor-expressing cell lines and
that this activation is dependent on PLC and protein
kinase C (PKC) (22, 23, 38). These data thus suggest
the involvement of Gq/11-mediated signaling events.
The role of Gi/o in MAPK activation in response to
GnRH has also been the subject of much investigation.
ERK activation in T3-1 cells has been suggested to
depend on a dual mechanism involving Gq/11 and
Gi/o (39). Similarly, in Caov-3 ovarian cancer cells,
Fig. 5. cAMP Assays Determining the Effects of GnRH-I and
Isoproterenol on Intracellular cAMP Accumulation
MEF S19 cells were treated with vehicle (0.2% propylene
glycol), 3 M isoproterenol (Iso), 1 M GnRH-I, or 1 M
GnRH-I and 3 M isoproterenol together for 30 min as indi-
cated after a 30-min incubation with 1 mM 3-isobutyl-1-meth-
ylxanthine. Intracellular cAMP levels were measured as de-
scribed in Materials and Methods. Data from at least three
independent experiments were quantified, and the mean fold
over control  SE is presented. ***, P  0.001, representing
statistical significance from vehicle-treated controls.
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which have been shown to express GnRH receptor
mRNA (although no evidence is given regarding ex-
pression at the protein level), ERK activation has been
hypothesized as being mediated by a combination of
interactions involving Gi/o and G (20). Studies us-
ing pertussis toxin have also indicated a role for Gi/o
in the GnRH-induced phosphorylation of JNK and P38
(17). Interestingly, our data contradict these studies
because we have found no evidence to support the
theory of GnRH-induced activation of these MAPKs by
Gi/o, even when Gi is artificially overexpressed in our
cell systems. We have, however, confirmed that Gq/
Fig. 6. Sulforhodamine B Assays Assessing the Effects of Gq and the ERK, JNK, and P38 Pathways on GnRH-I-Induced Cell
Growth Inhibition
A, Effect of Gq and the MAPK pathways on GnRH-I-induced cell growth inhibition in MEF S19 cells. MEF S19 cells transiently
transfected with vector (open symbols) or Gq cDNA (filled symbols) were incubated in medium containing 10% serum with or
without vehicle (dimethylsulfoxide;  and f), 50 M PD98059 (E and F), 50 M SP600125 ( and ), or 20 M SB203580 (‚ and
Œ) before being treated with vehicle (0.2% propylene glycol) or 100 nM GnRH-I for the indicated times. Data from at least three
independent experiments were quantified, and the mean percent cell growth relative to control  SE is presented. **, P  0.01;
***, P  0.001, representing statistical significance from vector-transfected vehicle-treated controls (for cells transfected with Gq
and incubated in media containing dimethylsulfoxide) and from Gq-transfected vehicle-inhibited controls (for cells incubated in
medium containing 50 M PD98059). B, Dose dependence of GnRH-I-induced cell growth inhibition in MEF S19 cells. MEF S19
cells transiently transfected with vector () or Gq cDNA (f) were incubated in medium containing 10% serum before being
treated with vehicle (0.2% propylene glycol) or increasing doses of GnRH-I (0.1, 1, 10, and 100 nM and 1 M) as indicated for 4 d.
Data from at least three independent experiments were quantified, and the mean percent cell growth relative to control at d 4 
SE is presented. *, P  0.05; **, P  0.01; ***, P  0.001, representing statistical significance from vehicle-treated controls. C, Effect
of Gq and the MAPK pathways on GnRH-I-induced cell growth inhibition in SCL60 cells. SCL60 cells were incubated in medium
containing 10% serum with or without vehicle (dimethylsulfoxide; f), 50 M PD98059 (F), 50 M SP600125 (), 20 M SB203580
(Œ), or 100 nM YM-254890 () before being treated with vehicle (0.2% propylene glycol) or 100 nM GnRH-I for the indicated times.
Data from at least three independent experiments were quantified, and the mean percent cell growth relative to control  SE is
presented. **, P  0.01; ***, P  0.001, representing statistical significance from vehicle-treated controls (for cells incubated in
medium containing dimethylsulfoxide) and from vehicle-inhibited controls (for cells incubated in medium containing 50 M
PD98059 or 100 nM YM-254890). D, Dose dependence of GnRH-I-induced cell growth inhibition in SCL60 cells. SCL60 cells were
incubated in medium containing 10% serum before being treated with vehicle (0.2% propylene glycol) or increasing doses of
GnRH-I (0.1, 1, 10, and 100 nM and 1 M) as indicated for 4 d. Data from at least three independent experiments were quantified,
and the mean percent cell growth relative to control at d 4  SE is presented. **, P  0.01; ***, P  0.001, representing statistical
significance from vehicle-treated controls.
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11-mediated signaling plays a pivotal role in the GnRH
receptor activation of the MAPKs.
Elegant studies have shown that coexpression of
Gqi5 with several other GPCRs successfully enables
Gi/o-coupled receptors to signal through PLC and
PKC (40). It follows then that the inability of GnRH to
induce phosphorylation of ERK, JNK, or P38 when Gqi5
is expressed suggests that the GnRH receptor does not
directly interact with G proteins of the Gi/o subfamily.
This conclusion is strengthened by the observation that
GnRH does not inhibit isoproterenol-induced cAMP ac-
cumulation. However, by definition, the only direct mea-
sure of G protein activation by an activated receptor is
receptor-catalyzed GDP/GTP exchange. Other analytical
approaches yield only indirect results and the notion of
GnRH receptor-Gi/o interaction has largely been de-
rived from circumstantial evidence using pertussis toxin.
In this case, our data, and the observations of Grosse
and colleagues (26), which reported exclusive GnRH re-
ceptor-mediated labeling of Gq/11 with [-
32P]GTP
azidoanilide, show definitively that the GnRH receptor
does not directly couple to Gi/o but does interact with
Gq/11. Reports by Shah and colleagues (41) using ac-
tivated G proteins as an output support this interpreta-
tion. Here, stimulation of T3-1 cells with GnRH agonists
resulted in elevated agonist-induced down-regulation of
Gq/11 reflecting increased G protein turnover. Gi/o re-
mained unaffected. Interestingly, it has recently been
shown that G protein -subunits can be activated di-
rectly by growth factor receptor tyrosine kinases (42).
Thus, it is possible that GnRH receptor-mediated recep-
tor tyrosine kinase transactivation could be responsible
for previous interpretations implicating a direct interaction
of the receptor with Gi/o. Furthermore, the demonstra-
tion that very high agonist concentrations are required to
facilitate GnRH receptor-mediated Gi/o signaling events
(43) suggests that these events may potentially occur
distally of the receptor-G protein interface.
In the early 1990s, Janovick and Conn (44) showed
that treatment of rat pituitary cultures with cholera toxin
increased LH release in response to GnRH treatment
and interpreted this finding as being indicative that the
GnRH receptor was directly coupled to Gs. Since then,
many other groups have studied this possibility, but the
results are inconclusive. The cAMP-protein kinase A
pathway is important for gonadotrope function (45, 46);
however, the involvement of Gs in this signaling cas-
cade is still debated. Using palmitoylation as a measure
of G protein activation, it was suggested that there was
a direct interaction between the GnRH receptor and Gs
in rat pituitary cells (47). This hypothesis was recapitu-
lated in the LT2 cell line using cell-permeable peptides
that uncouple Gs from the receptor (48). However,
based on these and other observations, the Gudermann
group (26) examined the possibility of a direct interaction
between the activated receptor and Gs and, in agree-
ment with our findings, failed to detect any Gs-medi-
ated signal transduction in response to GnRH treatment.
More recently, Larivière and colleagues identified a novel
signaling pathway involving PKC and -, which mediate
GnRH activation of a cAMP-sensitive promoter (49).
These results, viewed collectively with our own data,
question the possibility of a direct interaction between
the GnRH receptor and Gs. Interestingly, it has also
been shown that a dominant-negative mutant of Gs
blocked not only Gs-mediated signaling from the calci-
tonin receptor but also that mediated by Gq (50) and
that specific adenylate cyclase isoforms may be acti-
vated directly by G (51) or independently of G proteins
altogether (52). It would therefore seem possible to con-
clude that signal transduction involving GnRH induction
of the cAMP pathway remains to be fully elucidated but
is unlikely to involve a direct interaction between the
activated receptor and Gs. Indeed, given that we can-
not detect any cAMP accumulation in response to GnRH
in Gq/11-negative cells, taken together with the fact that
the 2-adrenergic receptor agonist isoproterenol can
elicit a marked increase in intracellular cAMP, we would
suggest that the GnRH receptor-evoked small cAMP
responses previously observed in certain cell lines are
not mediated by the direct coupling of the receptor to Gs.
The MAPK pathways are evolutionarily conserved ki-
nase cascades that link extracellular signals to the ma-
chinery that controls fundamental cellular processes
such as growth, proliferation, differentiation, migration,
and apoptosis. Historically, ERK signaling is synony-
mous with cell proliferation (53), although the JNK and
P38 pathways are regarded as being stress activated
(54). Involvement of the JNK and P38 signaling cascades
in GPCR-induced inhibition of cell proliferation has been
widely documented (53–56), and here the GnRH recep-
tor is no exception (16, 17, 21). In contrast to these data,
we showed, in agreement with previous studies (20, 57),
that P38 and JNK do not influence GnRH-induced cell
growth inhibition. Additionally, we find that the ERK sig-
naling pathway plays a critical role; inhibition of ERK
activation significantly decreased cell growth inhibition in
both cell lines tested.
ERK has been implicated in cell growth inhibition, cell
cycle arrest, and the induction of proapoptotic signaling
in a number of cell types (58, 59), and a large body of
evidence indicates that the strength and duration of the
ERK signal is kernel to determining cellular fate (19, 60,
61). Several studies have shown that strong and pro-
longed activation of ERK by constitutively active Ras or
Raf leads to arrest in the G1 phase of the cell cycle by
inducing the expression of cyclin-dependent kinase in-
hibitors such as p53 and p21 (62, 63). As such, it seems
plausible to speculate that continuous exposure of our
cells to GnRH would result in ERK activation of a similar
strength and duration. Thus, by inhibiting this pathway,
this activation is abolished and GnRH-induced cell
growth inhibition is significantly diminished. Interestingly,
Zhang and colleagues (64) demonstrated that in LT2
cells, p53 is phosphorylated by GnRH in a P38-depen-
dent manner. Although our results do not indicate a role
for P38 in GnRH-mediated cell growth inhibition in the
cell lines we have studied, it is possible that transforma-
tion of the LT2 cell line with SV40 large T antigen may
influence the signaling pathways involved. Additionally,
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MAPK activation in response to GnRH has also been
suggested to be dependent on the cell background
in which any studies are carried out (17, 21). Nota-
bly, however, some studies that report significant
effects of JNK and P38 on GnRH-induced cell
growth inhibition also imply the ability of the GnRH
receptor to couple to Gi/o (17, 65). Perhaps, given
our current findings, it would be prudent to directly
verify these data.
The ability of many hormones and neurotransmitters
to evoke diverse physiological and pathological re-
sponses, by binding to a single cognate receptor,
brought about the hypothesis that one GPCR may have
the inherent ability to activate multiple G proteins. As
such, the differential effects of GnRH analogs at central
and peripheral sites were thought to be mediated via
interactions of the activated receptor with Gq/11, Gi/o,
and Gs. In the present study, we provide direct evi-
dence, in multiple cellular contexts, that the GnRH re-
ceptor does not couple to G proteins of the Gi/o or Gs
subfamilies, that MAPK activation in response to GnRH
treatment is entirely dependent, of the three G protein
subtypes tested, on Gq/11, and that the ERK pathway is
significantly involved in GnRH-mediated cell death.
MATERIALS AND METHODS
Materials
The pMEP4 expression vector was kindly provided by Dr. Keith
Leppard, University of Warwick, UK. PD98059 (50 M),
SP600125 (50 M), and SB203580 (20 M) were all obtained
from Calbiochem (Nottingham, UK). YM-254890 was kindly
provided by Dr. Masatoshi Taniguchi, Astellas Pharma Inc.,
Japan. The Gq/11 and Gi1–3 protein cDNAs were obtained
from the Missouri S&T cDNA Resource Center (Rolla, MO). The
Gqi5 protein cDNA, the Gq/11-negative MEF cell line, and the
Gi1/2 and Gi3 antibodies were kindly provided by Professor
Graeme Milligan, University of Glasgow, Glasgow, UK. The Gq/
11-negative MEF cell line was originally derived from a combined
Gq/11 double-knockout mouse and has been previously shown
to have absolutely no endogenous Gq/11 (36, 37). The CHO cell
line stably expressing the M2-muscarinic receptor (designated
CHO-M2) was kindly provided by Professor Noel Buckley, Uni-
versity of Leeds (Leeds, UK). The LT2 cell line was kindly
provided by Dr. Pamela Mellon, University of California.
[35S]GTPS (1000–1250 Ci/mmol) and anti-IgG-coated scintil-
lation proximity assay (SPA) beads were purchased from GE
Healthcare (Buckinghamshire, UK), and the Gq/11 (C-19) and
Gi/o antibodies were purchased from Santa Cruz Biotechnol-
ogy (Heidelberg, Germany). All other reagents were obtained
from Sigma (Dorset, UK) unless otherwise stated.
Cell Culture and Transfection
Full-length GnRH receptor cDNA was subcloned into pMEP4
at Not1 and Xho1 and the construct transfected into Gq/11-
negative MEF cells by electroporation. Cloned cells were
selected using hygromycin resistance and screened by ra-
dioligand binding (Fig. 1) as previously described (66, 67).
After appropriate selection, cells stably expressing the GnRH
receptor (designated MEF S19) were maintained in DMEM
supplemented with 10% fetal calf serum, 2 mM glutamine,
appropriate antibiotics, and 50 g/ml hygromycin (Invitrogen
Life Technologies, Paisley, UK) at 37 C in a humidified 5%
CO2 atmosphere. Cells were seeded at a density of 1.0  10
5
cells/ml and allowed to grow in large culture flasks for 96 h
before transfection. Transient transfections were performed
by electroporation using a Bio-Rad Gene Pulser XCell (Bio-
Rad Laboratories, Hertfordshire, UK) at 320 V/500 F with 20
g plasmid DNA/0.4-cm electroporation cuvette. Before
stimulation, appropriately transfected or untransfected cells
were incubated in serum-free medium (DMEM supplemented
with 2 mM glutamine, appropriate antibiotics, 50 g/ml hy-
gromycin, and 10 mM HEPES) for 16 h for Western blotting for
pERK1/2, pJNK1, and pP38 and cAMP assays or medium
containing 10% serum for 24 h for sulforhodamine B staining.
Serum deprivation for 16 h is common practice in cell sig-
naling studies (16, 17, 68, 69). Nevertheless, the time-depen-
dent effects of starvation on basal MAPK phosphorylation
were first evaluated (supplemental Fig. 1, published as sup-
plemental data on The Endocrine Society’s Journals Online
web site at http://mend.endojournals.org). Agonist stimulations
were performed at 37 C in either serum-free medium or medium
containing 10% serum after appropriate incubation with chem-
ical inhibitors as described in the figure legends. HEK293 cells
stably expressing the rat GnRH receptor (designated
SCL60) generated previously within our laboratory, LT2
cells, and CHO-M2 cells were maintained in DMEM sup-
plemented with 10% fetal calf serum, 2 mM glutamine,
appropriate antibiotics, and (for SCL60 and CHO-M2 cells)
500 g/ml geneticin (G418) (PAA Laboratories, Somerset, UK).
Preparation of Cellular Extract and Immunoblotting
After ligand stimulation, cell monolayers were placed on ice,
washed once with ice-cold Dulbecco’s PBS, and lysed in a
Nonidet P-40 solubilization buffer (250 mM NaCl, 50 mM
HEPES, 0.5% Nonidet P-40, 10% glycerol, 2 mM EDTA, pH
8.0) supplemented with 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, and 10 g/ml leupeptin. Solu-
bilized lysates were clarified by centrifugation at 20,000  g
for 15 min, and nuclear contents were sheared by subse-
quent sonication. Sample protein concentrations were mea-
sured using the modified Bradford assay (Bio-Rad) and di-
luted to a concentration of 1 mg/ml total protein. Clarified
whole-cell lysates were mixed with an equal volume of 2
Laemmli sample buffer and resolved by SDS-PAGE. After
electrophoretic separation, proteins were electroblotted on to
polyvinylidene difluoride membranes (NEN Life Sciences,
Buckinghamshire, UK) for protein immunoblotting. Polyvinyli-
dene difluoride membranes were blocked in a 4% BSA (50
mM Tris-HCl, 0.05% Tween 20, 0.05% Nonidet P-40, pH 7.0)
blocking solution. Immunoblotting of endogenous pERK1/2,
pJNK1, or pP38 was performed using a 1:1000 dilution of
rabbit antihuman phosphorylated ERK1/2, JNK1, or P38 an-
tisera (Cell Signaling, Hertfordshire, UK), respectively. A
1:1000 dilution of rabbit antihuman total ERK1/2 antiserum was
used to verify protein loading. Visualization of the phosphory-
lated or unphosphorylated protein was achieved by addition of
a 1:10,000 dilution of alkaline phosphatase-conjugated poly-
clonal antirabbit IgG as a secondary antibody. Each alkaline
phosphatase-labeled protein was visualized using an enzyme-
linked chemifluorescence reaction (Amersham) and quantified
using a Typhoon 9400 PhosphorImager GE Healthcare.
Phosphoinositide Hydrolysis
Assays for ligand stimulation of inositol phosphate produc-
tion were performed as previously described (66, 67). Briefly,
appropriately transfected MEF S19 cells were labeled over-
night with 1 Ci/ml myo-D-[3H]inositol (Amersham) in inositol-
free DMEM containing 1% dialyzed fetal calf serum before
being incubated in 0.5 ml buffer A (140 mM NaCl, 20 mM
HEPES, 8 mM glucose, 4 mM KCl, 1 mM MgCl2, 1 mM CaCl2,
1 mg/ml BSA) containing 10 mM LiCl at 37 C for 30 min.
Thereafter, appropriate ligand stimulation was carried out
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for an additional 30 min. The reaction was terminated by
removal of the medium and addition of 0.5 ml of 10 mM
formic acid. The [3H]inositol phosphates were isolated
from the formic acid extracts using Dowex AG 1-X8 ion
exchange resin (Bio-Rad), collected with 1 M ammonium
formate containing 0.1 M formic acid and quantified by
liquid scintillation counting.
Membrane Preparation
Cells were collected in a harvesting buffer (20 mM HEPES, 100
mM EDTA, pH 7.5) and ruptured with 20 strokes of a glass
dounce homogenizer. Nuclei and unbroken cells were sepa-
rated by centrifugation at 200  g for 15 min. The resultant
supernatant was then subjected to a high-speed spin at
40,000  g for 45 min and resuspended in a GTPS assay
buffer (5 mM MgCl2, 100 mM NaCl, 20 mM HEPES, 1 mM EDTA,
1 mM dithiothreitol). To ensure optimal assay conditions, mem-
branes were prepared fresh rather than stored. Membrane con-
centrations were determined as previously described (70).
Scintillation Proximity Assay
The SPA was performed as previously described (71). Briefly,
cell membranes expressing the receptor of interest (approxi-
mately 75 g protein/well) were incubated in the presence or
absence of ligand and 200 pM [35S]GTPS for 1 h at 25 C. After
incubation, membranes were solubilized in a 0.3% Nonidet
P-40 solution for 30 min. Thereafter, antibodies (using
dilutions of 1:440 for Gi1/2 and Gi3 and 1:1000 for Gq/11)
and anti-IgG-coated SPA beads were added and incu-
bated for an additional 3 h. Plates were centrifuged at
3000  g for 10 min and counted on a Wallac MicroBeta
Trilux -counter [PerkinElmer Life and Analytical Sciences,
(UK) Ltd., Buckinghamshire, UK].
Measurement of Intracellular cAMP
After a 30-min incubation with 1 mM 3-isobutyl-1-methylxan-
thine and appropriate ligand stimulation, cell monolayers
were placed on ice, washed twice with ice-cold PBS, and
lysed in 0.1 M HCl. Intracellular cAMP concentrations were
determined using an ELISA kit (Biomol, Exeter, UK) as per the
manufacturer’s instructions.
Measurement of Cell Growth
After continuous agonist stimulation, cell monolayers were
placed on ice, and an equal volume of cold 25% trichloroacetic
acid was added directly to the culture medium. Cells were left at
4 C for 1 h after which cell growth was determined using the
sulforhodamine B assay as previously described (72).
Statistical Analysis
All experiments were repeated independently at least three
times. In addition, all assays were performed in triplicate.
Statistical significance was set at P  0.05, indicated by
asterisks in figures, and analyses were performed using the
Student’s t test. For agonist dose-response analyses, data
representing the mean  SE from at least three independent
experiments were plotted and analyzed using GraphPad
Prism 5.0 (GraphPad Software, San Diego, CA). Sigmoidal
dose-response curves were fitted to the relevant data sets
and the EC50 value determined.
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tor. Hence, receptor activation may influence the function of 
neuronal networks in the brain and the maturation of repro-
ductive tissue epithelia. GnRH may also potentially influence 
the biology of cancerous cells in reproductive tissue since 
receptor activation may signal terminal differentiation, cell 
cycle arrest or apoptosis. In this context, the cell surface ex-
pression of GnRH receptor is important since it influences 
the intensity of intracellular signaling, and correlates with 
the ability to inhibit proliferation in transformed cells in vi-
tro. Here, we review data on the effects of GnRH agonists on 
cell proliferation and apoptosis, and put forward hypotheses 
for investigation to determine whether the GnRH receptor 
acts as a tumor suppressor in neuroendocrine or epithelial 
cells.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Gonadotropin-releasing hormone (GnRH) is a ten-
amino-acid residue neuropeptide hormone (pGlu-His-
Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ) involved in the 
control of the reproductive system  [1] . Pulsatile secretion 
of GnRH from hypothalamic neurons acts upon recep-
tors in the anterior pituitary to stimulate release of the 
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 Abstract 
 Gonadotropin-releasing hormone (GnRH) receptor activa-
tion has been demonstrated to inhibit cell proliferation in 
vitro and in vivo. These effects are dependent on the degree 
of receptor expression and the intracellular signaling protein 
milieu. The physiological and pathophysiological relevance 
is largely undefined, and its potential for exploitation in the 
treatment of specific malignancies is the subject of ongoing 
investigations. GnRH receptors are expressed in embryonic, 
juvenile and adult tissues, including brain, pituitary, gonads, 
accessory reproductive organs and placenta. The levels of 
receptor expression vary, from high in pituitary gonado-
tropes to low in peripheral tissues, although quantification 
of functional receptor protein has been determined in rela-
tively few cell types. Roles for GnRH receptor signaling at 
different stages of animal development and its influence on 
reproductive health remain largely unexplored, except in 
cases of hereditary hypogonadal infertility. In addition to 
regulating hormone secretion, GnRH is postulated to act as 
a chemokine or a growth- and differentiation-inducing fac-
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gonadotropins: luteinizing hormone and follicle-stimu-
lating hormone. In mammals there are two forms of 
GnRH: GnRH-I which regulates gonadotropin produc-
tion and GnRH-II which is extrahypothalamic and ap-
pears to have a neuromodulatory role in influencing re-
productive behavior  [1] . The GnRH-II precursor gene is 
inactive or deleted in certain mammalian species  [2] . 
Similarly, the cognate receptor for GnRH-II (the type II 
GnRH receptor) is disrupted by frameshift mutations or 
premature stop codons  [2–4] . Thus it appears that   endog-
enous GnRH-II signaling occurs through the type I 
GnRH receptor in relevant mammalian species, includ-
ing man.
 Clinically, GnRH analogs (synthetic agonists and an-
tagonists) are used to influence ovulation in assisted re-
production and for the treatment of a wide range of hor-
mone-dependent pathologies  [5] . Chronic stimulation of 
pituitary GnRH receptors by exogenously administered 
GnRH analogs leads to decreased luteinizing hormone 
and follicle-stimulating hormone production. This re-
sults in a decline in circulating sex steroid hormone lev-
els, leading to pharmacological castration. Nonetheless, 
the occurrence of GnRH and GnRH receptors in extra-
pituitary tissues such as ovary, endometrium, placenta, 
breast, testis and prostate suggests that GnRH analogs 
may also have direct therapeutic actions at these sites  [6–
8] . Here, we review evidence concerning the distribution 
and temporal variation in expression of GnRH and GnRH 
receptors, the potential function of this expression and its 
possible relationship to a selection of malignancies. We 
also reconsider the utilization of GnRH agonists in the 
treatment of reproductive tissue malignancy and present 
an updated perspective on this field of research. In order 
to retain focus, we do not review the application of GnRH 
antagonists or cytotoxic GnRH analogs.
 GnRH Receptor Expression: Tissue Distribution and 
Developmental Modulation 
 The cDNAs and genes encoding human, mouse and 
rat GnRH precursors and GnRH receptors were charac-
terized between 1984 and the mid-1990s  [9–11] . Early ev-
idence suggested that these genes were expressed in hy-
pothalamus, pituitary, gonads and the reproductive tract. 
Since Northern blot signals were relatively weak, these 
data suggested that GnRH gene expression occurs in a 
small population of cells in discrete tissues. Similar re-
sults from numerous reverse transcription polymerase 
chain reaction analyses and in situ hybridization and im-
munohistochemistry studies confirm this interpretation. 
However, the full spectrum of mammalian cell types ex-
pressing functionally important levels of GnRH system 
components in adult, juvenile or embryonic tissues cur-
rently remains uncertain.
 Epithelial cells in adult reproductive tissues have been 
the focus of investigation as possible sites for autocrine/
paracrine effects of GnRH  [12–15] , although additional 
expression of GnRH components in the neuronal com-
partment within the reproductive system has not been 
explored in detail. A small number of gene promoter-re-
porter experiments  [16, 17] , some elegantly performed in 
transgenic mice  [18] , have not fully addressed the possi-
bility that autocrine/paracrine GnRH systems exist in 
these tissues. Perhaps cell-targeted transgenic GnRH re-
ceptor expression would be useful in providing data re-
garding the functional consequences of GnRH system 
upregulation in particular tissues. For the time being, 
analyses of the developmental origins of reproductive tis-
sue epithelia suggest that certain cell lineage similarities 
are consistent with GnRH system expression in quite di-
verse types of epithelia. For example, pituitary gonado-
tropes develop from oral ectoderm epithelial cells and 
mammary gland epithelial cells develop from epidermal 
ectoderm. Also, ovarian surface epithelial cells and tes-
ticular Sertoli cells develop from celomic epithelium 
whilst prostate epithelial cells develop from urogenital 
sinus endoderm ( fig. 1 ). These cell lineages probably 
share aspects of gene programming given that overlap-
ping clusters of transcription factors are likely to be active 
in each lineage at particular periods during development. 
Furthermore, there is evidence that the GnRH system 
may be active at very early stages of development  [19] and 
is then subject to developmental repression. However, 
more knowledge on the properties of the gene promoters 
of the GnRH system is required to understand where and 
when tissue-specific GnRH gene expression normally oc-
curs. The availability of transgenic mice with the GnRH-
I proximal promoter (–3.4 kb) driving green fluorescent 
protein is valuable for such studies  [20–22] .
 The proximal promoters for prepro-GnRH-I and the 
type I GnRH receptor genes both possess multiple DNA 
sequence elements likely to influence cell type-specific 
expression. We analyzed the proximal 4-kb DNA se-
quences in the 5  f lanking region of each gene for puta-
tive transcription factor binding sites using bioinformat-
ics tools: Ensembl database (http://www.ensembl.org) 
and Genomatix MatInspector software (http://www.ge-
nomatix.de;  fig. 2 ). Certain transcription factor binding 
sites consistent with epithelial expression are present in 
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both human and rodent genes. For example, pituitary 
cell lineages and prostate basal epithelial cells both ex-
press the homeobox domain transcription factor NKX3.1 
 [23] and putative binding sites for this protein occur in 
the proximal promoters of GnRH system genes. Interest-
ingly, NKX3.1 expression is extinguished in mature go-
nadotropes and in mature secretory prostate epithelial 
cells, but is expressed in immature cells  [24] , suggesting 
a potential transient role for GnRH signaling during cell 
maturation. The GnRH system gene promoters also pos-
sess potential binding sites for the transcription factor 
Nanog, which is characteristically expressed in pluripo-
tent epithelial stem cells  [25] . However, the complexity 
and relative importance of  cis -interactions at the proxi-
mal promoters (including effects mediated by the distal 
promoter region and potential enhancer or repressor ele-
ments) cannot be understood without experimental in-
vestigation. Hence, these speculative in silico analyses of 
the GnRH precursor and GnRH receptor proximal pro-
moters suggest important regulatory mechanisms wor-
thy of further investigation. Investigation of physiologi-
cal or pathophysiological mechanisms responsible for in-
ducing elevated GnRH receptor expression, including 
the identity of key transcription factors, would result in 
useful contributions to understanding the significance of 
GnRH system activity in diseases affecting reproductive 
tissues and in developing interventions for clinical ther-
apy.
 Potential Functions of GnRH Receptors in Different 
Tissues 
 GnRH receptor activation elicits regulated secretion 
from pituitary gonadotropes. It seems plausible that the 
receptor may serve similar roles in other reproductive tis-
sues, such as secretory epithelium. Additional roles may 
involve the maintenance of cell differentiation in adult 
tissues or determination of the organization of cells in 
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 Fig. 1. Selected cell lineage relationships in reproductive tissues. The GnRH system is active during early stag-
es of development and cells retaining expression of GnRH system components in the brain, pituitary and re-
productive tissue epithelia have divergent developmental origins. Transcription factors responsible for deter-




gramming functions may be mediated via effects on 
transcription factor activity following GnRH receptor 
activation  [26, 27] . However, it remains uncertain wheth-
er expression of GnRH receptor in ovarian surface epi-
thelium, mammary gland epithelium, uterine epithelium 
or prostate epithelium serves a physiologically important 
role or whether it is the result of aberrant gene expression 
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 Fig. 2.  a Organization of genes encoding 
prepro-GnRH-I (and prepro-GnRH-II in 
humans) and type I GnRH receptors in 
man and laboratory rodents. Rectangular 
boxes represent exons. Coding regions are 
shaded, with GnRH peptide denoted by 
black shading. Selected putative transcrip-
tion factor-binding sites identified by bio-
informatics analyses are arrowed and the 
comparative abundance of individual 
binding sites between species is listed.  b 
Putative binding sites for Nanog in proxi-
mal promoter regions (first 4 kb analyzed 
for each gene) suggest possible expression 
of the GnRH system in cells expressing 
this transcription factor (often associated 
with pluripotent stem cells). Note the oc-
currence of binding sites for prostate epi-
thelial marker NKX3.1 and for pituitary 
markers Pit, LHX3 and LIM known to be 
important in regulating GnRH system 
gene expression. 
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 Relationship of GnRH Receptor Expression to 
Oncogenesis 
 The expression of GnRH receptors has been reported 
in a variety of tumor-derived samples and its functional 
effects have been studied in animal models of tumor 
growth. Several groups reported that mRNA coding for 
the receptor is expressed in prostate  [28–30] , breast  [31–
33] , endometrial  [34, 35] and ovarian  [36, 37] cancers – 
GnRH receptor expression has also been reported in 
nonreproductive tissue malignancies  [38–41] – and the 
nucleotide sequence of the cDNA coding for the type I 
GnRH receptor in breast and ovarian tumors is identical 
with the receptor present in the pituitary  [31] . In tumor-
derived cells of the male reproductive tract, receptor ex-
pression has been detected at the protein level. Western 
blot analysis using a monoclonal antibody raised against 
the native human pituitary receptor  [42] allowed Limon-
ta et al.  [43] to demonstrate a protein of approximately 64 
kDa in two prostate cancer cell lines. Taken together, 
these data indicate GnRH receptor expression in a range 
of reproductive tissue malignancies, although the func-
tionality of the receptor and the potential downstream 
effects of its activation remain contentious. Traditionally, 
receptor expression within samples has been character-
ized in terms of radioligand binding properties (receptor 
abundance and ligand binding affinity); however, various 
controversial results have thus far been published. Some 
studies have revealed only binding sites which exhibit low 
affinity for GnRH-I analogs in prostate cancer cells  [44] 
and others have observed similar binding parameters in 
endometrial and ovarian cancer cells and tissues  [34, 45] . 
Other studies have reported the presence of two types of 
receptors, one with high and one with low binding affin-
ity in breast and gynecological cancers  [46–48] . In con-
trast, one single class of high-affinity binding sites has 
been reported in breast, ovarian and endometrial cancers 
by different groups  [49–51] . At present, questions con-
cerning the binding affinity of these receptors in tumor-
derived samples and transformed cell lines are still a mat-
ter of debate, and ones which must be addressed before 
significant advances can be made.
 The presence of both GnRH and type I GnRH recep-
tors in tumors of the reproductive tract nevertheless 
prompted investigations into the possible role(s) of GnRH 
in the local control of tumor growth  [52] . Research in the 
laboratory of Motta and coworkers  [44] has shown that 
GnRH agonists exert an inhibitory effect on the prolif-
eration of prostate cancer cells in a dose-dependent man-
ner, and much of the work could be elegantly verified 
when the cells were xenografted into nude mice  [53] . Oth-
ers have confirmed similar antiproliferative activities of 
GnRH agonists when applied to breast, ovarian and en-
dometrial cancer cells, and we have developed receptor-
expressing model cell lines for use both in vitro and in 
vivo  [6, 54–56] . Since activation of the receptor in tumor 
cells is associated with antiproliferative effects, it is pos-
sible to hypothesize that in malignancies of the reproduc-
tive tract any locally expressed GnRH system might act 
as a negative regulator of tumor growth. Furthermore, 
this suggests that GnRH autocrine/paracrine signaling is 
often defective within growing tumors, possibly due to 
inadequate local production of GnRH. 
 GnRH Analogs in Clinical Trials for Cancer Therapy 
 GnRH agonists have been used in prostate cancer clin-
ical trials since the early 1980s  [57] and in uterine leiomy-
oma trials since the early 1990s  [58] . Studies of GnRH ago-
nist effects in recurrent uterine endometrial cancer, pre-










 Fig. 3. Hypothetical sites for GnRH agonist action in normal or 
diseased secretory glands ( a ) or surface epithelium ( b ) found in 
reproductive tissues (such as breast, prostate, uterus and ovary). 
Glandular epithelium or surface epithelium both contain a vari-
ety of epithelial cell subtypes, some of which may express an au-
tocrine/paracrine GnRH system, whilst other cells (in precancer-
ous lesions or inclusion cysts) may aberrantly express elevated 
levels of GnRH receptor and would, therefore, be targets for ther-




conducted  [59–62] . In all of these trials the main aim of 
GnRH agonist treatment was the suppression of sex steroid 
hormone levels to limit growth of steroid-responsive ma-
lignant cells. A variable proportion of tumors exhibit ob-
jective growth inhibition attributable to GnRH agonist 
treatment. Correlations between levels of GnRH receptor 
expression and disease outcome have occasionally been re-
ported  [63] and suggest a direct effect of GnRH agonists 
on tumor cells, including effects on steroid-insensitive 
cells. However, evidence for direct effects on tumor cells in 
patients needs to be verified by rigorously controlled trials 
with appropriate sample sizes. Furthermore, understand-
ing how GnRH receptor activation may affect cancer le-
sion progression is an important problem concerning the 
patient-specific (or even prophylactic) use of GnRH ago-
nists in the treatment of malignancy. For example, does 
GnRH receptor signaling maintain the differentiation 
state of normal cells, alter their mobility or induce apop-
tosis? Additionally, are any of these processes altered in 
transformed cells exposed to GnRH agonists? Information 
derived from basic science investigations may influence 
the way in which clinical trials are designed in the future.
 Details regarding the mechanism of GnRH agonist-
mediated inhibition of cell growth are only beginning to 
emerge. Some groups  [64, 65] have suggested that activa-
tion of the receptor in peripheral malignancies results in 
activation of the G protein G  i and that the consequent 
decrease of intracellular 3  ,5  -cyclic adenosine-5  -mono-
phosphate results in activation of phosphotyrosine phos-
phatases, thus interfering with growth factor-induced ty-
rosine phosphorylation and downstream intracellular 
signaling. Others  [66] have implicated the presence of a 
second type of GnRH receptor, with a preference for 
GnRH-II, in ovarian and endometrial cancers, which 
transmits significantly stronger antiproliferative effects 
than the type I receptor. Interestingly, neither we nor 
Grosse et al.  [67] found any evidence of G  i coupling us-
ing direct analytical techniques. In addition, we have 
shown that, in man, the type II receptor is effectively si-
lenced by a premature stop codon and a frameshift dele-
tion  [2] . Clearly, further elucidation of the complex sig-
naling cascades activated in response to GnRH agonists 
is necessary before we can begin to understand the mech-
anism of GnRH agonist-mediated cell growth inhibition. 
Also, the use of cultured cells currently forms the basis of 
experiments investigating GnRH agonist-mediated cell 
growth inhibition. The relevance of these models to in 
vivo disease pathology needs to be addressed and data 
generated using cell lines should be carefully character-
ized and compared to primary tumor samples.
 Developing Models for Characterization of GnRH 
Agonist-Mediated Cell Growth Inhibition 
 Several models need to be developed to explore the role 
of GnRH receptor signaling in reproductive tissue malig-
nancy. The different models are needed to encompass 
mechanisms particular to prostate cancer, ovarian cancer, 
uterine cancer and breast cancer since cell type-specific 
signaling has been proposed to be an important factor in-
fluencing responses to GnRH  [68] . Alternative types of 
cultured human cells derived from each of these tissues are 
available, including cells immortalized by experimental 
manipulations  [69] rather than by acquisition of disease-
associated oncogenic mutations. More recently, pluripo-
tent stem cells which may be the precursors of certain types 
of carcinoma have become accessible for in vitro studies 
 [70] . Analyses using these cells should more closely reflect 
the physiological responses elicited by GnRH in early-stage 
disease rather than in well-progressed metastatic cells.
 The determination of precisely how GnRH receptor ac-
tivation leads to cell cycle arrest and the induction of apop-
tosis remains a challenge. A sufficient level of cell surface 
GnRH receptor expression is required to elicit growth in-
hibition  [71, 72] . The mechanisms regulating the routing 
of GnRH receptor to the cell surface are poorly understood 
 [73] , although the process appears to be tightly regulated 
since often only a small proportion of total receptor pro-
tein resides in the plasma membrane in stably transfected 
cells. The ability to pharmacologically modulate GnRH re-
ceptor trafficking to the plasma membrane is an attractive 
therapeutic goal and the increased surface expression of 
wild-type as well as mutant receptors using cell-permeable 
small molecules demonstrated that this is achievable  [74] . 
Once at the cell surface, the type I GnRH receptor associ-
ates with protein scaffolds which facilitate signaling, the 
details of which are beginning to be characterized in depth 
 [75] . Further studies should determine whether cell growth 
inhibition is induced by signaling from the receptor di-
rectly to the machinery regulating apoptosis or whether 
there is an indirect effect through de novo gene expression 
or through compromise of the mitotic apparatus (such as 
checkpoint control, spindle dynamics and altered cell ad-
hesion during cytokinesis;  fig. 4 ,  5 ).
 Signaling Downstream from the GnRH Receptor 
 Theoretically, GnRH agonist-mediated inhibition of 
cell growth may involve activation of a number of intra-
cellular pathways. Binding of agonists to the GnRH re-
 Antiproliferative Effects of GnRH Neuroendocrinology 2008;88:67–79 73
ceptor triggers activation of G  q/11 proteins, which acti-
vate phospholipase C (PLC) isoforms   1–  4 to stimulate 
turnover of inositol trisphosphate (IP 3 ) and diacylglyc-
erol (DAG). These signaling molecules lead to the release 
of Ca 2+ from intracellular stores and protein kinase C 
(PKC) activation, respectively. Activation of G  q/11 also 
releases the G   dimer which can independently activate 
several isoforms of PLC, including PLC   2 , PLC   3 and 
PLC     [76, 77] . Other downstream effects of G  q/11 in-
clude interaction with RhoA via the Dbl family guanine 
nucleotide exchange factors (GEF) such as p63RhoGEF, 
Trio and Kalirin  [78] . The antiproliferative response pro-
voked by GnRH agonists may, therefore, be mediated by 
intracellular Ca 2+ elevation, downstream effects of DAG 
or small GTPase activation ( fig. 4 ).
 The cellular response to elevated intracellular Ca 2+ 
varies according to differentiation state. Activation of pi-
tuitary gonadotrope GnRH receptors results in oscilla-
tions in the level of intracellular Ca 2+ linked to activation 



























































 Fig. 4. Multiple signaling routes from the cell surface GnRH re-
ceptor to the machinery regulating the intrinsic pathway of apop-
tosis at the mitochondrial membrane. Signaling diverges follow-
ing activation of G  q/11 and G   , leading to activation of PLC    , 
generation of IP 3 , elevation of intracellular Ca 2+ , activation of 
DAG-sensitive proteins, such as PKC, and activation of transcrip-
tion factors. Apoptosis occurs in response to ‘inappropriate’ sig-
naling, but commitment to cell death may be modulated by a 
range of factors associated with, for example, Ca 2+ sensors and 
cytoskeletal components, including the focal adhesion complex 
and actin fibers. 
 Fig. 5. Selected phases of mitosis potentially sensitive to aberrant 
GnRH receptor signaling. Inappropriate elevation of intracellular 
Ca  2+ or protein phosphorylation following exposure to GnRH 
analogs may disrupt processes such as nuclear membrane disas-
sembly, spindle function or cell separation. Nuclear membrane 
disassembly requires tightly regulated modifications of proteins 
forming the nuclear membrane lamina and pores. Correct segre-
gation of replicated chromosomes requires coordinated regula-
tion of spindle protein kinases and kinetochore components. Sep-
aration of daughter cells requires regulation of proteins forming 
the cortical cytoskeleton in the region of the actomyosin ring. 
Disruption of some of these processes, by induction of GnRH re-
ceptor signaling, may lead to stage-specific arrest of mitosis fol-
lowed by apoptosis as a consequence of inappropriate elevation of 
intracellular Ca 2+ , small GTPase activity, or alterations in DAG-




expression of a specialized apparatus, including an array 
of plasma membrane ion channels, to ensure a return to 
homeostasis following cellular activation. It is possible 
that activation of GnRH receptors expressed in inappro-
priately differentiated cells may lead to a Ca 2+ -mediated 
stress response  [82] . However, antiproliferative effects 
caused by transient increases in Ca 2+ may also be influ-
enced by Ca 2+ -sensing proteins such as the neuronal cal-
cium sensor (NCS) family or the calmodulin family.
 NCS proteins are small cytoplasmic proteins able to 
associate with membrane phospholipids and a variety of 
integral membrane proteins. They can modulate IP 3 sig-
naling, regulate exocytosis and influence G protein-cou-
pled receptor activity  [83] . Changes in protein conforma-
tion occur following the binding of Ca 2+ , thus mediating 
the response to receptor activation  [83, 84] . A role for 
NCS proteins in modulating antiproliferative effects is 
supported by a number of studies  [85–87] . One NCS pro-
tein, recoverin, is expressed in a number of tumor types 
including breast cancer, ovarian cancer and endothelial 
carcinomas  [86] , some of which have been shown to re-
spond to GnRH analogs. Another NCS, visinin-like pro-
tein-1, is highly expressed in less aggressive squamous 
cell carcinomas, whereas little or no expression is ob-
served in invasive squamous cell carcinomas  [88] . Vi-
sinin-like protein-1 influences cell adhesion and migra-
tion through regulation of fibronectin receptor expres-
sion  [89] . Therefore, loss of expression or inhibition of 
this Ca 2+ sensor may contribute to tumor progression 
and metastasis. Ca 2+ binding by other proteins has been 
shown to inhibit apoptosis and promote cancer cell sur-
vival. These include calmodulin, which promotes cell 
survival via activation of calcium/calmodulin-dependent 
kinase 2  [90] and by modulation of ERK1/2 activity  [91] 
(see below). Whether GnRH agonists induce protracted 
elevation of intracellular Ca 2+ in malignant cells, and 
how this impinges on Ca 2+ -sensing proteins, has not been 
studied in detail.
 In addition to IP 3 -stimulated Ca 2+ release, PLC activ-
ity also generates DAG, which is a potent activator of PKC 
isoforms and other target proteins such as   -chimerin 
 [92, 93] . PKC isoforms remain activated after the original 
activation signal or the Ca 2+ transient has waned  [94] . 
PKC    triggers a protein kinase cascade, consisting of Raf, 
mitogen-activated protein kinase/extracellular signal-
regulated kinase (MEK) and ERKs 1 and 2. PKC also ac-
tivates Raf indirectly through activation of Ras  [95] . Ras, 
Raf, MEK and ERKs 1 and 2 are ubiquitously expressed 
Table 1. Transcription factors, enzymes and receptors modulated following activation of ERK1/2, one of the principal protein kinases 
activated by GnRH receptor agonists
Protein targets down-
stream from ERK
Function: cellular response Refer-
ences
Brf1 Transcription factor subunit: hypertrophy 107
Calpain Protease: cell cycle progression, mobility, long-term potentiation, cell fusion 108
Creb Transcription factor: cancer 109
EGFR Receptor: phosphorylation by ERK blocks EGFR signaling 110
Elk1 Transcription factor: transcription of c-Fos and PARP1, growth, proliferation, differentiation 111, 112
ER81 Transcription factor: gene expression 113
c-Fos Forms AP-1 transcription factor with c-Jun: proliferation, differentiation, response to stress 114
IKK Kinase: activation of transcription factor NF-B 115
MLCK Kinase: cytoskeletal reorganization 116
MKP Phosphatase: regulation of MAPKs 117
MSK1/2 Kinase: phosphorylation of histone H3, HM.GI4 and Atf1 118
c-Myc Transcription factor: cell cycle regulation 119
p53 Transcription factor: cell cycle regulation, tumor suppressor 120
p90Rsk Kinase: phosphorylation of transcriptional regulators and polyribosomal proteins,
cell cycle regulation 121
Pax6 Transcription factor: development 122
PEA3 Transcription factor: oncogenesis 123
PO-B Transcription factor: differentiation 124
Sap1/2 Transcription factor: gene expression 125
Sos Guanine nucleotide exchange factor: required for efficient Ras signaling, development 126
Ubf Transcription factor: ribosomal transcription 127
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in mammalian cells and are implicated in control of cell 
proliferation, differentiation, survival and transforma-
tion  [96–98] . Activated ERKs translocate to the nucleus 
where they phosphorylate transcription factors as a 
means of regulating gene expression  [99] ( table 1 ). ERK 
has been implicated in cell cycle arrest in a number of cell 
types  [100, 101] , and a large body of evidence   indicates 
that the strength and duration of ERK activation is criti-
cal in determining the cellular response. Transient or cy-
clic ERK activation   has been linked to progression of the 
cell cycle, whilst sustained activity can lead to growth ar-
rest and differentiation  [102–104] . Thus the spatial and 
temporal activation of ERK is kernel in determining cel-
lular responses such as survival, proliferation and cell cy-
cle arrest. A variety of processes influence the nature of 
the ERK response. Significantly, differences in receptor 
levels markedly affect the intensity and duration of ERK 
activation  [103] .
 Very recently it has been shown that G  q/11 can acti-
vate RhoA via p63RhoGEF, Trio and Kalirin  [78] and, for 
this reason, potential activation of RhoA in response to 
GnRH has yet to be examined. Overexpression of RhoA 
has been shown to induce growth arrest in several cell 
types by disrupting the actin cytoskeleton and microtu-
bules  [105] . Cytoskeletal rearrangement occurs in cells 
treated with GnRH [ 106 ; for references  107–127 see  ta-
ble 1 ], although it is not known whether this is due to 
RhoA-mediated effects and requires further investiga-
tion.
 In summary, a number of GnRH agonist-stimulated 
signaling cascades, one example being the ERK pathway, 
have been implicated as being causative in antiprolifera-
tion and apoptosis. Conversely, multiple signaling cas-
cades activated following GnRH receptor activation, 
some of which we have highlighted here, require further 
investigation.
 Conclusions and Future Perspectives 
 The GnRH system has been the subject of intensive 
research for almost 40 years and a role for GnRH agonist 
signaling in the inhibition of reproductive tissue malig-
nancy has been promulgated for more than 20 years. Re-
productive biology, peptide chemistry, experimental 
pharmacology, molecular and cellular biology and exten-
sive clinical studies have all been brought to bear on the 
therapeutic development of GnRH analog drugs. The 
discovery that GnRH receptor activation can inhibit the 
growth of tumorigenic cells (by direct or indirect action) 
continues to offer therapeutic potential. However, more 
research is required to determine the extent to which the 
antiproliferative effects of GnRH agonists demonstrated 
in the laboratory are translatable into the treatment of 
human malignancies. Although the main therapeutic ef-
fect of GnRH agonist therapy is due to sex hormone
deprivation, it remains possible that particular sub-
groups of tumor cell types are prone to express elevated 
levels of GnRH receptor which may be a target for direct 
action. Therefore, more screening and phenotyping may 
identify patients likely to possess sufficiently high levels 
of GnRH receptor to ensure a significant additional re-
sponse to GnRH agonist therapy. The data from such 
analyses may help to refocus clinical studies. For exam-
ple, prospective studies involving classification of pa-
tients according to the level of GnRH receptor expression 
in malignant tissue have not been attempted so far. Ad-
vances in understanding where and when GnRH action 
is important in disease pathology, how levels of receptor 
expression can be manipulated pharmacologically and 
how receptor activation ultimately leads to cell apoptosis 
represent important goals in realizing the potential of a 
rare phenomenon – a G protein-coupled receptor linked 
to cell growth inhibition with sufficiently restricted tis-
sue distribution to offer therapeutic advantages and man-
ageable or reversible side effects.
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